# HARD COPY

# UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION



# ADMINISTRATIVE PROCEEDING File No. 3-17010

In the Matter of

the Registration Statement of

Scription Work Solutions, Inc. (f/k/a Transtech Solutions, Inc.) 848 N. Rainbow Blvd., Unit 1175 Las Vegas, NV 89107

Respondent.

# DIVISION OF ENFORCEMENT'S MOTION AND MEMORANDUM OF LAW SUPPORTING ENTRY OF A STOP ORDER BY DEFAULT AGAINST SCRIPTION WORK SOLUTIONS, INC.

The Division of Enforcement, pursuant to Rules 155(a) and 220(f) of the Commission's Rules of Practice, 17 C.F.R. §§ 201.155(a) and 201.220(f), moves for entry of an Order finding Respondent Scription Work Solutions, Inc. ("Scription") in default and determining these proceedings against it. In support of its motion, the Division states:

 On December 21, 2015, the Commission issued an Order Fixing Time and Place of Public Hearing and Instituting Proceedings Pursuant to Section 8(d) of the Securities Act of 1933 ("OIP") against Scription.

- 2. On December 23, 2015, pursuant to Rule 141(a)(2)(v), 17 C.F.R. § 201.141(a)(2)(v), Scription was personally served with the OIP by process server through its registered agent. (Exhibit A Affidavit of Process Server).
- 3. More than ten days have elapsed since the OIP was served upon Scription, and Scription has failed to file an Answer or otherwise respond to the OIP as required by Rule 220(b), 17 C.F.R. § 201.220(b). The OIP expressly warned Scription that if it failed to file an Answer to the OIP within ten days after service of the Order, it "may be deemed in default and the proceedings may be determined against the Respondent upon consideration of this Order, the allegations of which may be deemed to be true . . . ." (OIP at 3).

# 4. Rule 155(a) provides in relevant part:

A party to a proceeding may be deemed to be in default and the Commission or the hearing officer may determine the proceeding against that party upon consideration of the record, including the order instituting proceedings, the allegations of which may be deemed to be true, if that party fails (1) to appear, in person or through a representative, at a hearing or conference of which that party has been notified; [or] (2) to answer ... or otherwise to defend the proceeding ....

# 17 C.F.R. § 201.155(a) (emphasis added).

- 5. Similarly, Rule 220(f) of the Commission's Rules of Practice, 17 C.F.R. § 201.220(f), provides that a respondent who fails to file an answer within the prescribed time may be deemed in default pursuant to Rule 155(a).
- 6. Pursuant to Rules 155(a) and 220(f), the Law Judge may now deem true the allegations of the OIP as to Scription, thereby determining this proceeding against it due to its failure to file an Answer to the OIP or otherwise appear in this action. In addition, the evidence attached to this Motion further supports entry of a stop order suspending the effectiveness of the Registration Statement referred to in the OIP.

- 7. On Pages 1 and 2, the OIP alleges the following facts against Scription, which pursuant to Rule 155, the Law Judge, upon consideration of the record, including the OIP, should deem true:
  - a. Scription is a revoked Nevada corporation headquartered in Las Vegas, Nevada.
     (Exhibit B Nevada Secretary of State printout showing Scription's revoked status,
     IncSmart.biz as its registered agent, and Chris Weinhaupl as its sole officer and director).
  - b. On March 29, 2013 Scription filed a Form S-1 registration statement seeking to register the offer and sale of 20 million common shares. The registration statement was amended on May 10, 2013, June 28, 2013, twice on October 7, 2013, November 1, 2013, November 25, 2013, and January 21, 2014. (Composite Exhibit C –registration statements and amendments (collectively "Registration Statement")).
  - c. The Registration Statement includes untrue statements of material facts and omits to state material facts necessary to make the statements contained therein not misleading. As described in more detail below, while the Registration Statement claims that Christopher Weinhaupl is the sole officer and director, documentary and testimonial evidence indicates other undisclosed individuals (Paul Kwon, Amrit Hayer, and Andy Jagpal) acted as promoters and/or control persons.
  - d. The Registration Statement states that Scription "rel[ies] on Mr. Weinhaupl, to manage all aspects of our business." (Exhibit C, at p. 29<sup>2</sup>). This is false and misleading

<sup>&</sup>lt;sup>1</sup> The OIP references an amendment dated June 5, 2013. This was in error as the June 5th filing was not an amendment to the registration statement but rather a Form 8-K regarding Scription's name change.

<sup>&</sup>lt;sup>2</sup> The pages number refers to the pagination that appears at the bottom of pages in the registration statement and its amendments.

because Scription has undisclosed control persons and/or promoters who have taken the following actions on behalf of Scription:

- i. Drafted Scription's Form S-1, and communicated with the law firm that facilitated the filing of Scription's Registration Statement, providing it with draft responses to staff's comments to the Registration Statement (Composite Exhibit D Emails between Dean Law, Scription's counsel, and Amrit Hayer, bates # DLC 5234-5236, 3754, 3761, 3770; Emails between Paul Kwon and Andy Jagpal and Dean Law, bates # DLC 2975, 5251-5258, 5231, 5401; Email between Paul Kwon and Dean Law, bates # DLC 5134, 5232, 5814; E-mails between Paul Kwon and Amrit Hayer and Dean Law, bates # DLC 2937-2943).
- ii. Interacted with Scription's auditors regarding its financial statements (Exhibit E Emails between Paul Kwon using Chris Weinhaupl's email address and Kenne Ruan, Scription's auditor, bates # 974-978; Exhibit F sworn investigative testimony of Christopher Weinhaupl taken August 1, 2014<sup>3</sup>, p. 130, line 8 p. 131, line 12).

We submit specific limited excerpts of the sworn investigative testimony of Christopher Weinhaupl as admissions of Scription because he served as its purported sole officer and director. Sworn testimony may contain admissions within the meaning of Rule 250. In the Matter of Meissner et al., S.E.C. Release No. 768, 2015 WL 1534398 \*3 (April 7, 2015). This reasoning applies equally in the context of a default judgment motion, as the admissions of Scription's officer and director are "relevant evidence" admissible under Rule 320. In addition, in a similar stop order proceeding, Law Judge Grimes admitted the investigative testimony of a respondent's sole officer and director who failed to appear at the hearing, finding that the sole officer was a "party" within the meaning of Rule 235(a). In the Matter of the Registration Statement of International Precious Metals, Inc., Release No. 808, 2015 WL 3610557, at \*3 (June 10, 2015), Decision Final, Release No. 33-9866, 2015 WL 4465318 (July 22, 2015).

- iii. Provided false consulting invoices to Scription's auditors presumptively to justify Weinhaupl's withdrawal of \$25,000 from Scription's bank account for the benefit of another company (Exhibit F –Weinhaupl testimony, p. 145, line 4 6 and line 23 25, p. 146, line 1 11; p. 149, line 8 20; Composite Exhibit G false invoices totaling \$25,000; Exhibit H Scription's Balance Sheet produced by its auditor showing Weinhaupl's withdrawals as "consulting fees" and traced to invoices).
- iv. Had custody and control of Scription's corporate records (Exhibit F, Weinhaupl testimony, p. 27, line 6 9, p. 28, line 6 9).
- 8. In addition to the above-described material misstatements and omissions regarding undisclosed control persons and/or promoters, entry of a stop order is warranted because Scription's Registration Statement is false and misleading in other ways. The Registration Statement states that Scription is engaged in "Phase 1" of a two-phase business plan that included expenditures related to incorporation and drafting a business plan. The remaining portion of Phase 1 was to acquire additional funding. (Exhibit C, "Plan of Operations" contained at p. 26 in March 29, 2013 Form S-1, and at p. 25 in all amendments). This disclosure is false and misleading because Weinhaupl, Scription's sole officer and director improperly withdrew \$25,000 from Scription's bank account to fund one of his other medical transcription businesses. (Exhibit F, Weinhaupl testimony, p. 142, line 4 p. 144, line 9, p. 145, line 4 p. 146, line 11, p. 147, line 13 p. 149, line 20). This left Scription with \$5,000 in its account. (Composite Exhibit I, November 2013 and December 2013 Wells Fargo bank statements showing \$25,000 in withdrawals and \$5,072.25 remaining in Scription's bank account). Thus, instead of financing the business activities described in the

Registration Statement, Scription's money was actually being used to fund Weinhaupl's other business venture. (Exhibit F, Weinhaupl testimony, p. 142, line 4 - p. 144, line 9, p. 145, line 4 - p. 146, line 11, p. 147, line 13 - p. 149, line 20).

9. In addition, the Registration Statement states that since 2001 Scription's sole officer and director "has been a Senior Partner at 'mypharmacard'" and that "his experience working in the medical industry with 'mypharmacare' will assist Scription Work Solutions, Inc., and grow the business." (Exhibit C, Amendment No. 7 at p. 27<sup>4</sup>). These disclosures regarding Weinhaupl's relevant business experience are false and misleading because, as he admits, neither "mypharmacard" nor "mypharmacare" exist. (Exhibit F, Weinhaupl testimony, p. 112, line 13 – p. 114, line 7).

# **MEMORANDUM OF LAW**

"The essential purpose of [a registration statement] is to 'protect investors by promoting full disclosure of information thought necessary to informed investment decisions." The Application of mPhase Techs., Inc., Exchange Act Release No. 34-74187, 2015 WL 412910, at \*5 (Feb. 2, 2015) (Commission opinion) (quoting The Application of World Trade Fin. Corp., Exchange Act Release No. 66114, 2012 WL 32121, at \*7 (Jan. 6, 2012) (Commission opinion)). Under Section 8(d) of the Securities Act, a stop order may issue if "the registration statement includes any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading." "Information in a

<sup>&</sup>lt;sup>4</sup> The Registration Statement further references Weinhaupl's ownership of the non-existent "mypharmacard" at p. 28 of the March 29, 2013 Form S-1, and at p. 27 of Amendments No. 1 and 2. Weinhaupl is identified as Senior Partner of "mypharmacard" at p. 27 of Amendments 3-7.

registration statement is material when there is a substantial likelihood that a reasonable investor would attach importance to it in determining whether to purchase the security in question." *In re Petrofab International, Inc.*, 48 S.E.C. 998, 1005, 1988 SEC Lexis 782 \*16 (Apr. 20, 1998) (Citing *TSC Industries, Inc., v. Northway, Inc.*, 426 U.S. 438, 449 (1976)) (Commission opinion). For example, representations regarding the nature of a company's business operations are material. *See generally SEC v. North American Research & Development Corp.*, 375 F. Supp. 465, 470-71 (S.D.N.Y 1974), aff'd, 511 F.2d 1217 (2d Cir. 1975), cert. denied sub nom., *White v. SEC*, 423 U.S. 830 (1975) (misrepresentations regarding business operations were material).

Item 11(n) of Form S-1 requires the registrant to furnish the information required by Item 404 of Regulation S-K including the identity of any promoter or control person that the registrant has had within the last five fiscal years. *See* Item 11(n) of Form S-1; 17 C.F.R. § 229.404. Under Rule 405 of Regulation C, a "promoter" is defined to include "[a]ny person who, acting alone or in conjunction with one or more other persons, directly or indirectly takes initiative in founding and organizing the business or enterprise of an issuer." 17 C.F.R. § 230.405. Rule 405 defines "control" to mean "the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person." *Id.* The failure to disclose the existence of a promoter or control person has been found to be material. *See SEC v. Fehn*, 97 F.3d 1276, 1290 (9th Cir. 1996) (materially misleading to identify a new president and CEO as a recent addition when in fact he had been an undisclosed promoter and control person for over a year); *In re Hughes Capital Corp.*, 48 S.E.C. 802, 806-09, 1987 SEC Lexis 4158 (July 20, 1987) (failure to disclose promoter and control person in a registration statement is material) (Commission opinion).

According to the Registration Statement, the sole officer, Weinhaupl, is Scription's only member of management and control person. However, Scription failed to disclose in the Registration Statement the limited role Weinhaupl actually played, and the existence of Paul Kwon, Amrit Hayer, and Andy Jagpal as promoters and/or control persons. In fact, these three individuals were instrumental in Scription's formation and activities. They controlled multiple aspects of Scription's operations, and made critical decisions on its behalf. Kwon and Jagpal continued their involvement even during the staff's investigation of this matter. Weinhaupl admitted that Kwon compiled documents responsive to the staff's subpoena to Scription. (Exhibit F, Weinhaupl testimony, p. 32, line 23 – p. 33, line 18). He further admitted that Jagpal funded Scription's legal fees concerning the staff's examination and investigation (Exhibit F, Weinhaupl testimony, p. 70, line 15 – p. 71, line 7). Meanwhile in sharp contrast, Weinhaupl could not recall Dean Law, Scription's counsel, or Kenne Ruan, Scription's auditor. (Exhibit F, Weinhaupl testimony, p. 104, line 11 – p. 105, line 1, and p. 132, line 1 – 15, p. 133, line 15 – p. 134, line 4).

As detailed above, entry of a stop order is appropriate here because Scription's Registration Statement contains materially false and misleading statements. Scription's Registration Statement falsely states that Scription is dependent on the efforts of Weinhaupl and fails to disclose the roles of three control persons and/or promoters, which are material omissions. See SEC v. Fehn, 97 F.3d at 1290; In re Hughes Capital, 48 S.E.C. at 806-09. Stop orders have been entered by default in similar circumstances (i.e., the failure to disclose the true control persons and/or promotors) in the recent proceedings of In the Matter of the Registration Statement of International Precious Metals, Inc., Release No. 808, 2015 WL 3610557 (June 10,

2015), Decision Final, Release No. 33-9866, 2015 WL 4465318 (July 22, 2015); and *In the Matter of the Registration Statement of Kismet, Inc.*, Release No. 809, 2015 WL 3610558 (June 10, 2015), Decision Final, Release No. 33-9865, 2015 WL 4465317 (July 22, 2015). A stop order is also appropriate here because of the other false and misleading statements described above, namely the failure to disclose Weinhaupl's use of \$25,000 of Scription's funds to finance his other business and the claim that he owned or worked for businesses that were in fact non-existent.

In sum, the Division seeks an order finding Scription is in default, and that a stop order should issue suspending the effectiveness of the Registration Statement referred to herein. Taking the allegations of the OIP as true, and reviewing the evidence submitted herein, such findings and sanctions are appropriate and in the public interest.

January 6, 2016

Respectfully submitted,

Christine Nestor

Senior Trial Counsel

Direct Line: (305) 982-6367

nestorc@sec.gov

# CERTIFICATE OF SERVICE

I hereby certify that an original and three copies of the foregoing were filed with the Securities and Exchange Commission, Office of the Secretary, 100 F Street, N.E., Washington, D.C. 20549-9303, and that a true and correct copy of the foregoing has been served in the form indicated below, on this 6th day of January 2016, on the following persons entitled to notice:

Brenda P. Murray Chief Administrative Law Judge Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-2557 Service via Email: ALJ@sec.gov

Scription Work Solutions, Inc. c/o IncSmart.biz, Inc., as agent for service 4264 Lady Burton Street Las Vegas, NV 89129 Service via UPS Overnight Mail And U.S. Mail

Scription Work Solutions, Inc. (f/k/a Transtech Solutions, Inc.) 848 N. Rainbow Blvd. Unit 1175 Las Vegas, NV 89107
Service via UPS Overnight Mail And U.S. Mail

Christine Nestor, Esq.

# **EXHIBIT A**

# **AFFIDAVIT OF SERVICE**

in the Matter of the Registration Statement of Scription Work Sclutions, Inc. (fik/a Transtech Solutions, Inc.) 848 N. Rainbow Bivd., Unit 1176 Las Vegas, NV 89107

### Respondent

Received by Bullet Legal Services on the 22nd day of December, 2015 at 1:15 pm to be served on SCRIPTION WORK SOLUTIONS, INC., c/o InoSmart.biz, Inc. - Registered Agent, 4264 Lady Burton Street, Las Vegas, NV 89129.

I, Anthony Spada, being duly sworn, depose and say that on the 23rd day of December, 2015 at 1:41 pm, I:

served a corporate officer/agent of SCRIPTION WORK SOLUTIONS, INC. by delivering a true copy of the LETTER and ORDER FIXING TIME AND PLACE OF PUBLIC HEARING AND INSTITUTING PROCEEDINGS PURSUANT TO SECTION 8(d) OF THE SECURITIES ACT OF 1933; to: MICHAEL LASALLA as Registered Agent, in a corporate capacity for SCRIPTION WORK SOLUTIONS, INC., at the address of: IncSmart.biz; Inc. - Registered Agent, 4284 Lady Burton Street, Las Vegas, NV 88128, and informed said person of the contents therein, in compliance with state statutes.

Description of Person Served: Age: 55, Sex: M, Race/Skin Color: WHITE, Height: 6'11", Weight: 180, Hair: GREY, Glasses: N

I certify that at all times herein Affiant was and is a citizen of the United States, over 18 years of age, and not a party to or interested in the proceeding in which this affidavit is made.

State of Nevada County of Clark

Subscribed and Swom to before me on the 28th day of December \_\_\_\_\_, \_\_2015 \_\_ by the affiant

who is personally known to me.

B-045877

Anthony Spade

Bullet Légal Services 1930 Village Center Circle, #3-865 Las Vegas, NV 89134 (702) 823-1000

Our Job Serial Number: BRT-2015004459

BERT LOTT C Notary Public, State of Nevaida

Fight @ 1892-2013 Dajstrase Services, Inc. - Process Server's Toolbux V7.00

Appointment No. 07-4854-1 My Appt. Expires Sept 14, 2019

# **EXHIBIT B**

# **EXHIBIT B**



# SCRIPTION WORK SOLUTIONS INC

Business Entity Information							1	
Status:	Revoked					07/12/2011		
Туре:	Domestic Cor	poration			E	ntity Number:	E0392262011-0	
Qualifying State:	NV				List of	Officers Due:	07/31/2014	
Managed By:					Ex	piration Date:		
Foreign Name:					Or	Admin Hold:	No	
NV Business ID:	NV201114588	54			Business	License Exp:	07/31/2014	
Additional Information								
Central Index Key								
Registered Agent Information								
Name	INCSMART.E	BIZ, INC.			Address 1:	4264 LADY B	URTON ST	
Address 2					City:	LAS VEGAS		
State	NV				Zip Code:	89129		
Phone					Fax:			
Mailing Address 1				Mailing	Address 2:			
Mailing City				Ma	ailing State:	NV		
Mailing Zip Code								
Agent Type	Commercial	Registered Agent - Corpo	oration					
Jurisdiction	n: NEVADA				Status:	Active		
View all business entities unde	this registered	l agent ()						
Financial Information							<del></del>	
<u> </u>	r Share Count:	0		<u> </u>		Capital Amount	\$ 75,000.00	
	ar Share Count:	75,000,000.00				ar Share Value		
	- Chart Count.	10,000,000.00		l	<u>·</u>	ar Onaro Vario	14.00.	
Officers							☐ Include Inactive Officers	
President - CHRIS WEINHAUP								
Address 1:				Address 2:				
City: CALGAR	Y			State:				
Zip Code:				Country:	CAN			
Status: Active				Email:				
Secretary - CHRIS WEINHAUPI								
Address 1:				Address 2:				
City: CALGAR	Υ			State:				
Zip Code:				Country:	CAN			
Status: Active		· · · · · · · · · · · · · · · · · · ·		Email:		_		
Treasurer - CHRIS WEINHAUPI			r					
Address 1:		<u> </u>		Address 2:				
City: CALGAR	Υ			State:				
Zip Code:			t	Country:				
Status: Active				Email:				
Status: Active Director - CHRIS WEINHAUPL Address 1:								

Zip Code:		Country:	CAN
Status:	Active	Email:	
Actions\Amendment	B	_	
Click here to view 5 a	ctions\amendments associated with this company	70	

Disclaimer ()

# COMPOSITE EXHIBIT C



# UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

# **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Form S-1, registration statement, received in this Commission on March 29, 2013, under the name of Transtech Solutions, Inc., (Now known as: Scription Work Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Mills, Larry

Digitally signed by Mills, Larry DN: dc=GOV, dc=SEC, dc=AD, ou=Common, ou=Metro DC, ou=COSO, ou=Employee, cn=Mills, Larry, email=MillsL@SEC.GOV Date: 2015.09.28 15:07:09 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

Secretary

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1

# REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# Transtech Solutions Inc.

(Exact name of registrant as specified in its charter)

<u>Nevada</u>
(State or other jurisdiction of
incorporation or organization)

# <u>7374</u>

(Primary Standard Industrial Classification Code Number)

41-2281519

(I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp.
601 Union Street, Suite 4200
Seattle, Washington 98101
Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public:

as soon as practicable after the effective date of this Registration Statement.

f any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
f this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.
f this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
f this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registrationstatement number of the earlier effective registration statement for the same offering.
indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer □ Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☑

(Do not check if a smaller reporting company)

### **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(1)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$27.28

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

An amendment has been made to the exhibit index of this registration statement to list the legal opinion as Exhibit 5.1. The absence of the legal opinion as Exhibit 5.1 was caused by human error while editing the registration statement.

Subject to completion, dated March 28, 2013.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

# TRANSTECH SOLUTIONS, INC. 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

# 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and has no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

					Net Proceeds
			Net Proceeds	Net Proceeds	to Company
			to Company	to Company	After Offering
	Offering Price		After Offering	After Offering	Expenses
	to the Public		Expenses	Expenses	(100% of
	Per Share	Commissions	(20% of Shares Sold)	(50% of Shares Sold)	Shares Sold)
Common Stock	\$0.01	Not Applicable	\$20,000.00	\$80,000.00	\$180,000.00
Total	\$0.01	Not Applicable	\$20,000.00	\$80,000.00	\$180,000,00

The Date of this prospectus is March 28, 2013.

# **Table of Contents**

# **TABLE OF CONTENTS**

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

#### PROSPECTUS SUMMARY

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Transtech Solutions Inc.

### Company Overview

Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription solutions for businesses of all sizes. We intend to launch a web-based platform that will give us the ability to reach thousands of potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 2-3 months after we obtain a Notice of Effectiveness of this Offering and our initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We hope to realize our full plan of operations by raising money through the sale of our securities, as contemplated within this Offering. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription platform solution. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

#### **Table of Contents**

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance such a company, he has experience running a business. We intend to retain qualified website/software developers to build and maintain our website and transcription platforms that we envision. We also plan to hire qualified marketing and sales personnel staff if we are successful in raising capital through this Offering. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, excluding professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$20,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

#### Table of Contents

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

### **SUMMARY OF THIS OFFERING**

The Issuer Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price

The selling stockholders may offer their shares through public or private transactions, on or off OTCBB, at a

fixed price of \$0.01 per share. We will pay all expenses of registering the securities, estimated at approximately

\$9,000.

**Termination of the Offering** The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no

longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Securities Issued And to be

Issued

50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

Use of Proceeds We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for

the Selling Stockholders.

# Table of Contents

# **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

								1.5	1 No.	- 41 1	. '''.		#1. ·		:	As of Dec 31, (Audited	
Balance Sheet															-		
Total Assets															\$		40,048
Total Liabilities															\$		0
Stockholders' Equity															\$		40,048
	.7.5 				:	ja.		, TE	i i		188 T T			#12 -		Period from July (date of incept Dec 31, 2012 (A	ion) to
Income Statement	• • •								••••	•		T give				*** ** *** *** *** *** *** *** *** ***	
Revenue															\$		-
Total Operating Expenses															\$		10,052
Net Loss															\$		(10,052)
														1.8	•	As of Dec 31, 2011 (Audited)	
Balance Sheet		175								. 18		19	7.				
Total																	
Assets													\$				0
Total Liabilities									100			1	\$				0
Stockholders' Equity													\$				0
				-366			\$6. 							Thr	ee m	onths ended Dec 3 (Audited)	1, 2011
Income Statement			7-5 m					1.000			1287	12.11%					
Revenue													\$				-
Total Operating Expenses													\$				(10,000)
Net Loss													2				(10,000)

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

There is substantial doubt about our ability to continue, as a going concern, as a result of our lack of revenues and financial resources, and if we are unable to generate significant revenue or secure financing, we may be required to cease or curtail our operations.

Our lack of operating history and financial resources raise substantial doubt about our ability to continue as a going concern. The financial statements do not include adjustments that might result from the outcome of this uncertainty, and if we are unable to generate significant revenue or secure financing, we may be required to cease or curtail our operations. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

#### Table of Contents

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

#### Table of Contents

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the day spa soil remediation industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing soil remediation services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. ChristopherWeinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough vendors and clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. ChristopherWeinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. ChristopherWeinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. ChristopherWeinhaupl.

### Risks Relating To Our Common Stock

# Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

# If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

# We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

# FINRA sales practice requirements may limit a stockholder's ability to buy and sell our stock.

FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may have the effect of reducing the level of trading activity and liquidity of our common stock. Further, many brokers charge higher transactional fees for penny stock transactions. As a result, fewer broker-dealers may be willing to make a market in our common stock, reducing a stockholder's ability to resell shares of our common stock.

# Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. Indeed, we do not have any audit or compensation committee. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO ChristopherWeinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to her. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

Although we believe that we currently have adequate internal control over financial reporting, we are exposed to risks from recent legislation requiring companies to evaluate internal control over financial reporting.

Section 404 of the Sarbanes-Oxley Act of 2002 ("Section 404") requires our management to report on the operating effectiveness of the Company's Internal Controls over financial reporting for the year ended December 31, 2012 and from the period from inception (July 12, 2011) to December 31, 2012. We must establish an ongoing program to perform the system and process evaluation and testing necessary to comply with these requirements. We expect that the cost of this program will require us to incur expenses and to devote resources to Section 404 compliance on an ongoing basis.

It is difficult for us to predict how long it will take to complete Management's assessment of the effectiveness of our internal control over financial reporting for each year and to remediate any deficiencies in our internal control over financial reporting. As a result, we may not be able to complete the assessment and process on a timely basis. In the event that our Chief Executive Officer, Chief Financial Officer or independent registered public accounting firm determine that our internal control over financial reporting is not effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our shares will be affected.

•

### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### **Use of Proceeds**

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions, on or off OTCBB, at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### **Dilution**

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

### Selling Shareholders

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

- the number of shares owned by each prior to this offering;
- the total number of shares that are to be offered for each;
- the total number of shares that will be owned by each upon completion of the offering; and
- the percentage owned by each upon completion of the offering.

		Total Number Of Shares To		
Name Of Selling Shareholder	Shares Owned Prior To This Offering	Be Offered For Selling Shareholders Account	Total Shares to Be Owned Upon Completion Of This Offering	Percentage of Shares owned Upon Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000	NII	IVII
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000		INII
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil

Dinah Parreno	100,000	100,000	Nil	Nil	
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil	
Enric B. Alarca	100,000	100,000	Nil	Nil	
Josephine P. Laroa	100,000	100,000	Nil	Nil	
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil	
Kell B. Esguerra	100,000	100,000	Nil	Nil	
Melvina P. Alib	100,000	100,000	Nil	Nil	
Jose Jay N. Briton	100,000	100,000	Nil	Nil	
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil	
Cherry Grace N. Briton	100,000	100,000	Nil	Nil	
Arlene M. Morato	100,000	100,000	Nil	Nil	
Ernesto Bejeno	100,000	100,000	Nil	Nil	
Total	20,000,000	20,000,000	Nil	Nil	

.

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 50,100,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

# PLAN OF DISTRIBUTION: TERMS OF THE OFFERING

# **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

#### Offering Price

The selling stockholders, who are underwriters, will sell their shares at an offering price of \$0.01 per share. Thereafter, the sales price offered by the selling stockholders to the public may be:

- 1. the market price prevailing at the time of sale;
- 2. a price related to such prevailing market price; or
- 3. such other price as the selling stockholders determine from time to time.

Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

# Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### **State Securities Laws**

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$9,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

# **Selling Shareholders**

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

		Total Number Of Shares To		
		Be Offered	<b>Total Shares to Be Owned</b>	Percentage of Shares owned
Name Of Selling	<b>Shares Owned Prior</b>	•	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000	1411	1811
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000		1411
John Paul Bornasal	2,200,000	2,200,000		Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
	600,000	600,000	Nil	Nil
	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	-	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
		200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000		Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000		Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000		Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000		Nil
Kell B. Esguerra	100,000	100,000		Nil
Melvina P. Alib	100,000	100,000		Nil
Jose Jay N. Briton	100,000	100,000	Nil	Nil
Daryl Nhon N. Briton	100,000	100,000		Nil .
Cherry Grace N. Briton	100,000	100,000		Nil
Arlene M. Morato	100,000	100,000		Nil
Ernesto Bejeno	100,000	100,000	Nil	Nil
Total	20,000,000	20,000,000	Nil	Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;

•						•
• •						
		*****	 		 	
		***	 		 	
•						
• .						
* * * * * * * * * * * * * * * * * * * *			 		 	
					,	
				•		
					•	
i'						
•						
	**** * ** * ##***	. •	 		 	
· · · · · · · · · · · · · · · · · · ·						
		••••••	 		 	
				•		

20

3. is a broker-dealer; or broker-dealer's affiliate.

### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

# **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

## **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

## INFORMATION WITH RESPECT TO REGISTRANT

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHIS WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

## **Description of Business:**

# Organization:

Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Transtech will begin by providing services to the Nevada medical community by offering our medical transcription service through the use of digital equipment and careful proofing. The company will cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Transtech will incorporate outsourcing operations overseas to take advantage of lower cost of labor in addition to our hired medical transcriptionists, pending our sales effort success. This technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we will penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

Transtech's core service offering will be to provide medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

# **Industry Overview**

The Bureau of Labor Statistics (BLS http://www.bls.gov/ooh/healthcare/medical-transcriptionists.htm) reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. The volume of healthcare services is expected to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. An aging population contributing to an increased number of healthcare visits, combines with a continued emphasis of accessible documentation, is anticipated to simulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

## Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. The growth of the medical transcription field has been spurred due to insurance company requirements for legible notes prompting a great deal of demand for qualified medical transcriptionists. This is a highly fragmented and competitive industry that will continue to grow over the years. Demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### Market Needs

Transtech is providing its customers with a reliable, flexible, medically-trained transcription service. The following benefits are important to our customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of non-essential activities. For transcription services this means a recent surge in demand for transcription services from customers that are now relying on outsourced service providers.

#### **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

## Competition

The competition takes two general forms:

- 1. **General transcription service-** these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- 2. Specialized medical transcription- there are a number of exclusive medical transcription service providers. The market is controlled by larger companies that have established their brand over the years. Many of the smaller companies that provide are being driven out of the industry due to the larger more reputable companies being able to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

# Transtech's Competitive Advantage

The majority of competition is in the form of small mom & pop companies with annual revenues of less than \$500,000. Many of these small shops are being pushed out of the industry due to the pressure of new technology, global outsourcing, turnaround-time demands and volume demands. There exits huge potential within the market. Transtech will build its reputation on fast-turnaround, accuracy and quality customer service.

## **Plan of Operations**

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

All aspects of Phase 1 have been completed, with the exception of raising additional funding. To date, our founder, ChristopherWeinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we will offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through the sale of our securities and see us through Phase 2 and 3. Phase 2 involves purchasing a medical transcription software platform and we do not intend on entering Phase 2 until the Company raises additional funding either through completion of this Offering or through third parties if the Company does not receive sufficient proceeds from this Offering.

#### **Products and Services**

Transtech provides medical transcription services for the medical community. We typically transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Customers may simply and efficiently use phone dictation or send voice files via the Internet.

- Next Day Turnaround: Transtech offers 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, they also provide STAT transcription services with turnaround in less than 4 hours.
- Physician Portal: Physicians may review and correct the transcribed report using standard Word functionality and any changes are saved to the server and may be accessed or distributed to all users. The physician signs the document with a single mouse click upon which the report is electronically stamped and marked as final. The final report is then distributed based on the user defined distribution rules.
- 98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts are graded by proof-readers based on the American Association of Medical Transcription standards. Transtech guarantees 98% accuracy or better or files are provided free.
- 24 Hour Data Access: Transtech provides 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.
- Quality Assurance: Transtech provides 4 to 6 months of training to all transcriptionists that join Transtech. Once training is complete, transcriptionists are placed in a live environment where all their work is scrutinized for accuracy. Only after 2 to 3 years are transcriptionists promoted to Assistant Quality Assurance positions in the Quality Assurance Department. All transcripts are guaranteed for 98% accuracy or better based on American Association of Medical Transcription Standards.
- Easy File Transfers: Transtech's interface was architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface allows clients to copy their dictations from their recorders and send it to Transtech's servers with just 3 clicks of a mouse.
- **HIPAA Compliant**: Transtech's medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA) guidelines and the HIPAA administrative simplification provision, PHI.

Upon completion of this Offering, and assuming we are able to successfully raise funding from the sale of our securities, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to develop the medical transcription platform. While we are developing the medical transcription software, we will begin initial preparations for the launch of our platform and website. Assuming we are able to raise the maximum amount of funds from this offering, the full extent of Phase 2 of our business plan and development will include:

Raising capital – We will begin raising funding through the sale of our securities as set for within this Registration Statement. This will start as soon as we received a Notice of Effectiveness from the SEC. We believe the expenses involved with becoming a public company will be approximately \$20,000.

Platform development—We plan to develop our medical transcription platform and hire a website developer to design our website. The development of our platform and website will entail the bulk of Phase 2. We plan to allocate \$65,000 to develop the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and software platform.

Hire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, ChristopherWeinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

Beta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and marketing platform.

Acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

# Management

Christopher Weinhaupl has been an accomplished serial entrepreneur over the last 15 years. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

ChristopherWeinhaupl holds ownership and founder of Canadapack a North American cross boarder Logistics Company, "mypharmacard" a payment processor solution for web based Pharma companies, and "Superframe" an Internet DSL bonding technology for the SMB market.

#### **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

# **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website platform. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

# Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform and Website Developers	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Total		\$180,000

# **Outstanding Equity Awards since Inception:**

		OPTION AWARDS					STOCK	AWARDS	
								_	Equity Incentive
								Equity	Plan
								Incentive	Awards:
							Market	Plan	Market
						Number	Value	Awards:	or
			Equity			of	of	Number	Payout
			Incentive			Shares	Shares	of	Value of
			Plan			or	or	Unearned	Unearned
			Awards:			Units	Units	Shares,	Shares,
			Number of			of	of	Units or	Units or
	Number of		Securities			Stock	Stock	Other	Other
	Securities		Underlying	• • • • •		that	that	Rights	Rights
	Underlying	Number of Securities	Unexercised	Option		have	have	that have	that have
	Unexercised	Underlying Unexercised	Unearned	Exercise	Option	not	not	not	not
	Options (#)	Options (#)	Options	Price	Expiration	Vested	Vested	Vested	Vested
Name	Exercisable	Unexercisable	(#)	(\$)	Date	(#)	(\$)	(\$)	(\$)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)
Christopher Weinhaup	- —	0	0		0	0	0	. 0	0

#### Long-Term Incentive Plans

We currently have no Long-Term Incentive Plans.

# **Director Compensation**

None.

### Director Independence

Our board of directors is currently composed of one member, ChristopherWeinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, ChristopherWeinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

# SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at March 28, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of March 28, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 501 Santiago Avenue Long Beach, CA 90814	30,100,000	60%
	Total	50,100,000	100%

(1)

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

## CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to ChristopherWeinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

# Disclosure of Commission Position of Indemnification for Securities Act Liabilities

Our Bylaws, subject to the provisions of Nevada Law, contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

## COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Balance Sheet as of December 31, 2011				36
Statement of Operations as of December 31, 2011				37
Statement of Cash Flows as of December 31, 2011				38
Statement of Stockholder's Equity as of December 31, 2011				39
Notes to the Financial Statement as of December 31, 2011	en e	· · · · · · · · · · · · · · · · · · ·	 1 12 12 12 12 14 14 14 14 14 14 14 14 14 14 14 14 14	40
Balance Sheet as of December 31, 2012				43
Statement of Operations as of December 31, 2012				44
Statement of Cash Flows as of December 31, 2012				45
Statement of Stockholder's Equity as of December 31, 2012				46
Notes to the Financial Statement as of December 31, 2012				47

# Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders Transtech Solutions Inc. (A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Transtech Solutions Inc (A Development Stage Company)

We have audited the accompanying balance sheets of Transtech Solutions Inc. (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the period July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Transtech Solutions Inc. as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the period July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut March 28, 2013

# **BALANCE SHEETS**

Asset Current Assets		Dec-31 2011 0
Total Asset	Cash	0
Liabilities and Stockholders' Equity		
Current Liabilities	Accounts Payable	
Long Term Liabilities Total Liabilities		0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 10,000,000 shares issued and outstanding Additional paid-in-capital Deficit accumulated during the development	10,000 0 -10,000
Retained Earnings	stage	-10,000
Total Stockholder's Equity Total liabilities and stockholder's equity		-10,000 -10,000

# **STATEMENT OF OPERATIONS**

	For the Period From Inception (July 12, 2011) to December 31, 2011
Ganaral and Administration	5
<u>.</u>	124
Professional Fees	9,871
Net (loss) from Operation before Taxes	-10,000
	0
•	-10,000
0	
50,100,000	
	0

STATEMENT OF CASH FLOWS		For the Period From Inception (July 12, 2011) to December 31, 2011
Operating Activities		
Net cash (used) for operating activities	Net (loss)	-10,000 - <b>10,000</b>
Financing Activities		
	Loans from Director	0
	Sale of common stock	10,000
	Net cash provided by financing activities	10,000
Net increase (decrease) in cash and equivalents		0
Cash and equivalents at beginning of the period		0
Cash and equivalents at end of the period		0
Supplemental cash flow information		0
Cash paid for:		0
Interest		0
Taxes	•	0
Non-Cash Activities		0

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception (July 12, 2011) to Dec 31, 2011

(July 12, 2011) to Dec 31, 2011	Common	Stock	Additional Paid in	(Deficit) Accumulated During the Development	
Description	Shares	Amount	Capital	Stage	Totals
Balance at inception	0	\$	\$	\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0	0	10,000
Net (loss) for the period	0	0	0	-10,000	-10,000
Balance as of December 31, 2011	10,000,000	10,000	0	-10,000	0

Transtech Solutions Inc.
(A Development Stage Company)
Notes to the Financial Statements
December 31, 2011
(Unaudited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Transtech Solutions Inc. ("the Company") was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2011 the Company has \$0 in cash.

## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

# b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

## c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

# f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

## h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

## 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between inception (July 12, 2011) to December 31, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christpher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

There were no further issuances of stock as at December 31, 2011.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2011.

## 5. INCOME TAXES

For the year ended December 31, 2011 and from inception (July 12, 2011) to December 31, 2011, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2011, the Company had approximately \$10,000 of federal and state net operating losses.

# Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders Transtech Solutions Inc. (A Development Stage Company)

To the Board of Directors and Stockholders of TRANSTECH SOLUTIONS Inc.

We have reviewed the accompanying balance sheet of TRANSTECH SOLUTIONS Inc. as of December 31, 2011 and the related statements of income, stockholders' equity and comprehensive income, and cash flows for the three month period ended December 31, 2011. These financial statements are the responsibility of the company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompany interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut March 28, 2013

BALANCE SHEETS			
		Dec-31 2012	Dec-31 2011
Asset			
Current Assets			
	Cash	40,048	0
Total Asset		40,048	0
Liabilities and Stockholders' Equity			
Current Liabilities			
	Accounts Payable		
Lang Trans Link Web		•	•
Long Term Liabilities Total Liabilities		0 <b>0</b>	0 <b>0</b>
Total Diabilities		v	U
Shareholder's Equity			
	Common Stock, \$0.001 par		
	value, 75,000,000 shares		
	authorized;		
	50,100,000 shares issued and	40.400	
	outstanding	40,100	10,000
	Additional paid-in-capital Deficit accumulated during	0	0
	the development stage	-10,052	-10,000
Retained Earnings		-10,052	-10,000
Total Stockholder's Equity		-10,052	-10,000
Total liabilities and stockholder's equity		-10,052	-10,000

## **STATEMENT OF OPERATIONS**

Expenses		December 31, 2012	December 31, 2011	For the Period From July 12, 2011 (inception) to December 31, 2012
Expenses	General and Administration	61	5	66
	Incorporations Fees	0	124	124
	Professional Fees Net (loss) from Operation	0	9,871	9,871
	before Taxes	-61	-10,000	-10,061
Other Income		9	0	9
Provision for Income Taxes		0	0	0
Net (loss)		-52	-10,000	-10,052
Basic and Diluted Loss per Common Share Weighted Outstanding Shares			0 50,100,000	0 50,100,000

See Notes to Financial Statements

## STATEMENT OF CASH FLOWS

		December 31, 2012	December 31, 2011	For the Period From July 12, 2011 (inception) to December 31, 2012
Operating Activities				
. •	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities		-52	-10,000	-10,052
Financing Activities				
•	Loans from Director	0	0	0
	Sale of common stock  Net cash provided by financing	40,100	10,000	50,100
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		-52	0	-52
Cash and equivalents at beginning of the period		40,100	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception
(July 12, 2011) to December 31, 2012

(July 12, 2011) to December 31, 2012	Common	Stock	Additional Paid in	(Deficit) Accumulated During the Development	
Description	Shares	Amount	Capital	Stage	Totals
Balance as of July 12, 2011	0	\$	\$	\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0	0	10,000
Net (loss) for the period	0	0	0	(10,000)	-10,000
Balance as of December 31, 2011	10,000,000	10,000	0	(10,000)	0
Common stock issued for cash (\$0.001/share)	40,100,000	40,100	0	0	40,100
Net (loss) for the period	0	0	0	-52	-52
Balance as of December 31, 2012	50,100,000	50,100	0	(10,052)	40,048

Transtech Solutions Inc.
(A Development Stage Company)
Notes to the Financial Statements
December 31, 2012
(Unaudited)

## 1. ORGANIZATION AND BUSINESS OPERATIONS

Transtech Solutions Inc. ("the Company") was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

# b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

## c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

## e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

## f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

# h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# i) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

## 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to ChristopherWeinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. ChristopherWeinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. ChristopherWeinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

# 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

# **Information Not Required In the Prospectus**

# Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT		
SEC Registration Fee*	\$27.28		
Accounting Fees and Expenses*	\$15,000		
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72		
Total*	\$20,000		

<sup>\*</sup> Estimated Figures

#### Indemnification of Directors and Officers

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);

- (3) a transaction from which the director derived an improper personal profit; and
- (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. This advance of expenses is to be made upon receipt of an undertaking by or on behalf of such person to repay said amounts should it be ultimately determined that the person was not entitled to be indemnified under our bylaws or otherwise.

Our bylaws also provide that no advance shall be made by us to any officer in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made: (a) by the board of directors by a majority vote of a quorum consisting of directors who were not parties to the proceeding; or (b) if such quorum is not obtainable, or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, that the facts known to the decision- making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to our best interests.

### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit	
Number	Description
3.1	Articles of Incorporation of Transtech Solutions, Inc.
3.2	Bylaws of Transtech Solutions, Inc.
4.2	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered
23.1	Auditor Consent
23.2	Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

### **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

### The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

### **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on March 28, 2013.

### TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.


**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ ChristopherWeinhaupl ChristopherWeinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director

March 28, 2013



### **CORPORATE CHARTER**


I, ROSS MILLER, the duly elected and qualified Nevada Secretary of State, do hereby certify that TRANSTECH SOLUTIONS INC, did on July 12, 2011, file in this office the original Articles of Incorporation; that said Articles of Incorporation are now on file and of record in the office of the Secretary of State of the State of Nevada, and further, that said Articles contain all the provisions required by the law of said State of Nevada.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on July 12, 2011.

ROSS MILLER

Secretary of State

You may verify this certificate online at http://www.nvsos.gov/







ROSS MILLER Secretary of State 204 North Carson Street, Suite 4 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov

# Articles of Incorporation (PURSUANT TO NRS CHAPTER 78)

Filed in the office of	Document Number
	20110512408-24
· de Mes	Filing Date and Time
Ross Miller	07/12/2011 1:34 PM
Secretary of State	Entity Number
State of Nevada	F0392262011-0

(This document was filed electronically.) ABOVE SPACE IS FOR OFFICE USE ONLY

USE BLACK INK ONLY - D	O NOT HIGHLIGHT		ABOVE SPACE IS FOR OFFICE USE ONLY
1. Name of Corporation:	TRANSTECH SOLUTIONS INC.		
2. Registered Agent for Service of Process: (check only one box)	Commercial Registered Agent: INCS Name Noncommercial Registered Agent (name and address below)	OR Offi	ce or Position with Entity ame and address below)
	Name of Noncommercial Registered Agent OR	Name of Title of Office or Of	her Position with Entity
			Nevada
	Street Address	City	Zip Code
			Nevada
	Mailing Address (if different from street address)	City	Zip Code
3. Authorized Stock: (number of shares corporation is authorized to issue)	Number of shares with par value: 75000000	Par value per share: \$ 0.001	Number of shares without par value:
4. Names and Addresses of the Board of	1) CHRIS WEINHAUPL Name	CALGARY	AB T

<b>Directors/Trustees:</b>	I TO DOTTO TITLE STEEDINGS			
(each Director/Trustee must be a natural person at least 18 years of age;	Street Address	City	State	Zip Code
	2)			
	Name			
attach additional page if more than two				
directors/trustees)	Street Address	City	State	Zip Code
5. Purpose: (optional;	The purpose of the corporation shall be:			
see instructions)				
6. Name, Address				
and Signature of	CHRIS WEINHAUPL	X CHRIS WEINH	AUPL	
Incorporator: (attach	Name	Incorporator Signature		
additional page if more than one incorporator)		CALGARY	AB	
	Address	City	State	Zip Code
7. Certificate of	I hereby accept appointment as Regis	stered Agent for the above named	l Entity.	
Acceptance of				
Appointment of	X INCSMART.BIZ, INC.		7/12/2	ν <b>Λ11</b>
Registered Agent:	INCOMART.DIZ, INC.		: //1.44.4	:U11

This form must be accompanied by appropriate fees.

Nevada Secretary of State NRS 78 Articles Revised: 4-10-09

### BYLAWS OF TRANSTECH SOLUTIONS INC.

July 12, 2011

### **ARTICLE I**

#### OFFICES AND CORPORATE SEAL

SECTION 1.1 Registered Office. Transtech Solutions Inc., (hereinafter the "Corporation") shall maintain a registered office in the State of Nevada. In addition to its registered office, the Corporation shall maintain a principal office at a location determined by the Board. The Board of Directors may change the Corporation's registered office and principal office from time to time.

SECTION 1.2 Other Offices. The Corporation may also maintain offices at such other place or places, either within or without the State of Nevada, as may be designated from time to time by the Board of Directors (hereinafter the "Board"), and the business of the Corporation may be transacted at such other offices with the same effect as that conducted at the principal office.

SECTION 1.3 Corporate Seal. A Corporate seal shall not be requisite to the validity of any instrument executed by or on behalf of the Corporation, but nevertheless if in any instance a corporate seal be used, the same shall be a circle having on the circumference thereof the name of the Corporation and in the center the words "corporate seal", the year incorporated, and the state where incorporated.

#### **ARTICLE II**

### **SHAREHOLDERS**

SECTION 2.1 Shareholders Meetings. All meetings of the shareholders shall be held at the principal office of the Corporation between the hours of 9:00 a.m. and 5:00 p.m., or at such other time and place as may be fixed from time to time by the Board, or in the absence of direction by the Board, by the President or Secretary of the Corporation, either within or without the State of Nevada, as shall be stated in the notice of the meeting or in a duly executed waiver of notice thereof. A special or annual meeting called by shareholders owning a majority of the entire capital stock of the Corporation pursuant to Sections 2.2 or 2.3 shall be held at the place designated by the shareholders calling the meeting in the notice of the meeting or in a duly executed waiver of notice thereof.

SECTION 2.2 Annual Meetings. Annual meetings of a shareholders shall be held on a date designated by the Board of Directors or if that day shall be a legal holiday, then on the next succeeding business day, or at such other date and time as shall be designated from time to time by the Board and stated in the notice of the meeting. At the annual meeting, shareholders shall elect the Board and transact such other business as may properly be brought before the meeting. In the event that an annual meeting is not held on the date specified in this Section 2.2, the annual meeting may be held on the written call of the shareholders owning a majority of the entire capital stock of the Corporation issued, outstanding, and entitled to vote.

SECTION 2.3 Special Meetings of Shareholders. Special meetings of the shareholders, for any purpose or purposes, unless otherwise prescribed by Nevada statute or by the Articles of Incorporation (hereinafter the "Articles"), may be called by the President and shall be called by the President or Secretary at the request in writing of a majority of the Board, or at the request in writing of shareholders owning a majority of the entire capital stock of the Corporation issued, outstanding, and entitled to vote. Such request shall state the purpose or purposes of the proposed meeting. In

the event that the President or Secretary fails to call a meeting pursuant to such a request, a special meeting may be held on the written call of the shareholders owning a majority of the entire capital stock of the Corporation issued, outstanding, and entitled to vote.

SECTION 2.4 List of Shareholders. The officer who has charge of the stock transfer books for shares of the Corporation shall prepare and make, no more than two (2) days after notice of a meeting of a shareholders is given, a complete list of the shareholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address and the number of shares registered in the name of each shareholder. Such list shall be open to examination and copying by any shareholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any shareholder present.

SECTION 2.5 Notice of Shareholders Meetings. Written notice of the annual meeting stating the place, date and hour of the meeting and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be given, either personally or by mail, to each shareholder of record entitled to vote at such meeting not less than ten (10) nor more than sixty (60) days before the date of the meeting. If mailed, such notice shall be deemed to be delivered when mailed to the shareholder at his address as it appears on the stock transfer books of the Corporation. Business transacted at any special meeting of shareholders shall be limited to the purposes stated in the notice unless determined otherwise by the unanimous vote of the holders of all of the issued and outstanding shares of the Corporation present at the meeting in person or represented by proxy.

SECTION 2.6 Closing of Transfer Books or Fixing of Record Date. For the purpose of determining shareholders entitled to notice of, or permitted to vote at, any meeting of shareholders or any adjournment thereof, or for the purpose of determining shareholders entitled to receive payment of any dividend, or in order to make a determination of shareholders for any other proper purpose, the board may provide that the stock transfer books shall be closed for a stated period but not to exceed, in any case, sixty (60) days. If the stock transfer books shall be closed for the purpose of determining shareholders entitled to notice of, or permitted to vote at, a meeting of shareholders, such books shall be closed for at least ten (10) days immediately preceding such meeting. In lieu of closing the stock transfer books, the board may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than sixty (60) days and, in case of a meeting of shareholders, not less than ten (10) days prior to the date on which the particular action requiring such determination of shareholders is to be taken. If the stock transfer books are not enclosed and no record date is fixed for the determination of shareholders entitled to notice of, or permitted to vote at, a meeting of shareholders, or for the determination of shareholders entitled to receive payment of a dividend. the record date shall be 4:00 p.m. on the day before the day on which notice of the meeting is given or, if notice is waived, the record date shall be the day on which, and the time at which, the meeting is commenced. When a determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this section. such determination shall apply to any adjournment thereof, provided that the board may fix a new record date for the adjourned meeting and further provided that such adjournments do not in the aggregate exceed thirty (30) days. The record date for determining shareholders entitled to express consent to action without a meeting pursuant to Section 2.9 shall be the date on which the first shareholder signs the consent.

### SECTION 2.7 Quorum and Adjournment.

- (a) The holders of a majority of the shares issued, outstanding, and entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum at all meetings of the shareholders for the transaction of business except as otherwise provided by Nevada statute or by the Articles.
- (b)
  Business may be conducted once a quorum is present and may continue until adjournment of the meeting notwithstanding the withdrawal or temporary absence of sufficient shares to reduce the number present to less than a quorum. Unless the vote of a greater number or voting by classes is required by Nevada statute or the Articles, the

affirmative vote of the majority of the shares then represented at the meeting and entitled to vote on the subject matter shall be the act of the shareholders; provided, however, that if the shares then represented are less than required to constitute a quorum, the affirmative vote must be such as would constitute a majority if a quorum were present; and provided further, that the affirmative vote of a majority of the shares then present shall be sufficient in all cases to adjourn a meeting.

(c) If a quorum shall not be present or represented at any meeting of the shareholders, the shareholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting to another time or place, without notice other than announcement at the meeting at which adjournment is taken, until a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each shareholder of record entitled to vote at the meeting.

SECTION 2.8 Voting. At every meeting of the shareholders, each shareholder shall be entitled to one vote in person or by proxy for each share of the capital stock having voting power held by such shareholder, but no proxy shall be voted or acted upon after six (6) months from its date, unless the proxy provides for a longer period not to exceed seven (7) years.

SECTION 2.9 Action Without Meeting. Any action required or permitted to be taken at any annual or special meeting of shareholders may be taken without a meeting, without prior notice, and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of a majority of the outstanding shares entitled to vote with respect to the subject matter of the action unless a greater percentage is required by law in which case such greater percentage shall be required.

Section 2.10 Waiver. A shareholder's attendance at a meeting shall constitute a waiver of any objection to defective notice or lack of notice of the meeting unless the shareholder objects at the beginning of the meeting to holding the meeting or transacting business at the meeting, and shall constitute a waiver of any objection to consideration of a particular matter at the meeting unless the shareholder objects to considering the matter when it is presented. A shareholder may otherwise waive notice of any annual or special meeting of shareholders by executing a written waiver of notice either before, at or after the time of the meeting.

SECTION 2.11 Conduct of Meetings. Meetings of the shareholders shall be presided over by a chairman to be chosen, subject to confirmation after tabulation of the votes, by a majority of the shareholders entitled to vote at the meeting who are present in person or by proxy. The secretary for the meeting shall be the Secretary of the Corporation, or if the Secretary of the Corporation is absent, then the chairman initially chosen by a majority of the shareholders shall appoint any person present to act as secretary. The chairman shall conduct the meeting in accordance with the Corporation's Articles, Bylaws and the notice of the meeting, and may establish rules for conducting the business of the meeting. After calling the meeting to order, the chairman initially chosen shall call for the election inspector, or if no inspector is present then the secretary of the meeting, to tabulate the votes represented at the meeting and entitled to be cast. Once the votes are tabulated, the shares entitled to vote shall confirm the chairman initially chosen or shall choose another chairman, who shall confirm the secretary initially chosen or shall choose another secretary in accordance with this section. If directors are to be elected, the tabulation of votes present at the meeting shall be announced prior to the casting of votes for the directors.

Section 2.12 Election Inspector. The Board of Directors, in advance of any shareholders meeting, may appoint an election inspector to act at such meeting. If an election inspector is not so appointed or is not present at the meeting, the chairman of the meeting may, and upon the request of any person entitled to vote at the meeting shall, make such appointment. If appointed, the election inspector will determine the number of shares outstanding, the authenticity, validity and effect of proxies and the number of shares represented at the meeting in person and by proxy; receive and count votes, ballots and consents and announce the results thereof; hear and determine all challenges and questions pertaining to proxies and voting; and, in general, perform such acts as may be proper to ensure the fair conduct of the meeting.

### ARTICLE III

### **DIRECTORS**

- SECTION 3.1 Number and Election. The number of directors that shall constitute the whole Board shall initially be one; provided, such number may be changed by the shareholders so long as the number of directors shall not be less than one or more than nine. Directors shall be elected by the shareholders, and each director shall serve until the next annual meeting and until his successor is elected and qualified, or until resignation or removal.
- SECTION 3.2 Powers. The business and affairs of the Corporation shall be managed by the Board, which may exercise all such powers of the Corporation and do all such lawful acts as are not by Nevada statute, the Articles, or these Bylaws directed or required to be exercised or done by the shareholders.
- SECTION 3.3 Resignation of Directors. Any director may resign his office at any time by giving written notice of his resignation to the President or the Secretary of the Corporation. Such resignation shall take effect at the time specified therein or, if no time be specified therein, at the time of the receipt thereof, and the acceptance thereof shall not be necessary to make it effective.
- SECTION 3.4 Removal of Directors. Any director or the entire Board may be removed, with or without cause, by a vote of the holders of a majority of the shares then entitled to vote at an election of directors at a meeting of shareholders called expressly for that purpose.
- SECTION 3.5 Vacancies. Vacancies resulting from the resignation or removal of a director and newly created directorships resulting from any increase in the authorized number of directors shall be filled by the shareholders in accordance with Section 3.1.
- SECTION 3.6 Place of Meetings. Unless otherwise agreed by a majority of the directors then serving, all meetings of the Board of Directors shall be held at the Corporation's principal office between the hours of 9:00 a.m. and 5:00 p.m., and such meetings may be held by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section 3.6 shall constitute presence in person at such meeting.
- SECTION 3.7 Annual Meetings. Annual meetings of the Board shall be held immediately following the annual meeting of the shareholders and in the same place as the annual meeting of shareholders. In the event such meeting is not held, the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the Board, or as shall be specified in a written waiver of notice by all of the directors.
- SECTION 3.8 Regular Meetings. Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board.
- SECTION 3.9 Special Meetings. Special meetings of the Board may be called by the President or the Secretary with seven (7) days notice to each director, either personally, by mail, by telegram, or by telephone; special meetings shall be called in like manner and on like notice by the President or Secretary on the written request of two (2) directors and shall in such case be held at the time requested by those directors, if the President or Secretary fails to call the special meeting as requested, then the meeting may be called by the two requesting directors ad shall be held at the time designated by those directors in the notice.
- SECTION 3.10 Quorum and Voting. A quorum at any meeting of the Board shall consist of a majority of the number of directors then serving, but not less than two (2) directors, provided that if and when a Board comprised of one member is authorized, or in the event that only one director is then serving, then one director shall constitute a quorum. If a quorum shall not be present at any meeting of the Board, the directors then present may adjourn the meeting to another time or place, without notice other than announcement at the meeting, until a quorum shall be present. If a quorum is present, then the affirmative vote of a majority of directors present is the act of the Board of Directors.

SECTION 3.11 Action Without Meeting. Unless otherwise restricted by the Articles of these Bylaws, any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting, if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.

SECTION 3.12 Committee of the Board. The Board, by resolution, adopted by a majority of the full Board, may designate from among its members an executive committee and one or more other committees each of which, to the extent provided in such resolution and permitted by law, shall have and may exercise all the authority of the Board. The Board, with or without cause, may dissolve any such committee or remove any member thereof at any time. The designation of any such committee and the delegation thereto of authority shall not operate to relieve the Board, or any member thereof, of any responsibility imposed by law.

SECTION 3.13 Compensation. To the extent authorized by resolution of the Board and not prohibited or limited by the Articles, these Bylaws, or the shareholders, a director may be reimbursed by the Corporation for his expenses, if any, incurred in attending a meeting of the Board of Directors, and may be paid by the Corporation for his expenses, if any, incurred in attending a meeting of the Board of Directors, and may be paid by the Corporation a fixed sum or a stated salary or both for attending meetings of the Board. No such reimbursement or payment shall preclude any director from serving the Corporation in any such capacity and receiving compensation therefore.

SECTION 3.14 Waiver. A director's attendance at or participation in a meeting shall constitute a waiver of any objection to defective notice or lack of notice of the meeting unless the director objects at the beginning of the meeting or promptly upon his arrival to holding the meeting or transacting business at the meeting and does not thereafter vote for or assent to action taken at the meeting. A director may otherwise waive notice of any annual, regular or special meeting of directors by executing a written notice of waiver either before or after the time of the meeting.

SECTION 3.15 Chairman of the Board. A Chairman of the Board may be appointed by the directors. The Chairman of the Board shall perform such duties as from time to time may be assigned to him by the Board, the shareholders, or these Bylaws. The Vice Chairman, if one has been elected, shall serve in the Chairman's absence.

SECTION 3.16 Conduct of Meetings. At each meeting of the Board, one of the following shall act as chairman of the meeting and preside, in the following order of precedence:

(a)

The Chairman of the Board;

(b)

The Vice Chairman;

(c)

The President of the Corporation; or

(d)

A director chosen by a majority of the directors present, or if a majority is unable to agree on who shall act as chairman, then the director with the earliest date of birth shall act as the chairman.

The Secretary of the Corporation, or if he shall be absent from such meeting, the person whom the chairman of such meeting appoints, shall act as secretary of such meeting and keep the minutes thereof. The order of business and rules of procedure at each meeting of the Board shall be determined by the chairman of such meeting, but the same may be changed by the vote of a majority of those directors present at such meeting. The Board shall keep regular minutes of its proceedings.

### **ARTICLE IV**

#### **OFFICERS**

SECTION 4.1 Titles, Offices, Authority. The officers of the Corporation shall be chosen by the Board of Directors and

shall include a President, a Secretary and a Treasurer, and may, but need not, include a Chairman, a Vice Chairman, a Chief Executive Officer, a Chief Operating Officer, a Vice President, additional Vice Presidents, one or more assistant secretaries and assistant treasurers, or any other officer appointed by the Board. Any number of offices may be held by the same person, unless the Articles or these Bylaws otherwise provide. If only one person is serving as an officer of this Corporation, he or she shall be deemed to be President and Secretary. An officer shall have such authority and shall perform such duties in the management of the Corporation as may be provided by the Articles or these Bylaws, or as may be determined by resolution of the Board or the shareholders in accordance with Article V.

SECTION 4.2 Subordinate Officers. The Board may appoint such subordinate officers, agents or employees as the Board may deem necessary or advisable, including one or more additional Vice Presidents, one or more assistant secretaries, and one or more assistant treasurers, each of whom shall hold office for such period, have authority and perform such duties as are provided in these Bylaws or as the Board may from time to time determine. The Board may delegate to any executive officer or to any committee the power to appoint any such additional officers, agents or employees. Notwithstanding the foregoing, no assistant secretary or assistant treasurer shall have power or authority to collect, account for, or pay over any tax imposed by any federal, state or city government.

SECTION 4.3 Appointment, Term of Office, Qualification. The officers of the Corporation shall be appointed by the Board and each officer shall serve at the pleasure of the Board until the next annual meeting and until a successor is appointed and qualified, or until resignation or removal.

SECTION 4.4 Resignation. Any officer may resign his office at any time by giving written notice of his resignation to the President or the Secretary of the Corporation. Such resignation shall take effect at the time specified therein or, if no time be specified therein, at the time of the receipt thereof, and the acceptance thereof shall not be necessary to make it effective.

SECTION 4.5 Removal. Any officer or agent may be removed by the Board whenever in its judgment the best interests of the Corporation will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Appointment of an officer or agent shall not of itself create contract rights.

SECTION 4.6 Vacancies. A vacancy in any office, because of death, resignation, removal, or any other cause, shall be filled for the unexpired portion of the term in the manner prescribed in Sections 4.1, 4.2 and 4.3 of this Article IV for appointment to such office.

SECTION 4.7 The President. The President shall preside at all meetings of shareholders. The President shall be the principal executive officer of the Corporation and, subject to the control of the Board, shall in general supervise and control all of the business and affairs of the Corporation. He may sign, when authorized by the Board, certificates for shares of the Corporation and deeds, mortgages, bonds, contracts, or other instruments which the Board has authorized to be executed, except in cases where the signing and execution thereof shall be expressly delegated by the Board or by these Bylaws to some other officer or agent of the Corporation, or shall be required by law to be otherwise signed or executed; and in general shall perform all duties incident to the office of the President and such other duties as may be prescribed by the Board from time to time.

SECTION 4.8 The Vice President. Each Vice President shall have such powers and perform such duties as the Board or the President may from time to time prescribe and shall perform such other duties as may be prescribed by these Bylaws. At the request of the President, or in case of his absence or inability to act, the Vice President or, if there shall be more than one Vice President then in office, then one of them who shall be designated for the purpose by the President or by the Board shall perform the duties of the President, and when so acting shall have all powers of, and be subject to all the restrictions upon, the President.

SECTION 4.9 The Secretary. The Secretary shall act as secretary of, and keep the minutes of, all meetings of the Board and of the shareholders; he shall cause to be given notice of all meetings of the shareholders and directors; he shall be the custodian of the seal of the Corporation and shall affix the seal, or cause it to be affixed, to all proper instruments when deemed advisable by him; he shall have charge of the stock book and also of the other books, records and papers of the Corporation relating to its organization as a Corporation, and shall see that the reports, statements and other

documents required by law are properly kept or filed; and he shall in general perform all the duties incident to the office of Secretary. He shall also have such powers and perform such duties as are assigned to him by these Bylaws, and he shall have such other powers and perform such other duties, not inconsistent with these Bylaws, as the Board shall from time to time prescribe. If no officer has been named as Secretary, the duties of the Secretary shall be performed by the President or a person designated by the President.

SECTION 4.10 The Treasurer. The Treasurer shall have charge and custody of, and be responsible for, all the funds and securities of the Corporation and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all monies and other valuable effects in the name of and to the credit of the Corporation in such banks and other depositories as may be designated by the Board, or in the absence of direction by the Board, by the President; he shall disburse the funds of the Corporation as may be ordered by the Board, taking proper vouchers for such disbursements, and shall render to the President and to the directors at the regular meetings of the Board or whenever they may require it, a statement of all his transactions as Treasurer and an account of the financial condition of the Corporation; and, in general, he shall perform all the duties incident to the office of Treasurer and such other duties as may from time to time be assigned to him by the Board. He may sign, with the President or a Vice President, certificates of stock of the Corporation. If no officer has been named as Treasurer, the duties of the Treasurer shall be performed by the President or a person designated by the President.

SECTION 4.11 Compensation. The Board shall have the power to set the compensation of all officers of the Corporation. It may authorize any officer, upon whom the power of appointing subordinate officers may have been conferred, to set the compensation of such subordinate officers.

### ARTICLE V

### AUTHORITY TO INCUR CORPORATE OBLIGATIONS

SECTION 5.1 Limit on Authority. No officer or agent of the Corporation shall be authorized to incur obligations on behalf of the Corporation except as authorized by the Articles or these Bylaws, or by resolution of the Board or the shareholders. Such authority may be general or confined to specific instances.

SECTION 5.2 Contracts and Other Obligations. To the extent authorized by the Articles or these Bylaws, or by resolution of the Board or the shareholders, officers and agents of the Corporation may enter into contracts, execute and deliver instruments, sign and issue checks, and otherwise incur obligations on behalf of the Corporation.

### **ARTICLE VI**

### SHARES AND THEIR TRANSFER

SECTION 6.1 Certificates for Shares. Certificates representing shares of the Corporation shall be in such form as shall be determined by the Board. Such certificates shall be signed by the President or a Vice President and by the Secretary or an assistant secretary. The signatures of such officers upon a certificate may be facsimiles if the certificate is manually signed on behalf of a transfer agent or a registrar, other than the Corporation itself or one of its employees. Each certificate for shares shall be consecutively numbered or otherwise identified. The name and address of the person to whom the shares represented thereby are issued, with the number of shares and date of issue, shall be entered on the stock transfer books of the Corporation. All certificates surrendered to the Corporation for transfer shall be cancelled and no new certificate shall be issued until the former certificate for a like number of shares shall have been surrendered and cancelled, except that in case of a lost, destroyed or mutilated certificate a new one may be issued therefore upon such terms and indemnity to the Corporation as the Board may prescribe.

SECTION 6.2 Issuance. Before the Corporation issues shares, the Board shall determine that the consideration received or to be received for the shares is adequate. A certificate shall not be issued for any share until such share is fully paid.

SECTION 6.3 Transfer of Shares. Transfer of shares of the Corporation shall be made only on the stock transfer books

of the Corporation by the holder of record thereof or by his legal representative, who shall furnish proper evidence of authority to transfer, or by his attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the Corporation, and on surrender for cancellation of the certificate for such shares. The person in whose name shares stand on the books of the Corporation shall be deemed by the Corporation to be the owner thereof for all purposes.

### ARTICLE VII

### FISCAL YEAR

The fiscal year of the Corporation shall be May 31.

#### ARTICLE VIII

### **DIVIDENDS**

From time to time the Board may declare, and the Corporation may pay dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and its Articles.

### ARTICLE IX

### **INDEMNIFICATION**

The Corporation may indemnify and advance litigation expenses to its directors, officers, employees and agents to the extent permitted by law, the Articles or these Bylaws, and shall indemnify and advance litigation expenses to its directors, officers, employees and agents to the extent required by law, the Articles or these Bylaws. The Corporation's obligations of indemnification, if any, shall be conditioned on the Corporation receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Corporation may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

### **ARTICLE X**

### REPEAL, ALTERATION OR AMENDMENT

These Bylaws may be repealed, altered, or amended, or substitute Bylaws may be adopted at any time by a majority of the Board at any regular or special meeting, or by the shareholders at a special meeting called for that purpose. Any amendment made by the shareholders shall be valid.

IN WITNESS WHEREOF, the undersigned, being the directors of Transtech Solutions Inc., adopt the foregoing Bylaws, effective as of the date first written above.

DIRECTOR:

/s/ Christopher Weinhaupl

Christopher Weinhaupl ~ DIRECTOR

### CERTIFICATION

The undersigned, as secretary of Transtech Solutions Inc	, hereby certifies that the foreg	going Bylaws were duly adopted
by the Board of Directors.		

/s/ Christopher Weinhaupl

Christopher Weinhaupl ~ SECRETARY

**Transtech Solutions Inc.** 

Tel: 206.274.4598

Fax: 206.493.2777

e-mail: info@deanlawcorp.com

March 28, 2013

### Via EDGAR

Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Ladies and Gentlemen:

### Re: Transtech Solutions, Inc. (the "Company")

We have acted as special counsel for the Company for the limited purpose of rendering this opinion in connection with the filing of the Registration Statement on Form S-1 with the Securities and Exchange Commission. In our capacity as special counsel to the Company, we have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company, and other documents we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents. Please be advised that, we have reached the following conclusions regarding the offering:

- 1. The Company is a duly and legally organized and existing Nevada State Corporation, with its registered office and principal place of business located in Las Vegas, Nevada. The Articles of Incorporation and corporate registration fees were submitted to the Nevada Secretary of State's office and filed with the office on July 12, 2011. The Company's existence and form is valid and legal pursuant to Nevada law.
- 2. The Company is a fully and duly incorporated Nevada corporate entity. The Company has one class of Common Stock at this time. Neither the Articles of Incorporation, Bylaws, nor amendments thereto, nor subsequent resolutions change the non-assessable characteristics of the Company's common shares of stock. The Common Stock previously issued by the Company is in legal form and in compliance with the laws of the State of Nevada, its Constitution and reported judicial decisions interpreting those laws and when such stock was issued it was duly authorized, fully paid for and non-assessable.
- 3. To our knowledge, the Company is not a party to any legal proceedings nor are there any judgments against the Company, nor are there any actions or suits filed or threatened against it or its officers and directors, in their capacities as such, other than as set forth in the registration statement. We know of no disputes involving the Company and the Company has no claim, actions or inquiries from any federal, state or other government agency, other than as set forth in the registration statement. We know of no claims against the Company or any reputed claims against it at this time, other than as set forth in the registration statement.
- 4. The Company's outstanding shares are all common shares. There are no liquidation preference rights held by any of the Shareholders upon voluntary or involuntary liquidation of the Company.
- 5. The directors and officers of the Company are indemnified against all costs, expenses, judgments and liabilities, including

attorney's fees, reasonably incurred by or imposed upon them or any of them in connection with or resulting from any action, suit or proceedings, civil or general, in which the officer or director is or may be made a party by reason of his being or having been such a director or officer. This indemnification is not exclusive of other rights to which such director or officer may be entitled as a matter of law.


- 6. The Company's Articles of Incorporation presently provide the authority to the Company to issue 75,000,000 shares of common stock, with a par value of \$0.001 per share.
- 7. Under the applicable law of the State of Nevada (including statutory, regulatory and case law), the 20,0000,000 shares of common stock of the Company being registered pursuant to the Registration Statement for resale by the selling shareholders were duly authorized by all necessary corporate action on the part of the Company and are validly issued, fully paid and nonassessable and, when sold as contemplated in the Registration Statement, will continue to be validly issued, fully paid and nonassessable.

We consent to filing this opinion as an exhibit to the Registration statement and also consent to the reference of our name in the prospectus which forms a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Yours very truly,

/s/ Dean Law Corp.

DEAN LAW CORP.



### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Transtech Solutions Inc. of our report dated February 8, 2012, relating to the financial statements for the period from July 12, 2011 (inception) to December 31, 2012, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut March 28, 2013



### UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

### **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 1 to Form S-1, registration statement, received in this Commission on May 10, 2013, under the name of Transtech Solutions Inc., (Now known as: Scription Work Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Mills, Larry ou=Common, ou=Metro DC, ou=OSO, ou=Employee, cn=Mills, Larry.

Digitally signed by Mills, Larry DN: dc=GOV, dc=SEC, dc=AD, email=MillsL@SEC.GOV Date: 2015.09.28 15:09:38 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

But J. File

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM S-1

### Amendment No. 1

## REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

### **Transtech Solutions Inc.**

(Exact name of registrant as specified in its charter)

<u>Nevada</u> (State or other jurisdiction of incorporation or organization) 7374 (Primary Standard Industrial Classification Code Number) 41-2281519 (I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 <u>1 (866) 998-6920</u>

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp.
601 Union Street, Suite 4200
Seattle, Washington 98101
Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public:

as soon as practicable after the effective date of this Registration Statement.

f any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, theck the following box.
f this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
f this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
f this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration tatement number of the earlier effective registration statement for the same offering.
ndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See lefinitions of "large accelerated filer," "accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☑
Do not check if a smaller reporting company)

### **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum		
		Offering	Aggregate	Amount of	
Title of Each Class	Amount to be	Price Per	Offering Price	Registration	
of Securities to be Registered	Registered	Share	(1)	Fee (1)	
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$27.28	

<sup>(1)</sup> Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated May 10, 2013.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

### TRANSTECH SOLUTIONS, INC. 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

#### 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is May 10, 2013.

### TABLE OF CONTENTS

	Pag
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

### **PROSPECTUS SUMMARY**

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Transtech Solutions Inc.

### Company Overview

Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Transtech Solutions intends to purchase our own transcription platform, which our medical transcriptionists will use to transcibe medical documents for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

Regardless of admission on the OTCBB, upon effectiveness of the registration statement, pursuant to Section 15(d) of the Securities Exchange Act, we will be required to file periodic reports with the Commission.

The regulatory requirements imposed on Section 15(d) registrants are more limited than those imposed upon fully reporting companies. Investors in Section 15(d) companies do not have the protections of proxy rules, Section 16 short swing profit requirements, beneficial ownership reporting, institutional investment manager reporting rules, and third party tender offer rules.

### **SUMMARY OF THIS OFFERING**

The Issuer

Transtech Solutions Inc.

Securities being offered

Up to 20,000,000 shares of Common Stock

Offering Type

The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the Offering

The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two years from the effective date of this registration statement.

Securities Issued And to be

Issued

50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of 20,000,000 shares will be sold by existing shareholder

**Use of Proceeds** 

We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for the Selling Stockholders.

### **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

	As of Dec 31, 2012 (Audited)
Balance Sheet	 
Total Assets	\$ 40,048
Total Liabilities	\$ 0
Stockholders' Equity	\$ 40,048
	Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)
Income Statement	
Revenue	\$ -
Total Operating Expenses	\$ 10,052
Net Loss	\$ (10,052)

### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Due to his other business commitments, Mr. Weinhaupl is committed to thirty hours a week to Transtech. This may hinder the speed of future business development, as it may conflict with his current business commitments.

### Risks Relating To Our Common Stock

### Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk or being suspended.

We have less than 300 shareholders, thus risk of the possibility that our reporting obligations will be suspended pursuant to Section 15(d) of the Exchange Act of 1934 due to a limited number of record holders. In that event, protection of investors, such supplementary and periodic information, documents, and reports required will not be available to the shareholders.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

Under the Emerging Growth Company exemption, we will not be required to disclose the evaluation of our internal financial controls.

As an smaller reporting company, under the Emerging Growth Company exemption, we will not be required to make effectiveness evaluations of our internal controls over financials reports, or disclose the results of such evaluations until the filing of our second annual report. Additionally, we will not be required to obtain an auditor attestation with respect to management's conclusions about the effectiveness of internal control over financial reporting so long as we remain a smaller reporting company.

#### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

#### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

#### PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

#### **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

#### Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### **State Securities Laws**

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

#### **Selling Shareholders**

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

		Total Number Of Shares To	)	
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned
Name Of Selling	<b>Shares Owned Prior</b>	For Selling Shareholders	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000	Nii	NII
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000	NII	NII
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco		600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo		600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000	Nil	Nil
Jose Jay N. Briton	100,000	100,000	Nil	Nil
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil
Cherry Grace N. Briton	100,000	100,000	Nil	Nil
Arlene M. Morato	100,000	100,000	Nil	Nil
Ernesto Bejeno	100,000	100,000	Nil	Nil
Emesio Dejeno	100,000	100,000		
Total	20,000,000	20,000,000	Nil	Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

#### **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

#### **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

#### **INFORMATION WITH RESPECT TO REGISTRANT**

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

#### **Description of Business:**

#### Organization:

Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- · Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

#### **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### Market Needs

Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of nonessential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

#### Competition

The competition takes two general forms:

- General transcription service- these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- 2. Specialized medical transcription- there are a number of exclusive medical transcription service providers. The market is controlled by larger companies that have established their brand over the years. Many of the smaller companies that provide are being driven out of the industry due to the larger more reputable companies being able to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

#### Transtech's Competitive Advantage

Many smaller firms in the medical transciption industry are being forced to work within the pressure of new technology, global outsourcing, turnaround-time demands and volume demands. We believe there exists huge potential within the market. Transtech plans to build its reputation on fast-turnaround, accuracy and quality customer service. Despite current industry changes, we believe there is opportunity for our company in this market by turning the pressures of the industry to our advantage. We intend to set up our operation overseas to take advantage of lower operation costs. By having our operations overseas, we will face additional industry pressures such as the language barrier and finding qualified transcriptionists.

#### Plan of Operations

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our founder, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### **Products and Services**

Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

- Next Day Turnaround: Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.
- Physician Portal: Physicians may review and correct the transcribed report using standard Word functionality and any changes are saved to the server and may be accessed or distributed to all users. The physician signs the document with a single mouse click upon which the report is electronically stamped and marked as final. The final report is then distributed based on the user defined distribution rules.
- 98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Transtech plans to guarantee 98% accuracy or better or files are provided free.
- 24 Hour Data Access: Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.
- Quality Assurance: Transtech projects to provide 4 to 6 months of training to all transcriptionists that join
  Transtech. Once training is complete, transcriptionists will be placed in a live environment where all their work is
  scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be promoted to Assistant Quality Assurance
  positions in the Quality Assurance Department. We plan for all transcriptions to be guaranteed for 98% accuracy
  or better based on American Association of Medical Transcription Standards.
- Easy File Transfers: Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Transtech's servers with just 3 clicks of a mouse.
- HIPAA Compliant: Transtech's medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA) guidelines and the HIPAA administrative simplification provision, PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

Platform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

Hire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

Beta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

Acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct or planned operations is approximately twelve months.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Total		\$180,000

#### Management

#### Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has been an accomplished serial entrepreneur over the last 15 years. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Christopher Weinhaupl holds ownership and founder of Canadapack a North American cross boarder Logistics Company, "mypharmacard" a payment processor solution for web based Pharma companies, and "Superframe" an Internet DSL bonding technology for the SMB market.

#### **COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

#### **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

#### **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

#### Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

#### **Outstanding Equity Awards since Inception:**

		OPTION AWA	RDS				STOCK	AWARDS	3
									Equity
								Equity	Incentive
								Incentive	Plan
							Market	Plan	Awards:
							Value	Awards:	Market
			Equity			Number	of	Number	or Payout
			Incentive			of	Shares	of	Value of
			Plan			Shares	or	Unearned	Unearned
			Awards:			or Units	Units	Shares,	Shares,
			Number of			of	of	Units or	Units or
	Number of		Securities			Stock	Stock	Other	Other
	Securities		Underlying			that	that	Rights	Rights
	Underlying		Unexercised	Option		have	have	that have	that have
	Unexercised	Number of Securities	Unearned	Exercise		not	not	not	not
	Options (#)	Underlying Unexercised	Options		Expiration		Vested	Vested	Vested
Name	Exercisable	Options (#) Unexercisable	(#)	(\$)	Date	(#)	(\$)	(\$)	(\$)
(a)	<u>(b)</u>	(c)	(d)	<u>(e)</u>	<u>(f)</u>	(g)	<u>(h)</u>	<u>(i)</u>	(j)
ChristopherWeinhaupl	0	0	0	0	0	0	0	. 0	0

#### **Long-Term Incentive Plans**

We currently have no Long-Term Incentive Plans.

#### **Director Compensation**

None.

#### Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

#### Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

#### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at March 28, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of March 28, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

#### **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

### TRANSTECH SOLUTIONS INC. (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	36
Balance Sheet	37
Statement of Cash Flows	38
Statement of Operations	36
Statement of Stockholders' Equity	37
Notes to Financials	38

### Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders Transtech Solutions Inc. (A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Transtech Solutions Inc (A Development Stage Company)

We have audited the accompanying balance sheets of Transtech Solutions Inc. (A development stage company) as of December 31, 2012, and the related statements of operations, stockholders' equity and cash flows for the period July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Transtech Solutions Inc. as of December 31, 2012, and the results of its operations and its cash flows for the period July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut March 28, 2013

BALANCE SHEETS Asset		Dec-31 2012 (audited)	Dec-31 2011 (audited)
Current Assets Total Asset	Cash	40,048 40,048	0 0
	Accounts Payable		
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued and outstanding Additional paid-in-capital Deficit accumulated during the development stage	50,100 0 (10,052)	10,000 0 (10,000)
Total Stockholder's Equity Total liabilities and stockholder's equity		40,048 <b>40,048</b>	0 <b>0</b>

#### STATEMENT OF OPERATIONS

Expenses	General and Administration Incorporations Fees Professional Fees Net (loss) from Operation before Taxes	December 31, 2012 (audited) 61 0	December 31, 20 (audited) 5 124 9,871 -10,000	For the Period From July 12, 2011 (inception) to December 31, 11 2012 66 124 9,871 -10,061
Other Income Provision for Income Taxes		9	0	9 <sup></sup> 0
Net (loss)		-52	U	U
			-10,000	-10,052
Basic and Diluted Loss per Common Share Weighted Outstanding Shares			0 50,100,000	0 50,100,000

#### STATEMENT OF CASH FLOWS

Occupation Assisting		December 31, 2012 (audited)	December 31, 2011 (audited)	For the Period From July 12, 2011 (inception) to December 31, 2012
Operating Activities	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities	1401 (1055)	-52	-10,000	-10,052
Financing Activities				
	Loans from Director	0	0	0
	Sale of common stock Net cash provided by financing	40,100	10,000	50,100
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		-52	0	-52
Cash and equivalents at beginning of the period		40,100	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0

### STATEMENT OF SHAREHOLDER EQUITY From the Period From Inception

(July 12, 2011) to December 31, 2012	Common	Stock	Additional Paid in	(Deficit) Accumulated During the	
Description	Shares	Amount	Capital	Development Stage	Totals
Balance as of July 12, 2011	0	\$	\$	\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0	0	10,000
Net (loss) for the period	0	0	0	(10,000)	10,000
Balance as of December 31, 2011	10,000,000	10,000	0	(10,000)	0
Common stock issued for cash (\$0.001/share)	40,100,000	40,100	0	0	40,100
Net (loss) for the period	0	0	0	-52	-52
Balance as of December 31, 2012	50,100,000	50,100	0	(10,052)	40,048

Transtech Solutions Inc.
(A Development Stage Company)
Notes to the Financial Statements
December 31, 2012
(Audited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Transtech Solutions Inc. ("the Company") was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

#### c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

#### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

#### g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be

accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

#### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

#### j) Fiscal Periods

The Company's fiscal year end is December 31.

#### k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

#### 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

#### 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

#### Information Not Required In the Prospectus

#### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT
SEC Registration Fee*	\$27.28
Accounting Fees and Expenses*	\$15,000
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72
Total*	\$20,000

<sup>\*</sup> Estimated Figures

#### **Indemnification of Directors and Officers**

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
- (3) a transaction from which the director derived an improper personal profit; and
- (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

#### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit	
Number	scription
3.1	Articles of Incorporation of Transtech Solutions, Inc.
3.2	Bylaws of Transtech Solutions, Inc.
4.1	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered
23.1	Auditor Consent
23.2	Consent of Dean Law Corn (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

#### **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the

offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

#### **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on May 10, 2013.

#### TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director May 10, 2013

#### Via EDGAR

Ivan Griswold United States Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Dear Mr. Griswold:

Re: Transtech Solutions, Inc. (the "Company")
Amendment No.1 to Registration Statement on Form S-1
Filed March 29, 2013
File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. Your comments are reprinted below along with our response and, if applicable, our proposed changes to the Registration Statement:

1. Since you appear to qualify as an "emerging growth company," as defined in the Jumpstart Our Business Startups Act, please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications. Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.

ANSWER: We have not approached potential investors with any written communications. To our knowledge, there have been no published research reports that have been distributed by any brokers or dealers. We are not affiliated with any brokers or dealers in this offering.

2. Transtech Medical Solutions, a Texas-based company, also provides medical transcription services. Please tell us whether you are affiliated with that company; also tell us whether the existence of a business with a substantially similar name in the same business sector creates any investment or other material risks.

ANSWER: We are not affiliated with Transtech Medical Solutions. We were contacted by the legal counsel of Transtech Medical Solutions, and are in the process of changing our company name to Scription Work Solutions Inc to minimize any investment or other material risks.

3. Your cover page disclosure and your disclosure elsewhere in your document indicate that your transaction is a resale offering and that the company will not receive any proceeds from the offering. Please therefore remove the tabular disclosure on the cover page specifying the net proceeds to be received by the company since this disclosure is inconsistent with the terms of your offering. Review your disclosure throughout your document to eliminate similar inconsistent statements that suggest the company will generate proceeds from this offering. As examples, without limitation, we note your statements on page 3 that you will obtain certain proceeds from this offering and on pages 5 and 27 that you hope to raise money through the sale of securities, as contemplated in this offering, and that if sufficient funds are raised, you would be able to launch your company.

ANSWER: The disclosure has been amended to eliminate inconsistent statements that suggest the company will generate proceeds from this offering.

4. Please remove your statements regarding amending the exhibit index to include the legality opinion as Exhibit 5.1.

ANSWER: The statement has been removed.

Prospectus Summary Company Overview, page 5

5. Please include a brief description of what medical transcription solutions entail and what specific medical transcription solutions or platforms you intend to offer. In addition, briefly clarify the steps you have taken or plan to take with respect to developing the solutions you intend to market and discuss your anticipated timing with respect to having a market-ready solution.

ANSWER: The following disclosure has been added.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Transtech Solutions intends to purchase our own transcription platform, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

6. You state both that you will need to raise a minimum of \$200,000 to operate over the next 12 months and that you estimate your costs to be approximately \$20,000 over the next 12 months. Please revise to address this apparent inconsistency.

ANSWER: The disclosure has been amended.

7. You state that your headquarters are located in Las Vegas, Nevada. However, the tabular disclosure on page 31 indicates that your sole officer and director Christopher Weinhaupl resides in Long Beach, California. Please explain how the company's principal executive offices are located in Las Vegas, Nevada, when the company's sole executive appears to reside in Long Beach, California.

ANSWER: The disclosure has been amended. The company's sole executive resides in Calgary. Although the headquarters are located in Nevada, Christopher Weinhaupl travels frequently, and plans to work at both locations once Transtech commences operations.

8. You state that you are endeavoring to be a reporting company due to the transparency provided by the public reporting process. Please revise to clarify that regardless of admission on the OTCBB, upon effectiveness of the registration statement, pursuant to Section 15(d) of the Securities Exchange Act, you will be required to file periodic reports with the Commission. Please also consider adding a risk factor informing potential investors of how the regulatory requirements imposed on Section 15(d) registrants are more limited than those imposed upon fully reporting companies and discuss the resulting risks. For example, investors in Section 15(d) companies do not have the protections of proxy rules, Section 16 short swing profit requirements, beneficial ownership reporting, institutional investment manager reporting rules, and third party tender offer rules.

ANSWER: The disclosure has been amended to include the following:

Regardless of admission on the OTCBB, upon effectiveness of the registration statement, pursuant to Section 15(d) of the Securities Exchange Act, we will be required to file periodic reports with the Commission.

The regulatory requirements imposed on Section 15(d) registrants are more limited than those imposed upon fully reporting companies. Investors in Section 15(d) companies do not have the protections of proxy rules, Section 16 short swing profit requirements, beneficial ownership reporting, institutional investment manager reporting rules, and third party tender offer rules.

#### Risk Factors, page 10

9. It appears likely that you may have less than 300 record holders following the completion of the offering. Please consider adding risk factor that informs stockholders of the possibility that your reporting obligations may be suspended pursuant to Section 15(d) of the Exchange Act of 1934 due to a limited number of record holders as well as the resultant risks in that event.

ANSWER: We have added the following disclosure.

# We have less than 300 record holders following the completion of the offering, and pose the risk or being suspended.

We have less than 300 shareholders, thus risk of the possibility that our reporting obligations will be suspended pursuant to Section 15(d) of the Exchange Act of 1934 due to a limited number of record holders. In that event, protection of investors, such supplementary and periodic information, documents, and reports required will not be available to the shareholders.

10. You assert that you are a shell company as defined in Securities Act Rule 405. Accordingly, please add a risk factor that highlights the unavailability of Securities Act Rule 144 for purposes of meeting the safe harbor requirement from the definition of underwriter, including any effect on the liquidity of your shares and on your ability to attract additional capital to implement your business plan or sustain operations.

ANSWER: The following disclosure has been added.

# We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

11. Please expand your disclosures relating to the Emerging Growth Company exemption, to fully clarify that as a smaller reporting company you will not be required to make the effectiveness evaluations of your internal control over financial reports, and disclose the results of such evaluation, until the filing of your second annual report. Additionally, you will not be required to obtain an auditor attestation with respect to management's conclusion about the effectiveness of internal control over financial reporting for so long as you remain a smaller reporting company.

ANSWER: The following disclosure has been added:

# Under the Emerging Growth Company exemption, we will not be required to disclose the evaluation of our internal financial controls.

As an smaller reporting company, under the Emerging Growth Company exemption, we will not be required to make effectiveness evaluations of our internal controls over financials reports, or disclose the results of such evaluations until the filing of our second annual report. Additionally, we will not be required to obtain an auditor attestation with respect to management's conclusions about the effectiveness of internal control over financial reporting so long as we remain a smaller reporting company.

There is substantial doubt about our ability to continue as a going concern..., page 10

12. This risk factor appears to substantially overlap with the second risk factor on page 12. In order to minimize duplicative disclosure, please consider revising this section to combine these risk factors. Likewise, the risk factors at the bottom of page 13 and top of page 14 addressing penny stocks and the requirements on broker-dealers appear to be duplicative and should similarly be revised.

ANSWER: The disclosure has been amended to include the following:

# Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have

to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

Our lack of an established brand name and relative lack of resources..., page 12

13. You state that you intend to engage in the sale of medical transcription solutions. However, on page 12, you indicate that you will be competing in the day spa soil remediation industry. Please revise to ensure that your intended business is described in a consistent manner.

ANSWER: The disclosure has been amended.

Although we believe that we currently have adequate internal control..., page 14

14. You state that management is required to report on the effectiveness of your internal control over financial reporting for the year ended December 31, 2012 and from the period from inception (July 12, 2011) to December 31, 2012. Please tell us why you believe you are required to comply with paragraphs (a) and (b) of Item 308 of Regulation S-K at December 31, 2012 or revise your disclosures accordingly. We refer you to the Instructions to Item 308 of Regulation S-K.

ANSWER: We are not required to comply with paragraphs (a) and (b) of Item 308 of Regulation S-K at December 31, 2012, and have revised our disclosure accordingly.

## Determination of Offering Price, page 15

15. You state that the selling shareholders may offer their shares "on or off OTCBB." It appears that you should remove the reference to selling shares on the OTCBB since your shares on not quoted there. Please revise or advise.

ANSWER: The disclosure has been revised.

Plan of Distribution; Terms of the Offering, page 17

16. In discussing the offering price, you state that selling shareholders will sell their shares at a fixed price and that thereafter, the sales price may be the market price, a price related to the market price or as some other price. Please revise your disclosure to clarify that the shares will be sold at the fixed price until your shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices.

ANSWER: The disclosure has been revised to the following:

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

## Expense of Registration, page 19

17. You state that you expect to incur \$9,000 in costs relating to the registration of your common stock; however, on page 49, you indicate that you expect to incur \$20,000 in expenses in connection with this offering. Please revise throughout to reconcile this discrepancy.

ANSWER: The disclosure has been amended to reconcile this discrepancy.

#### Selling Shareholders, page 19

18. The information included in this section appears duplicative of the information under the same heading disclosed on page 16. Similarly, we also note that you appear to provide redundant information in Disclosure of Commission Position of Indemnification for Securities Act Liabilities on pages 32 and 33. Please revise your registration statement to eliminate duplicative disclosure sections.

ANSWER: The registration statement has been amended to eliminate duplicative disclosure sections.

Information with Respect to the Registrant, page 23

19. Since you are a development stage company with no current operations, customers or revenues, please ensure that your business description accurately reflects your current business activities and distinguishes your current capabilities from your future business plans. In some instances you describe your business as having current operations. For instance, on page 25 you state that Transtech is providing its customers with a medically-trained transcription service and on page 27 you provide a list of products and services you typically provide. Please revise throughout to provide a clear, consistent and accurate description of your current activities, which are distinguished from your future plans.

ANSWER: The disclosure has been revised throughout to distinguish our current activities with our future plans.

20. Any discussion of your business plans should be balanced with disclosure that your business may not materialize in the event you are unable to execute your plan. For example, on page 23, you state that your company will cater to the healthcare sectors by providing "timely, highly accurate medical transcription of dictated patient reports," and that your technology "will allow an efficient way to manage transcription services on a web-based platform." To the extent your filing continues to include statements that predict accomplishments in the future, expand to provide meaningful discussion of the events or circumstances that may prevent the accomplishment of these objectives.

ANSWER: The disclosure has been amended to provide meaningful discussion of the events or circumstances that may prevent the accomplishment of our objectives.

- 21. Please revise your disclosures to ensure that any qualitative descriptions regarding industry growth are reasonably substantiated. For example, please provide support for the following statements:
- "The growth of the medical transcription field has been spurred due to insurance company requirements for legible notes...," (page 24);
- "For transcription services this means a recent surge in demand for transcription services from customers that are now relying on outsourced service providers," (page 25); and
- "The majority of competition is in the form of small mom & pop companies with annual revenues of less than \$500,000." (page 26).

ANSWER: The disclosure has been amended to ensure that any qualitative descriptions regarding industry growth are reasonably substantiated.

Industry Overview, page 24

22. You state that the Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow six percent from 2010 to 2020. Please ensure that your disclosure is balanced and accurately reflects any reports you cite. For instance, it appears that you should expand your disclosure to explain that according to BLS, this growth rate is slower than average for all occupations. Please also revise any other projections that rely on this study to provide insight into potential industry growth.

ANSWER: The disclosure has been expanded to include that the growth rate is slower than average for all occupations.

23. We note that you have included in your document a hyperlink to the Bureau of Labor Statistics website. Please refer to Securities Act Release No. 33-7856 regarding the implications of including hyperlinked information in your document.

ANSWER: The hyperlink to the Bureau of Labor Statistics website has been removed.

Transtech's Competitive Advantage, page 26

24. You state that many small shops are being pushed out of the industry due to the pressure of new technology, global outsourcing, turnaround time-demands and volume demands. You also indicate that there is significant potential within market. Please provide additional detail explaining why this is an opportunity for your company and how the identified pressures affect your business plans.

ANSWER: The following disclosure has been added:

Despite current industry changes, we believe there is opportunity for our company in this market by turning the

pressures of the industry to our advantage. We will be setting up our operation overseas to take advantage of lower operation costs. By having our operations overseas, we will face additional industry pressures such as the language barrier and finding qualified transcriptionists.

Plan of Operations, page 26

General

25. Please revise to include a liquidity discussion pursuant to Item 303(a)(1) of Regulation S-K and ensure you disclose the minimum period of time that you will be able to conduct your planned operations using currently available capital resources. We refer you also to Instructions 2 and 3 to Item 303(a) of Regulation S-K for additional guidance.

ANSWER: The following disclosure has been added:

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct or planned operations is approximately twelve months.

# Management, page 28

26. Please provide all of the information required by Item 401(a) and (b) of Regulation S-K. In addition, tell us whether you have complied with paragraphs (f) and (g) of this Item.

ANSWER: The registration statement has been amended to include all of the information required by Item 401(a) and (b) of Regulation S-K. We have also complied with paragraphs (f) and (g) of this Item.

27. Please revise the description relating to Mr. Weinhaupl's professional background to ensure that it fully complies with Item 401(e) of Regulation S-K. For example, disclose Mr. Weinhaupl's principal occupations and employment, including the names of the companies or employers, in a chronologically complete manner for the past five years. If Mr. Weinhaupl is currently employed elsewhere, please provide clear disclosure to this effect.

ANSWER: Contacted CHRIS

Employees and Consultants, page 29

28. Mr. Weinhaupl has committed to devote up to 30 hours per week to your company. Please consider including a risk factor discussing the risks associated with the fact that Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company. In addition, tell us what consideration you gave to discussing any conflicts of interest that may arise based on Mr. Weinhaupl's other business activities.

ANSWER: The following disclosure has been added:

# Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Due to his other business commitments, Mr. Weinhaupl is committed to thirty hours a week to Transtech. This may hinder the speed of future business development, as it may conflict with his current business commitments.

29. You include certain expense disclosures, relating ostensibly to your plan of operations, under Legal Proceedings. Please revise, or explain why this disclosure is appropriate in this section.

ANSWER: The disclosure has been revised and placed in the appropriate section.

Certain Relationships and Related Transactions, page 32

30. Please tell us whether Mr. Weinhaupl falls within the definition of the term "promoter" as defined in Rule 405, and consequently whether disclosure regarding his status is required to be included in the registration statement pursuant to Item 404(c) of Regulations S-K

ANSWER: Mr. Weinhaupl does not fall under the definition of the term "promoter" as defined in Rule 405. The disclosure

regarding his status is not required to be included in the registration statement pursuant to Item 404(c) of Regulation S-K.

#### **Financial Statements**

General

31. Please tell us why you included a separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011 when this information is already included alongside the fiscal 2012 financial statements. Alternatively, revise to remove the financial statements and related footnote disclosures on pages 36 – 41 and ensure that your footnote disclosures beginning on page 47 refer to fiscal 2011 operations, where appropriate.

ANSWER: The 2011 audited financial statements and notes to financials have been removed.

Report of Independent Registered Public Accounting Firm, page 35

32. Please revise to ensure that the report from your independent registered public accounting firm opines on the statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012 and for the period from inception (July 12, 2011) to December 31, 2011 in addition to the cumulative-to-date period from July 12, 2011 to December 31, 2012.

ANSWER: The report from our independent registered public accountant has been revised.

33. Tell us why you included the review report of your independent registered public accounting firm on page 42 or revise to remove this report.

ANSWER: The review report from our independent registered public accounting firm has been removed.

# Balance Sheets, page 43

34. Revise to include audited balance sheets in which total assets equals total liabilities and stockholders' equity.

ANSWER: The Balance Sheet has been revised to include an audited balance sheet in which total assets equals total liabilities and stockholders' equity.

#### General

35. Revise to disclose the date through which subsequent events have been evaluated and state whether that date is the date the financial statements were issued or the date the financial statements were available for issuance pursuant to ASC 855-10-50-1.

ANSWER: The following disclosure has been added.

## 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

### Exhibit 23

36. We note that the consent of your independent registered public accounting firm refers to a report dated February 8, 2012; however, the report of the independent registered public accounting firm as filed on page 35 is dated March 28, 2013. Please revise accordingly. Also, to the extent that you make reference to specific financial statements in the consent, please ensure that you refer to all of the audited financial statements. In this regard, we refer you to our comment above under the report of your independent registered public accounting firm. Alternatively, you may choose to refer to the report date only.

ANSWER: The consent of our independent registered public accounting firm has been amended to refer to the correct date.

#### Indemnification of Directors and Officers, page 49

37. The summary of the indemnification provisions of your bylaws does not appear to reflect the provisions of Article IX of your bylaws. For example, your bylaws do not appear to include a provision under which independent legal counsel would provide a written opinion. Please revise this section to ensure that it accurately summarizes the applicable indemnification provisions of your bylaws.

ANSWER: The Indemnification of Directors and Officers has been amended to reflect the provisions of Article IX of our Bylaws.

# Exhibits, page 51

38. Please file the form of subscription agreement that you will require investors in the offering to execute. We note the disclosure at page 51 in this respect.

ANSWER: A form of the subscription agreement has been filed.

Thank you.

Road, Woodbridge, CT

# CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Transtech Solutions Inc. of our report dated March 28, 2013, relating to the financial statements for the period from July 12, 2011 (inception) to December 31, 2012, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut May 10, 2013

# Transtech Solutions Inc 848 N. Rainbow Blvd., Unit 1175 Las Vegas, Nevada 89107

# **Private Placement Subscription Agreement**

Purchaser Information	Name Address	,	(the " <b>Purchaser</b> ")	
	City	Province		
	Postal Code	Country	* · · · · · · · · · · · · · · · · · · ·	
	Telephone Number	DL/SIN/Passport #		
	Signature of Purchase	er		
Payment	**	Fransfer [_] Check / Bank Draft / N	"	
These securities have not been registered under the Securities Act of 1933 (the "US Securities Act") and may not be offered or sold in the United States or to U.S. persons (other than distributors) unless the securities are registered under the US Securities Act, or an exemption from the registration requirements of the US Securities Act is available. Hedging transactions involving these securities may not be conducted unless in compliance with the US Securities Act.  The foregoing Subscription is accepted for and on behalf of Transtech Solutions Inc.:				
By: Date: Christopher Weinhaupl, President				

# 1.0 Purchase and Sale of Shares

1.1 The Purchaser subscribes for and agrees to purchase common shares of Transtech Solutions Inc., a Nevada corporation (the "Issuer") in the amount set out above (the "Shares"), to be recorded in the name of the Purchaser at the address set out above.

# 2.0 Representations, Warranties and Acknowledgements of the Purchaser

- 2.1 No oral representations or oral information furnished to the Purchaser, or relied upon by the Purchaser, in connection with the Purchaser's purchase of the Shares, were in any way inconsistent with the written material provided by the Issuer.
- The Purchaser acknowledges that no information furnished by the Issuer constitutes investment, accounting, legal or tax advice. The Purchaser is relying solely upon itself and its professional advisors, if any, for such advice.
- 2.3 The representations, warranties and acknowledgements of the Purchaser contained in this Section will survive the Closing (as defined below).

#### 2.4 The Purchaser certifies that:

- (a) the Purchaser is not a U.S. person and is not acquiring the securities for the account or benefit of any U.S. person; or
- (b) the Purchaser is a U.S. person who purchased securities in a transaction that did not require registration under the U.S. Securities Act.
- 2.5 The Purchaser agrees not to engage in hedging transactions with regard to the Shares unless in compliance with the US Securities Act.

## 3.0 Representations, Warranties and Acknowledgements of the Issuer

The Issuer acknowledges, represents and warrants as of the date of this Agreement that the Shares, when issued, will be fully paid and non-assessable shares of the Issuer and will be issued free and clear of all liens, charges and encumbrances of any kind whatsoever, subject only to the re-sale restrictions under applicable securities laws.

# 4.0 Restriction of Securities and Disposition

4.1 **No registration**. The Purchaser acknowledges and understands that the Shares have not been registered under the US Securities Act or any other securities laws, are not qualified for resale in the U.S., and that the Shares must be held indefinitely unless subsequently registered under the US Securities Act or an exemption from such registration is available.

The Issuer shall refuse to register any transfer of the Shares not made in accordance with the provisions of Regulation S of the US Securities Act pursuant to registration under the US Securities Act, or pursuant to an available exemption from registration.

4.2 <u>Legending of the Shares</u>. The Purchaser also acknowledges and understands that the certificates representing the Shares will be stamped with the following legend (or substantially equivalent language) restricting transfer in the following manner:

"The transfer of the securities represented by this certificate is prohibited except in accordance with the provisions of Regulation S promulgated under the United States Securities Act of 1933, as amended (the "Act"), pursuant to registration under the Act or pursuant to an available exemption from registration. In addition, hedging transactions involving such securities may not be conducted

unless in compliance with the Act."

The Purchaser hereby consents to the Issuer making a notation on its records or giving instructions to any transfer agent of the Shares in order to implement the restrictions on transfer described in this Agreement.

#### 5.0 Closing

5.1 The Issuer will confirm whether or not the Agreement is acceptable, whereupon the Issuer will deliver to the Purchaser a signed copy of this Agreement (the "Closing"), and within one year shall deliver a certificate representing the Shares, registered in the name of the Purchaser.

### 6.0 Withdrawal of Subscription

6.1 The Purchaser has a two day cancellation right and can cancel this Agreement by sending notice to the Issuer by midnight on the second business day after the Purchaser signs this Agreement.

# 7.0 Miscellaneous

7.1 Except as expressly provided in this Agreement, this Agreement contains the entire agreement between the parties with respect to the Shares and there are no other terms, conditions, representations or warranties whether expressed, implied, or written by statute, by common law, by the Issuer, by the Purchaser or by anyone else.

[END OF SUBSCRIPTION AGREEMENT]



# UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

# **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 2 to Form S-1, registration statement. received in this Commission on June 28, 2013, under the name of Scription Work Solutions, Inc. (Formerly known as: Transtech Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Digitally signed by Mills, Larry DN: dc=GOV, dc=SEC, dc=AD. Mills, Larry ou=Common, ou=Metro DC, ou=Cou=Cou=Employee, cn=Mills, Larry, email=Millst@SEC.GOV Date: 2015.09.28 15:11:19 -04'00' ou=Common, ou=Metro DC, ou=OSO,

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1

Amendment No. 2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# **Scription Work Solutions Inc.**

(Formerly known as: Transtech Solutions Inc.) (Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization) 7374
(Primary Standard Industrial Classification Code Number)

41-2281519 (I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp.
601 Union Street, Suite 4200
Seattle, Washington 98101
Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public:

as soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer □ Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☑
(Do not check if a smaller reporting company)

# **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(I)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$27.28

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated , 2013

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

Scirption Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

#### 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2013.

# TABLE OF CONTENTS

	F	Page
Prospectus Summary		5
The Offering		8
Risk Factors		10
Determination of Offering Price		15
Use of Proceeds		15
Dilution		15
Plan of Distribution; Terms of the Offering		17
Description of Securities		21
Interests of Named Experts and Counsel		22
Description of Business		23
Plan of Operations		26
Management		28
Outstanding Equity Awards since Inception	:	30
Security Ownership of Beneficial Owners and Management		31
Certain Relationships and Related Transactions		32
Commission Position on Indemnification for Securities Act Liabilities		33
Index to Financial Statements	,	F-1

## **PROSPECTUS SUMMARY**

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" fk/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

#### Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. Christopher Weinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be

subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

### **SUMMARY OF THIS OFFERING**

The Issuer Scription Work Solutions Inc, f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

The selling shareholders will sell our shares at a fixed price of \$0.01 per share. Offering Type

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 Per Share Price

per share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the Offering The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no

longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Securities Issued And to be

Issued

50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

**Use of Proceeds** We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for

the Selling Stockholders.

# **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

	As of Dec 31, 2012 (Audited)		
Balance Sheet			
Total Assets	\$	40,048	
Total Liabilities	\$	0	
Stockholders' Equity	\$	40,048	
		Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)	
Income Statement			
Revenue	\$	•	
Total Operating Expenses	\$	10,052	
Net Loss	\$	(10.052)	

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions.

#### Risks Relating To Our Common Stock

## Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

# We have less than 300 record holders following the completion of the offering, and pose the risk or being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both 500 or more security holders and greater than \$10 million in assets. This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

#### We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

#### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

#### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

## PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

## **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

## Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### **State Securities Laws**

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

#### Selling Shareholders

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

Total Number Of Shares To				
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned
Name Of Selling		r For Selling Shareholders	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000		
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000		
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000		Nil
Mirafe Fiel Alferez	100,000	100,000		Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000		Nil
Jose Jay N. Briton	100,000	100,000		Nil
Daryl Nhon N. Briton	100,000	100,000		Nil
Cherry Grace N. Briton	100,000	100,000		Nil
Arlene M. Morato	100,000	100,000		Nil
Ernesto Bejeno	100,000	100,000		Nil
Total	20,000,000	20,000,000		Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### **Preferred Stock**

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

#### **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

#### **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

#### INFORMATION WITH RESPECT TO REGISTRANT

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

## **Description of Business:**

#### Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

#### **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### **Market Needs**

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of nonessential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### Market Growth

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

### Competition

The competition takes two general forms:

- 1. **General transcription service-** these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- Specialized medical transcription- there are a number of exclusive medical transcription service providers. The
  market is controlled by larger companies that have established their brand over the years. Many of the smaller
  companies that provide are being driven out of the industry due to the larger more reputable companies being able
  to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

# Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

#### Plan of Operations

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our founder, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### **Products and Services**

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

- Next Day Turnaround: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.
- Physician Portal: Physicians may review and correct the transcribed report using standard Word functionality
  and any changes are saved to the server and may be accessed or distributed to all users. The physician signs the
  document with a single mouse click upon which the report is electronically stamped and marked as final. The final
  report is then distributed based on the user defined distribution rules.
- 98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.
- 24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.
- Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to
  all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live
  environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be
  promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all
  transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical
  Transcription Standards.
- Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.
- HIPAA Compliant: Scription Work Solutions Inc, f/k/a Transtech's medical transcription services will be fully
  compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA) guidelines and the HIPAA
  administrative simplification provision, PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

Platform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

Hire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

Beta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

Acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct or planned operations is approximately twelve months.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Total		\$180,000

# Management

# Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has been an accomplished serial entrepreneur over the last 15 years. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

# COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

# **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

# **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

# Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

# **Outstanding Equity Awards since Inception:**

		OPTION AWA	ARDS				STOCK	AWARDS	<u>S</u>
									Equity
								Equity	Incentive
								Incentive	Plan
							Market	Plan	Awards:
							Value	Awards:	Market
			Equity			Number	of	Number	or Payout
			Incentive			of	Shares	of	Value of
			Plan			Shares	or	Unearned	Unearned
			Awards:			or Units	Units	Shares,	Shares,
			Number of			of	of	Units or	Units or
	Number of		Securities			Stock	Stock	Other	Other
	Securities		Underlying			that	that	Rights	Rights
	Underlying		Unexercised	Option		have	have	that have	that have
	Unexercised	Number of Securities	Unearned	Exercise	•	not	not	not	not
	Options (#)	Underlying Unexercised	Options		Expiration		Vested	Vested	Vested
Name	Exercisable	Options (#) Unexercisable	(#)	(\$)	Date	(#)	(\$)	(\$)	(\$)
(a)	<u>(b)</u>	(c)	<u>(d)</u>	(e)	<u>(f)</u>	(g)	<u>(h)</u>	<u>(i)</u>	(j)
ChristopherWeinhaupl	0	0	0	0	0	0	0	0	0

#### **Long-Term Incentive Plans**

We currently have no Long-Term Incentive Plans.

# **Director Compensation**

None.

# Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

# SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at March 28, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of March 28, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

#### **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	34
Balance Sheet as of December 31, 2012	3:
Statement of Cash Flows as of December 31, 2012	36
Statement of Operations as of December 31, 2012	3
Statement of Stockholders' Equity as of December 31, 2012	38
Notes to Financials	39
Balance Sheet as of March 31, 2013	41
Statement of Cash Flows as of March 31, 2013	42
Statement of Operations as of March 31, 2013	43
Notes to Financials	44

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc. (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

BAL	ANCI	SHE	ETS
-----	------	-----	-----

Asset		2012 (audited)	2011 (audited)
Current Assets	Cash	40.048	0
Total Asset		40,048	0

# **Accounts Payable**

Shar	ehold	er's	Eq	uity
------	-------	------	----	------

Total Stockholder's Equity Total liabilities and stockholder's equity

Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued		
and outstanding	50,100	10,000
Additional paid-in-capital	0	0
Deficit accumulated during		
the development stage	(10,052)	(10,000)
	40,048	0
	40,048	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF OPERATIONS

Expenses	General and Administration Incorporations Fees Professional Fees Net (loss) from Operation before Taxes	December 31, 2012 (audited) 61 0 0 -61	December 31, 2011 (audited) 5 124 9.871 -10,000	For the Period From July 12, 2011 (inception) to December 31, 2012 66 124 9,871 -10,061
Other Income		9	0	9
Provision for Income Taxes		0	0	0
Net (loss)		-52	-10,000	-10,052
Basic and Diluted Loss per Common Share Weighted Outstanding Shares			0 50,100,000	0 50,100,000

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF CASH FLOWS

Operating Activities		December 31, 2012 (audited)	December 31 2011 (audited)	For the Period From July 12, 2011 (inception) 1, to December 31, 2012
Operating Activities	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities	1101 (1033)	-52	-10,000	-10,052
Financing Activities				
	Loans from Director Sale of common stock Net cash provided by financing	0 40,100	0 10,000	0 50,100
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		-52	0	-52
Cash and equivalents at beginning of the period		40,100	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception
(July 12, 2011) to December 31, 2012

(July 12, 2011) to December 31, 2012	Common	Stock	Additional Paid in	(Deficit) Accumulated During the	
Description	Shares	Amount	Capital	Development Stage	Totals
Balance as of July 12, 2011	0	\$	\$	\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0	0	10,000
Net (loss) for the period	0	0	0	(10,000)	10,000
Balance as of December 31, 2011	10,000,000	10,000	0	(10,000)	0
Common stock issued for cash (\$0.001/share) Net (loss) for the period	40,100,000 0	40,100 0	0 0	0 -52	40,100 -52
Balance as of December 31, 2012	50,100,000	50,100	0	(10,052)	40,048

Scription Work Solutions Inc. (f/k/a: Transtech Solutions Inc.) (A Development Stage Company) Notes to the Financial Statements December 31, 2012 (Audited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Solutions Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

# f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be

accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

# h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

#### j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

# 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

# 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

BALANCE SHEET

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS **AS OF MARCH 31, 2013**

As of March 31, 2012 As of December 31, 2012

		(unaudited)	Audited
Asset Current Assets Total Asset	Cash	34,751 34,751	40,048 40,048
Liabilities and Stockholders' Equity  Current Liabilities	Accounts Payable		
Long Term Liabilities Total Liabilities		o <b>o</b>	0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized;		
	50,100,000 shares issued and outstanding Additional paid-in-capital Deficit Accumulated During Development Stage (Deficit)	50,100 (15,349)	50,100
Total Stockholder's Equity Total (labilities and stockholder's equity See Notes to Financial Statements		34,751 34,751	40,048 <b>40,048</b>

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF MARCH 31, 2013

# STATEMENT OF OPERATIONS

		For the Three Months ended	For the Three Months ended	July 12, 2011 (Inception) to
		March 31, 2013	March 31, 2012	March 31, 2013
Expenses				
SG&A	General and Administration	0	0	66
	Incorporation Fees	0	0	124
	Professional Fees	5,300	0	15,171
	Bank Charges and Interest	(3)	0	(3)
	Other Income	0	0	(9)
Net (loss) from Operation before Taxes		(5,297)	0	(15,367)
Net (loss)		(5,297)	0	(15,367)
Basic and Diluted Loss per Common Share		0	o	
Weighted Outstanding Shares		50,100,000	50,100,000	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF MARCH 31, 2013

# STATEMENT OF CASH FLOWS

		For the Three Months ended March 31, 2013	For the Three Months ended March 31, 2012	July 12, 2011 (Inception) to March 31, 2013
Operating Activities				
	Net (loss)	(5,297)	•	(15,349)
Net cash (used) for operating activities		(5,297)	•	(15,349)
Financing Activities				
•	Loans from Director	0		0
	Sale of common stock	0	•	50,100
	Net cash provided by financing			
	activities	0	•	50,100
Net increase (decrease) in cash and equivalents		5.297	•	(52_
Cash and equivalents at beginning of the period		40,048	•	40,100
Cash and equivalents at end of the period		34,751	-	40,048
Supplemental cash flow information		0		0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		o	0	0

See Notes to Financial Statements

Scription Work Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)
Notes to the Financial Statements
March 31, 2013
(Unaudited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of March 31, 2013 the Company has \$34,751.45 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

# a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

# b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

#### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

# 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on March 31, 2013.

# 5. INCOME TAXES

For the quarter ended March 31, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2013, the Company had approximately \$15,349 of federal and state net operating losses.

# 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

# 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

# DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

# Information Not Required In the Prospectus

# Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT	
SEC Registration Fee*	\$27.28	
Accounting Fees and Expenses*	\$15,000	
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72	
Total*	\$20,000	

<sup>\*</sup> Estimated Figures

#### Indemnification of Directors and Officers

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
- (3) a transaction from which the director derived an improper personal profit; and
- (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

#### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit	
Number	scription
3.1	Articles of Incorporation of Scription Work Solutions, Inc.
3.2	Bylaws of Scription Work Solutions, Inc.
4.1	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered
23.1	Auditor Consent
23.2	Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

# **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the

offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

# **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on June 27, 2013.

SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director June 27, 2013

June 27, 2013

#### Via EDGAR

Ivan Griswold
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No.2 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013
File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. Your comments are reprinted below along with our response and, if applicable, our proposed changes to the Registration Statement:

1. Our preliminary review of your amended registration statement indicates that it fails in numerous material respects to comply with the requirements of the Securities Act of 1933, the rules and regulations under that Act, and the requirements of the form. We will not perform a detailed examination of the registration statement and we will not issue comments because to do so would delay the review of other disclosure documents that do not appear to contain comparable deficiencies.

Specifically, we note that your independent registered public accounting firm did not opine on all of the financial statements included in the filing. In this regard, the auditors should opine on the balance sheets for both December 31, 2012 and 2011. Also, the report of the independent registered public accounting firm should refer to their audit of the statement of operations, stockholders' equity and cash flows for the year ended December 31, 2012; the period from July 12, 2011 (date of inception) to December 31, 2011; and the period from July 12, 2011 (date of inception) to December 31, 2012. In addition, as previously indicated in comment 36 of our letter dated April 25, 2013, to the extent your independent registered public accounting firm makes reference to specific financial statements in their consent, please ensure that they refer to all of the audited financial statements. Alternatively, they may choose to refer to the report date only. Please ensure that the report and consent of your independent registered public accounting firm is revised accordingly.

If you were to request acceleration of the effective date of the registration statement in its present form, we would likely recommend that the Commission deny your request. We suggest that you consider filing a substantive amendment to correct the deficiencies.

ANSWER: The report from our independent registered public accounting firm has been amended to opine on all of the financial statements included in the filing.

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No.1 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013
File No. 333-187609

1. Since you appear to qualify as an "emerging growth company," as defined in the Jumpstart Our Business Startups Act, please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications. Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.

ANSWER: We have not approached potential investors with any written communications. To our knowledge, there have been no published research reports that have been distributed by any brokers or dealers. We are not affiliated with

any brokers or dealers in this offering.

2. Transtech Medical Solutions, a Texas-based company, also provides medical transcription services. Please tell us whether you are affiliated with that company; also tell us whether the existence of a business with a substantially similar name in the same business sector creates any investment or other material risks.

ANSWER: We are not affiliated with Transtech Medical Solutions. We were contacted by the legal counsel of Transtech Medical Solutions, and as of May 24, 2013, have change our company name to Scription Work Solutions, Inc to minimize any investment or other material risks.

3. Your cover page disclosure and your disclosure elsewhere in your document indicate that your transaction is a resale offering and that the company will not receive any proceeds from the offering. Please therefore remove the tabular disclosure on the cover page specifying the net proceeds to be received by the company since this disclosure is inconsistent with the terms of your offering. Review your disclosure throughout your document to eliminate similar inconsistent statements that suggest the company will generate proceeds from this offering. As examples, without limitation, we note your statements on page 3 that you will obtain certain proceeds from this offering and on pages 5 and 27 that you hope to raise money through the sale of securities, as contemplated in this offering, and that if sufficient funds are raised, you would be able to launch your company.

ANSWER: The disclosure has been amended to eliminate inconsistent statements that suggest the company will generate proceeds from this offering.

4. Please remove your statements regarding amending the exhibit index to include the legality opinion as Exhibit 5.1.

ANSWER: The statement has been removed.

Prospectus Summary Company Overview, page 5

5. Please include a brief description of what medical transcription solutions entail and what specific medical transcription solutions or platforms you intend to offer. In addition, briefly clarify the steps you have taken or plan to take with respect to developing the solutions you intend to market and discuss your anticipated timing with respect to having a market-ready solution.

ANSWER: The following disclosure has been added.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

6. You state both that you will need to raise a minimum of \$200,000 to operate over the next 12 months and that you estimate your costs to be approximately \$20,000 over the next 12 months. Please revise to address this apparent inconsistency.

ANSWER: The disclosure has been amended.

7. You state that your headquarters are located in Las Vegas, Nevada. However, the tabular disclosure on page 31 indicates that your sole officer and director Christopher Weinhaupl resides in Long Beach, California. Please explain how the company's principal executive offices are located in Las Vegas, Nevada, when the company's sole executive appears to reside in Long Beach, California.

ANSWER: The disclosure has been amended. The company's sole executive resides in Calgary. Although the headquarters are located in Nevada, Christopher Weinhaupl travels frequently, and plans to work at both locations once Scription Work

Solutions commences operations.

8. You state that you are endeavoring to be a reporting company due to the transparency provided by the public reporting process. Please revise to clarify that regardless of admission on the OTCBB, upon effectiveness of the registration statement, pursuant to Section 15(d) of the Securities Exchange Act, you will be required to file periodic reports with the Commission. Please also consider adding a risk factor informing potential investors of how the regulatory requirements imposed on Section 15(d) registrants are more limited than those imposed upon fully reporting companies and discuss the resulting risks. For example, investors in Section 15(d) companies do not have the protections of proxy rules, Section 16 short swing profit requirements, beneficial ownership reporting, institutional investment manager reporting rules, and third party tender offer rules.

ANSWER: The disclosure has been amended to include the following:

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

# Risk Factors, page 10

9. It appears likely that you may have less than 300 record holders following the completion of the offering. Please consider adding risk factor that informs stockholders of the possibility that your reporting obligations may be suspended pursuant to Section 15(d) of the Exchange Act of 1934 due to a limited number of record holders as well as the resultant risks in that event.

ANSWER: We have added the following disclosure.

We have less than 300 record holders following the completion of the offering, and pose the risk or being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of

Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both 500 or more security holders and greater than \$10 million in assets. This means that your access to information regarding our business will be limited.

10. You assert that you are a shell company as defined in Securities Act Rule 405. Accordingly, please add a risk factor that highlights the unavailability of Securities Act Rule 144 for purposes of meeting the safe harbor requirement from the definition of underwriter, including any effect on the liquidity of your shares and on your ability to attract additional capital to implement your business plan or sustain operations.

ANSWER: The following disclosure has been added.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

11. Please expand your disclosures relating to the Emerging Growth Company exemption, to fully clarify that as a smaller reporting company you will not be required to make the effectiveness evaluations of your internal control over financial reports, and disclose the results of such evaluation, until the filing of your second annual report. Additionally, you will not be required to obtain an auditor attestation with respect to management's conclusion about the effectiveness of internal control over financial reporting for so long as you remain a smaller reporting company.

ANSWER: The following disclosure has been added:

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

There is substantial doubt about our ability to continue as a going concern..., page 10

12. This risk factor appears to substantially overlap with the second risk factor on page 12. In order to minimize duplicative disclosure, please consider revising this section to combine these risk factors. Likewise, the risk factors at the bottom of page 13 and top of page 14 addressing penny stocks and the requirements on broker-dealers appear to be duplicative and should similarly be revised.

ANSWER: The disclosure has been amended to include the following:

# Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

Our lack of an established brand name and relative lack of resources..., page 12

13. You state that you intend to engage in the sale of medical transcription solutions. However, on page 12, you indicate that you will be competing in the day spa soil remediation industry. Please revise to ensure that your intended business is described in a consistent manner.

ANSWER: The disclosure has been amended.

Although we believe that we currently have adequate internal control..., page 14

14. You state that management is required to report on the effectiveness of your internal control over financial reporting for the year ended December 31, 2012 and from the period from inception (July 12, 2011) to December 31, 2012. Please tell us why you believe you are required to comply with paragraphs (a) and (b) of Item 308 of Regulation S-K at December 31, 2012 or revise your disclosures accordingly. We refer you to the Instructions to Item 308 of Regulation S-K.

ANSWER: We are not required to comply with paragraphs (a) and (b) of Item 308 of Regulation S-K at December 31, 2012, and have revised our disclosure accordingly.

Determination of Offering Price, page 15

15. You state that the selling shareholders may offer their shares "on or off OTCBB." It appears that you should remove the reference to selling shares on the OTCBB since your shares on not quoted there. Please revise or advise.

ANSWER: The disclosure has been revised.

Plan of Distribution; Terms of the Offering, page 17

16. In discussing the offering price, you state that selling shareholders will sell their shares at a fixed price and that thereafter, the sales price may be the market price, a price related to the market price or as some other price. Please revise your disclosure to clarify that the shares will be sold at the fixed price until your shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices.

ANSWER: The disclosure has been revised to the following:

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

Expense of Registration, page 19

17. You state that you expect to incur \$9,000 in costs relating to the registration of your common stock; however, on page 49, you indicate that you expect to incur \$20,000 in expenses in connection with this offering. Please revise throughout to reconcile this discrepancy.

ANSWER: The disclosure has been amended to reconcile this discrepancy.

Selling Shareholders, page 19

18. The information included in this section appears duplicative of the information under the same heading disclosed on page 16. Similarly, we also note that you appear to provide redundant information in Disclosure of Commission Position of Indemnification for Securities Act Liabilities on pages 32 and 33. Please revise your registration statement to eliminate duplicative disclosure sections.

ANSWER: The registration statement has been amended to eliminate duplicative disclosure sections.

Information with Respect to the Registrant, page 23

19. Since you are a development stage company with no current operations, customers or revenues, please ensure that your business description accurately reflects your current business activities and distinguishes your current capabilities from your future business plans. In some instances you describe your business as having current operations. For instance, on page 25 you state that Transtech Solutions is providing its customers with a medically-trained transcription service and on page 27 you provide a list of products and services you typically provide. Please revise throughout to provide a clear, consistent and accurate description of your current activities, which are distinguished from your future plans.

ANSWER: The disclosure has been revised throughout to distinguish our current activities with our future plans.

20. Any discussion of your business plans should be balanced with disclosure that your business may not materialize in the event you are unable to execute your plan. For example, on page 23, you state that your company will cater to the healthcare sectors by providing "timely, highly accurate medical transcription of dictated patient reports," and that your technology "will allow an efficient way to manage transcription services on a web-based platform." To the extent your filing continues to include statements that predict accomplishments in the future, expand to provide meaningful discussion of the events or circumstances that may prevent the accomplishment of these objectives.

ANSWER: The disclosure has been amended to provide meaningful discussion of the events or circumstances that may prevent the accomplishment of our objectives.

- 21. Please revise your disclosures to ensure that any qualitative descriptions regarding industry growth are reasonably substantiated. For example, please provide support for the following statements:
- "The growth of the medical transcription field has been spurred due to insurance company requirements for legible notes...," (page 24);
- "For transcription services this means a recent surge in demand for transcription services from customers that are now relying on outsourced service providers," (page 25); and
- "The majority of competition is in the form of small mom & pop companies with annual revenues of less than \$500,000." (page 26).

ANSWER: The disclosure has been amended to ensure that any qualitative descriptions regarding industry growth are reasonably substantiated.

Industry Overview, page 24

22. You state that the Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow six percent from 2010 to 2020. Please ensure that your disclosure is balanced and accurately reflects any reports you cite. For instance, it appears that you should expand your disclosure to explain that according to BLS, this growth rate is slower than average for all occupations. Please also revise any other projections that rely on this study to provide insight into potential industry growth.

ANSWER: The disclosure has been expanded to include that the growth rate is slower than average for all occupations.

23. We note that you have included in your document a hyperlink to the Bureau of Labor Statistics website. Please refer to Securities Act Release No. 33-7856 regarding the implications of including hyperlinked information in your document.

ANSWER: The hyperlink to the Bureau of Labor Statistics website has been removed.

Transtech's Competitive Advantage, page 26

24. You state that many small shops are being pushed out of the industry due to the pressure of new technology, global outsourcing, turnaround time-demands and volume demands. You also indicate that there is significant potential within market.

Please provide additional detail explaining why this is an opportunity for your company and how the identified pressures affect your business plans.

ANSWER: The following disclosure has been added:

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

# Plan of Operations, page 26

#### General

25. Please revise to include a liquidity discussion pursuant to Item 303(a)(1) of Regulation S-K and ensure you disclose the minimum period of time that you will be able to conduct your planned operations using currently available capital resources. We refer you also to Instructions 2 and 3 to Item 303(a) of Regulation S-K for additional guidance.

ANSWER: The following disclosure has been added:

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct or planned operations is approximately twelve months.

# Management, page 28

26. Please provide all of the information required by Item 401(a) and (b) of Regulation S-K. In addition, tell us whether you have complied with paragraphs (f) and (g) of this Item.

ANSWER: The registration statement has been amended to include all of the information required by Item 401(a) and (b) of Regulation S-K. We have also complied with paragraphs (f) and (g) of this Item.

27. Please revise the description relating to Mr. Weinhaupl's professional background to ensure that it fully complies with Item 401(e) of Regulation S-K. For example, disclose Mr. Weinhaupl's principal occupations and employment, including the names of the companies or employers, in a chronologically complete manner for the past five years. If Mr. Weinhaupl is currently employed elsewhere, please provide clear disclosure to this effect.

ANSWER: The following disclosure has been amended to the following:

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

# Employees and Consultants, page 29

28. Mr. Weinhaupl has committed to devote up to 30 hours per week to your company. Please consider including a risk factor discussing the risks associated with the fact that Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company. In addition, tell us what consideration you gave to discussing any conflicts of interest that may arise based on Mr. Weinhaupl's other business activities.

ANSWER: The following disclosure has been added:

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions.

29. You include certain expense disclosures, relating ostensibly to your plan of operations, under Legal Proceedings. Please revise, or explain why this disclosure is appropriate in this section.

ANSWER: The disclosure has been revised and placed in the appropriate section.

Certain Relationships and Related Transactions, page 32

30. Please tell us whether Mr. Weinhaupl falls within the definition of the term "promoter" as defined in Rule 405, and consequently whether disclosure regarding his status is required to be included in the registration statement pursuant to Item 404(c) of Regulations S-K

ANSWER: Mr. Weinhaupl does not fall under the definition of the term "promoter" as defined in Rule 405. The disclosure regarding his status is not required to be included in the registration statement pursuant to Item 404(c) of Regulation S-K.

## **Financial Statements**

## General

31. Please tell us why you included a separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011 when this information is already included alongside the fiscal 2012 financial statements. Alternatively, revise to remove the financial statements and related footnote disclosures on pages 36 – 41 and ensure that your footnote disclosures beginning on page 47 refer to fiscal 2011 operations, where appropriate.

ANSWER: The inclusion of a separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011 was an error. The 2011 audited financial statements and notes to financials have been removed.

Report of Independent Registered Public Accounting Firm, page 35

32. Please revise to ensure that the report from your independent registered public accounting firm opines on the statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012 and for the period from inception (July 12, 2011) to December 31, 2011 in addition to the cumulative-to-date period from July 12, 2011 to December 31, 2012.

ANSWER: The report from our independent registered public accountant has been revised.

33. Tell us why you included the review report of your independent registered public accounting firm on page 42 or revise to remove this report.

ANSWER: The review report from our independent registered public accounting firm has been removed.

## Balance Sheets, page 43

34. Revise to include audited balance sheets in which total assets equals total liabilities and stockholders' equity.

ANSWER: The Balance Sheet has been revised to include an audited balance sheet in which total assets equals total liabilities and stockholders' equity.

## General

35. Revise to disclose the date through which subsequent events have been evaluated and state whether that date is the date the financial statements were issued or the date the financial statements were available for issuance pursuant to ASC 855-10-50-1.

ANSWER: The following disclosure has been added.

## 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

#### Exhibit 23

36. We note that the consent of your independent registered public accounting firm refers to a report dated February 8, 2012; however, the report of the independent registered public accounting firm as filed on page 35 is dated March 28, 2013. Please revise accordingly. Also, to the extent that you make reference to specific financial statements in the consent, please ensure that you refer to all of the audited financial statements. In this regard, we refer you to our comment above under the report of your independent registered public accounting firm. Alternatively, you may choose to refer to the report date only.

ANSWER: The consent of our independent registered public accounting firm has been amended to refer to the correct date.

Indemnification of Directors and Officers, page 49

37. The summary of the indemnification provisions of your bylaws does not appear to reflect the provisions of Article IX of your bylaws. For example, your bylaws do not appear to include a provision under which independent legal counsel would provide a written opinion. Please revise this section to ensure that it accurately summarizes the applicable indemnification provisions of your bylaws.

ANSWER: The Indemnification of Directors and Officers has been amended to reflect the provisions of Article IX of our Bylaws.

Exhibits, page 51

38. Please file the form of subscription agreement that you will require investors in the offering to execute. We note the disclosure at page 51 in this respect.

ANSWER: A form of the subscription agreement has been filed.

Thank you.

## Scription Work Solutions, Inc 848 N. Rainbow Blvd., Unit 1175 Las Vegas, Nevada 89107

## **Subscription Agreement**

	Name		(the " <b>Purchaser</b> ")		
	Address		_		
	City	Province			
Purchaser Information	Postal Code	Country			
	Telephone Number	DL/SIN/Passport #			
	Signature of Purchas	er	9		
	Payment Method Wire Transfer [ ] Check / Bank Draft / Money Order []				
Payment	Number of Shares Purchased X \$0.001 per share =				
These securities have not been registered under the Securities Act of 1933 (the "US Securities Act") and may not be offered or sold in the United States or to U.S. persons (other than distributors) unless the securities are registered under the US Securities Act, or an exemption from the registration requirements of the US Securities Act is available. Hedging transactions involving these securities may not be conducted unless in compliance with the US Securities Act.					
The foregoing Subscription is accepted for and on behalf of Scription Work Solutions Inc.:					
By:Christopher Weinha	upl, President	Date:			

## 1.0 Purchase and Sale of Shares

1.1 The Purchaser subscribes for and agrees to purchase common shares of Scription Work Solutions Inc., a Nevada corporation (the "Issuer") in the amount set out above (the "Shares"), to be recorded in the name of the Purchaser at the address set out above.

## 2.0 Representations, Warranties and Acknowledgements of the Purchaser

- 2.1 No oral representations or oral information furnished to the Purchaser, or relied upon by the Purchaser, in connection with the Purchaser's purchase of the Shares, were in any way inconsistent with the written material provided by the Issuer.
- The Purchaser acknowledges that no information furnished by the Issuer constitutes investment, accounting, legal or tax advice. The Purchaser is relying solely upon itself and its professional advisors, if any, for such advice.
- 2.3 The representations, warranties and acknowledgements of the Purchaser contained in this Section will survive the Closing (as defined below).

#### 2.4 The Purchaser certifies that:

- (a) the Purchaser is not a U.S. person and is not acquiring the securities for the account or benefit of any U.S. person; or
- (b) the Purchaser is a U.S. person who purchased securities in a transaction that did not require registration under the U.S. Securities Act.
- 2.5 The Purchaser agrees not to engage in hedging transactions with regard to the Shares unless in compliance with the US Securities Act.

## 3.0 Representations, Warranties and Acknowledgements of the Issuer

The Issuer acknowledges, represents and warrants as of the date of this Agreement that the Shares, when issued, will be fully paid and non-assessable shares of the Issuer and will be issued free and clear of all liens, charges and encumbrances of any kind whatsoever, subject only to the re-sale restrictions under applicable securities laws.

## 4.0 Restriction of Securities and Disposition

4.1 **No registration**. The Purchaser acknowledges and understands that the Shares have not been registered under the US Securities Act or any other securities laws, are not qualified for resale in the U.S., and that the Shares must be held indefinitely unless subsequently registered under the US Securities Act or an exemption from such registration is available.

The Issuer shall refuse to register any transfer of the Shares not made in accordance with the provisions of Regulation S of the US Securities Act, or pursuant to an available exemption from registration.

4.2 <u>Legending of the Shares</u>. The Purchaser also acknowledges and understands that the certificates representing the Shares will be stamped with the following legend (or substantially equivalent language) restricting transfer in the following manner:

"The transfer of the securities represented by this certificate is prohibited except in accordance with the provisions of Regulation S promulgated under the United States Securities Act of 1933, as amended (the "Act"), pursuant to registration under the Act or pursuant to an available exemption from registration. In addition, hedging transactions involving such securities may not be conducted

unless in compliance with the Act."

The Purchaser hereby consents to the Issuer making a notation on its records or giving instructions to any transfer agent of the Shares in order to implement the restrictions on transfer described in this Agreement.

## 5.0 Closing

5.1 The Issuer will confirm whether or not the Agreement is acceptable, whereupon the Issuer will deliver to the Purchaser a signed copy of this Agreement (the "Closing"), and within one year shall deliver a certificate representing the Shares, registered in the name of the Purchaser.

## 6.0 Withdrawal of Subscription

6.1 The Purchaser has a two day cancellation right and can cancel this Agreement by sending notice to the Issuer by midnight on the second business day after the Purchaser signs this Agreement.

## 7.0 Miscellaneous

7.1 Except as expressly provided in this Agreement, this Agreement contains the entire agreement between the parties with respect to the Shares and there are no other terms, conditions, representations or warranties whether expressed, implied, or written by statute, by common law, by the Issuer, by the Purchaser or by anyone else.

[END OF SUBSCRIPTION AGREEMENT]

, Woodbridge, CT

## CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) of our report dated February 8, 2012, except the Company name change which is as of June 5, 2013, relating to the financial statements for the period from July 12, 2011 (inception) to December 31, 2012, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut June 27, 2013

## UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

## **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 3 to Form S-1, registration statement, received in this Commission on October 7, 2013, under the name of Scription Work Solutions, Inc. (Formerly known as: Scription Work Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Mills, Larry ou=Common, ou=Metro DC, ou ou=Employee, cn=Mills, Larry, on ou=Employee, cn=Mills, Larry, on outside MSEC GOV

Digitally signed by Mills, Larry DN: dc=GOV, dc=SEC, dc=AD, ou=Common, ou=Metro DC, ou=OSO, email=MillsL@SEC.GOV Date: 2015.09.28 15:12:55 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director. Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM S-1

Amendment No. 3

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

## Scription Work Solutions Inc.

(Formerly known as: Transtech Solutions Inc.)
(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

7374

(Primary Standard Industrial Classification Code Number)

41-2281519

(I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp.
601 Union Street, Suite 4200
Seattle, Washington 98101

Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public:	as soon as practicable after the effective date of this Registration Statement
Approximate date of proposed safe to the public:	as soon as dracticable after the effective date of this Registration Statement

Approximate date of proposed sale to the public:	as soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offer check the following box. 区	red on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
If this Form is filed to register additional securities for an offering Securities Act registration statement number of the earlier effective	pursuant to Rule 462(b) under the Securities Act, check the following box and list the registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 4 statement number of the earlier effective registration statement for	162(c) under the Securities Act, check the following box and list the Securities Act registration the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 4 statement number of the earlier effective registration statement for	62(d) under the Securities Act, check the following box and list the Securities Act registration the same offering.
	if filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See naller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer □ Accelerated f	filer □ Non-accelerated filer □ Smaller reporting company ☑

(Do not check if a smaller reporting company)

1

#### CALCULATION OF REGISTRATION FEE

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(1)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$27.28

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated \_\_\_\_\_, 2013

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

## PRELIMINARY PROSPECTUS

Scirption Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

## 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2013.

## TABLE OF CONTENTS

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

## PROSPECTUS SUMMARY

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" f/k/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

## Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

## **SUMMARY OF THIS OFFERING**

**The Issuer** Scription Work Solutions Inc, f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per

share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

**Termination of the Offering** The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no

longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Securities Issued And to be

Issued

50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

Use of Proceeds We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCRB, nor can there be any assurance that such an application for quotation will be approved if filed

the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for

the Selling Stockholders.

## **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

			As of Dec 31, 2012 (Audited)
Balance Sheet Total Assets Total Liabilities Stockholders' Equity		\$ \$ \$	40,048 0 40,048
	· · · · · · · · · · · · · · · · · · ·		Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)
Income Statement Revenue Total Operating Expenses Net Loss		\$ \$ \$	- 10,052 (10,052)

## **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions. Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to our operation. This employment

may also impact his flexibility.

## **Risks Relating To Our Common Stock**

Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk of being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors. officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both in excess of \$10 million and a class of equity securities (other than exempted securities) held of record by either (i) 2,000 persons, or (ii) 500 persons who are not accredited investors. For these purposes, the "held of record" definition in Section 12(g)(5) does not include securities held by persons who received the securities pursuant to an employee compensation plan in transactions exempt from the registration requirements under Section 5 of the Securities Act of 1933, as amended ("Securities Act"). This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our

internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

## Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

## **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

## Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

## PLAN OF DISTRIBUTION: TERMS OF THE OFFERING

## **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

## **Offering Price**

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

## Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company:
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

## Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

## State Securities Laws

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

## **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

## **Selling Shareholders**

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

Total Number Of Shares To					
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned	
Name Of Selling	<b>Shares Owned Prior</b>	For Selling Shareholders	Upon	Upon	
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering	
Domingo Mahusay			NUI	Nil	
Quinatagcan	2,200,000	2,200,000	Nil	NII	
John Michael Bornasal			XIII	NU	
Esmeralda	2,200,000	2,200,000	Nil	Nil	
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil	
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil	
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil	
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil	
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil	
Jacqueline P. Parreno	600,000	600,000	Nil	Nil	
Sarah Carmona	600,000	600,000	Nil	Nil	
Jonell P. Suganob	600,000	600,000	Nil	Nil	
Junneri Canata Cangas	600,000	600,000	Nil	Nil	
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil	
Leonel Canata Francisco	600,000	600,000	Nil	Nil	
Norma Parreno	600,000	600,000		Nil	
Czarina Mae Torres Justo	•	600,000	Nil	Nil	
Michael Tuazon Oris	200,000	200,000	Nil	Nil	
Elmar A. Pomoy	200,000	200,000		Nil	
Jonell M. Dimafelix	100,000	100,000	Nil	Nil	
Evangeline N. Carvajal	100,000	100,000	Nil	Nil	
Richard O. Cinco	100,000	100,000	Nil	Nil	
Roman M. Eleonor	100,000	100,000	Nil	Nil	
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil	
Jericko M. Erodias	100,000	100,000		Nil	
Dinah Parreno	100,000	100,000	Nil	Nil	
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil	
Enric B. Alarca	100,000	100,000		Nil	
Josephine P. Laroa	100,000	100,000		Nil	
Mirafe Fiel Alferez	100,000	100,000		Nil	
Kell B. Esguerra	100,000	100,000	Nil	Nil	
Melvina P. Alib	100,000	100,000		Nil	
Jose Jay N. Briton	100,000	100,000		Nil	
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil	
Cherry Grace N. Briton	100,000	100,000	Nil	Nil	
Arlene M. Morato	100,000	100,000	Nil	Nil	
Ernesto Bejeno	100,000	100,000		Nil	
Total	20,000,000	20,000,000	Nil	Nil	

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;

3. is a broker-dealer; or broker-dealer's affiliate.

## **Description of Securities**

## General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

## **Common Stock**

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

## **Preferred Stock**

We are not authorized to issue any shares of preferred stock.

## **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

## **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

## **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

## INFORMATION WITH RESPECT TO REGISTRANT

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

## **Description of Business:**

## Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions

Assessments

## **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

## Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

## **Market Needs**

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

## **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of non-essential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

## **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

## Competition

The competition takes two general forms:

- 1. **General transcription service-** these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- 2. Specialized medical transcription- there are a number of exclusive medical transcription service providers. The market is controlled by larger companies that have established their brand over the years. Many of the smaller companies that provide are being driven out of the industry due to the larger more reputable companies being able to provide cheaper and faster services.

### **Table of Contents**

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

### Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

### Plan of Operations

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

### Services

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

- Next Day Turnaround: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.
- Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.
- 98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.
- 24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.
- Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical Transcription Standards.
- Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.
- HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPPAA was a result of congressional healthcare reform proponents to reform healthcare. The HIPAA legislation has four primary objectives.
  - 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical conditions
  - 2. Reduce healthcare fraud and abuse
  - 3. Enforce standards for health information
  - 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organizations insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

Platform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

Hire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

Beta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

Acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Description	Description Time period Estimated maximum ex	
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Total		\$180,000

### Management

### Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

### COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

#### Table of Contents

### **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

# **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

### Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

# **Outstanding Equity Awards since Inception:**

		OPTION AW	ARDS				STOCK	AWARDS	
									Equity Incentive
								Equity	Plan
								Incentive	Awards:
							Market	Plan	Market
						Number	Value	Awards:	or
			Equity			of	of	Number	Payout
			Incentive			Shares	Shares	of	Value of
			Plan			or	or	Unearned	Unearned
			Awards:			Units	Units	Shares,	Shares,
			Number of			of	of	Units or	Units or
	Number of		Securities			Stock	Stock	Other	Other
	Securities		Underlying			that	that	Rights	Rights
	Underlying		Unexercised	Option		have	have	that have	that have
	Unexercised	Number of Securities	Unearned	Exercise	Option	not	not	not	not
	Options (#)	Underlying Unexercised	Options	Price	Expiration	Vested	Vested	Vested	Vested
Name	Exercisable	Options (#) Unexercisable	(#)	(\$)	Date	(#)	(\$)	(\$)	(\$)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)
<b>ChristopherWeinhaupl</b>	0	0	0	0		0	0	0	0

### Long-Term Incentive Plans

We currently have no Long-Term Incentive Plans.

# **Director Compensation**

None.

### Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at March 28, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of March 28, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	Christopher Weinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

(1)

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

### CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

# **Table of Contents**

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm			34
Balance Sheet as of December 31, 2012			35
Statement of Cash Flows as of December 31, 2012			36
Statement of Operations as of December 31, 2012			37
Statement of Stockholders' Equity as of December 31, 2012			38
Notes to Financials			39
Balance Sheet as of March 31, 2013			41
Statement of Cash Flows as of March 31, 2013			42
Statement of Operations as of March 31, 2013			43
Notes to Financials			44

### **Table of Contents**

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011 (date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# **BALANCE SHEETS**

Asset		<b>Dec-31 2012</b> (audited)	Dec-31 2011 (audited)
Current Assets	Cash	40,048	0
Total Asset		40,048	0

# **Accounts Payable**

Share	hold	er's	Equ	ity
-------	------	------	-----	-----

Total Stockholder's Equity

Total liabilities and stockholder's equity

Common Stock, \$0.001			
par value, 75,000,000			
shares authorized;			
50,100,000 shares issued			
and outstanding	50,100	10,000	
Additional paid-in-capital	0	0	
Deficit accumulated			
during the development			
stage	(10,052)	(10,000)	
	40,048	0	
	40,048	0	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.)

SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF OPERATIONS

			For the Period	For the Period
			From	From
			July 12, 2011	July 12, 2011
			(inception)	(inception)
		December 31,	to December 31,	to December 31,
		2012	2011	2012
Expenses		(audited)	(audited)	
	General and Administration	61	5	66
	Incorporations Fees	0	124	124
	Professional Fees	0	9,871	9,871
	Net (loss) from Operation			
	before Taxes	-61	-10,000	-10,061
Other Income		9	0	9
Provision for Income Taxes		0	0	0
		1994		
Net (loss)		-52	1870 1870 M	S S Risk
			-10,000	-10,052
*				
Basic and Diluted Loss per Common Share			0	0
Weighted Outstanding Shares			50,100,000	50,100,000
The state of the s			22 N.C. 44	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF CASH FLOWS

STATEMENT OF CASH FLOWS		December 31, 2012 (audited)	July 12, 2011 (inception)	For the Period From July 12, 2011 (inception) to December 31, 2012
Operating Activities				
Net cash (used) for operating activities	Net (loss)	-52 -52	-10,000 -10,000	-10,052 -10,052
Financing Activities				
	Loans from Director Sale of common stock Net cash provided by financing	0 40,100	0 10,000	0 50,100
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		40,048	0	-52
Cash and equivalents at beginning of the period		0	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0
			9	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception (July 12, 2011) to December 31, 2012

(July 12, 2011) to December 31, 2012	Common	Stock	Addi Paid	tional in	(Deficit) Accumulated During the Development	
Description	Shares	Amoun	t Capi	tal	Stage	Totals
Balance as of July 12, 2011	0	\$	\$		\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0		0	10,000
Net (loss) for the period	0	0	0		(10,000)	-10,000
Balance as of December 31, 2011	10,000,000	10,000	0		(10,000)	0
Common stock issued for cash (\$0.001/share)	40,100,0	00	40,100	0	0	40,100
Net (loss) for the period	0		0	0	-52	-52
Balance as of December 31, 2012	50,100,0	00	50,100	0	(10,052)	40,048

Scription Work Solutions Inc. (f/k/a: Transtech Solutions Inc.) (A Development Stage Company) Notes to the Financial Statements December 31, 2012 (Audited)

### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Solutions Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

# b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

### c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

### 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of December 31, 2012 the date the financial statements were issued, and there are no subsequent events to disclose.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS **AS OF JUNE 30, 2013**

BALANCE S	HEET
-----------	------

BALANCE SHEET		As of June 30, 2013	As of December 31, 2012
		(unaudited)	Audited
Asset Current Assets	Cash	33,880	40,048
Total Asset		33,880	40,048
Liabilities and Stockholders' Equity			
Current Liabilities	Accounts Payable		
Long Term Liabilities Total Liabilities		0 <b>0</b>	0 0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued and outstanding	50,100	50,100
	Additional paid-in-capital Deficit Accumulated During Development Stage (Deficit)	(16,220)	(10,052)
Total Stockholder's Equity Total liabilities and stockholder's equity See Notes to Financial Statements		33,880 <b>33,880</b>	40,048 <b>40,048</b>

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

See Notes to Financial Statements

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

# STATEMENT OF CASH FLOWS STATEMENT OF OPERATIONS

		For the Three	For the Three	For the Six	For the Six	July 12, 2011 (Inception)
		Months ended	Months ended	Months Ended	Months ended	to
		June 30, 2013	June 30, 2012	June 30, 2013	June 30, 2012	June 30, 2013
Expenses						
	General and	_	_	(=)	_	
SG&A	Administration	0	0	(7)	0	66
	Incorporation Fees	0	0	0	0	124
	Professional Fees	875	0	6,175	0	16,046
	Bank Charges and	(n)	_	_	_	
	Interest	(3)	0	0	0	(6)
	Other Income	0	0	0	0	(9)
Net (loss) from Operation before Taxes		(872)	0	(6,168)	0	(16,230)
Net (loss)		(872)	0	(6,168)	0	(16,221)
Basic and Diluted Loss per Common Share		0	0		0	0
Weighted Outstanding Shares		50,100,000	50,100,000	50,100,000	. 50,100,000	
			For the Six Months ended	For the Six Months end	ed (Ince	12, 2011 ption) to

		For the Six Months ended June 30, 2013	For the Six <b>Months ended</b> June 30, 2012	July 12, 2011 (Inception) to June 30, 2013
Operating Activities				
Net cash (used) for operating activities	Net (loss)	(6,168) <b>(6,168)</b>	•	(16,220) <b>(16,220)</b>
Financing Activities				
	Loans from Director	0	-	0
	Sale of common stock  Net cash provided by financing	0	•	50,100
	activities	0	•	50,100
Net increase (decrease) in cash and equivalents		(6,168)	•	33,880
Cash and equivalents at beginning of the period		40,048	-	0
Cash and equivalents at end of the period		33,880	-	33,880
Supplemental cash flow information		0		0

Cash paid for:
Interest
Taxes
Mon-Cash Activities

.

;

0	0	0
0	0	0
0	0	0
0	0	0

and the second of the second o

•

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of March 31, 2013 the Company has \$34,751.45 in cash.

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

### g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

# h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

### k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on March 31, 2013.

### 5. INCOME TAXES

For the quarter ended March 31, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2013, the Company had approximately \$15,349 of federal and state net operating losses.

### 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of June 30, 2013 the date the financial statements were issued, and there are no subsequent events to disclose.

# 20,000,000 SHARES COMMON STOCK

### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

# **Information Not Required In the Prospectus**

### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT
SEC Registration Fee*	\$27.28
Accounting Fees and Expenses*	\$15,000
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72
Total*	\$20,000

<sup>\*</sup> Estimated Figures

### **Indemnification of Directors and Officers**

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
- (3) a transaction from which the director derived an improper personal profit; and

(4) willful misconduct.

### **Table of Contents**

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

# Exhibit Number Description

- 3.1 Articles of Incorporation of Scription Work Solutions, Inc.
- 3.2 Bylaws of Scription Work Solutions, Inc.
- 4.1 Form of Subscription Agreement
- 5.1 Opinion of Dean Law Corp, re: the legality of the shares being registered
- 23.1 Auditor Consent
- 23.2 Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

# **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set

forth in the "Calculation of Registration Fee" table in the effective registration statement.

- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

### **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on October 7, 2013.

SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Chief Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director

October 7, 2013

October 7, 2013

### Via EDGAR

Ivan Griswold United States Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No.3 to Registration Statement on Form S-1
Filed June 28, 2013
File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. Your comments are reprinted below along with our response and, if applicable, our proposed changes to the Registration Statement:

### General

1. It appears that you have sought to change your company's name from Transtech Solutions, Inc. to Scription Work Solutions, Inc. However, it does not appear that you have completed the name change in EDGAR. You may contact EDGAR Filer Support if you require assistance in this regard. Further, it appears that a provider of medical transcription software, eScription, which you reference in your document, shares a substantially similar name. Please tell us what consideration you have given to including risk factor disclosure addressing the risks associated with having a name that is substantially similar to one of your competitors.

ANSWER: We have completed the name change in EDGAR. eScription has updated their software's name to The Dragon Medical 360 | eScription as per their website. Furthermore, their company name is Nuance, the reference above refers to names of software they offer. This has created enough of a distinction to not add a risk factor.

2. We note that you filed a current report on Form 8-K on June 6, 2013 to announce that you amended your articles of incorporation to effect a name change. Please note that until your registration statement is declared effective, you are not yet a reporting company under the Exchange Act. Accordingly, Exchange Act reports, including current reports on Form 8-K, are not yet required to be filed. Please file your amended articles of incorporation reflecting your name change as an exhibit to your amended registration statement.

ANSWER: We have filed our amended articles of incorporation reflecting our name change as an exhibit to our amended registration statement.

"Mr. Weinhaupl, the sole employee, officer and director...," page 12

3. Please revise this risk factor to disclose the number of hours per week Mr. Weinhaupl expects to devote to your business. It appears that you should also disclose that, in addition to his involvement with his other businesses, Mr. Weinhaupl is currently employed as Senior Network Support at Enterprise Contact Centers, which may impact his flexibility.

ANSWER: The following has been added to the risk factor:

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to our operation. This employment may also impact his flexibility.

"We have less than 300 record holders following the completion of the...," page 14

4. Please revise to clarify the subheading of this risk factor. In addition, you state that certain disclosure obligations will not apply to you unless you have both 500 or more security holders and greater than \$10 million in assets. Please

amend this disclosure in light of recent amendments to Section 12(g) of the Securities Exchange Act.

ANSWER: The risk factor has been amended in to reflect recent updates to Section 12(g) of the Securities Exchange Act.

Information with Respect the Registrant

Plan of Operations, page 25

5. We note your additional disclosure on page 27 where you state, using the currently available capital resources, the minimum period of time that you will be able to conduct your planned operations is approximately twelve months. However, we also note your disclosures on page 12 where you indicate that you estimate current available financial resources will sustain your operations only through the next few months. Please further revise these disclosures to address the apparent inconsistencies.

ANSWER: The disclosure on page 27 has been updated to be consistent with the disclosure on page 12. The disclosure appears as follows:

Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Products and Services, page 26

6. Your response to prior comment 20 notwithstanding, your discussion in this section requires additional revisions. Although this section is titled "Products and Services," it is unclear how the term "products" is applicable to your business as it appears that you intend to offer solely transcription services. In addition, your descriptions of the Physician Portal appear to suggest that the portal is currently operational. Please revise as appropriate.

ANSWER: We have updated the heading of this section to "Services". Reference to physician Portal has been amended to the following:

Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

7. We note your disclosure that your company's services will be fully compliant with the Health Insurance Portability and Accountability Act of 1996. Please clarify how the Act impacts your services and expand your disclosure to describe what is required in order for you to be HIPAA compliant. Refer to Item 101(h)(4)(ix) of Regulation S-K.

ANSWER: We have updated the disclosure to the following:

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPPAA was a result of congressional healthcare reform proponents to reform healthcare. The HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical conditions
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organizations insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of

the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Directors, Executive Officers, Promoters and Control Persons, page 27

8. You state that Christopher Weinhaupl has been "an accomplished serial entrepreneur" over the last 15 years. Please reasonably substantiate this characterization in your document or revise your disclosure as necessary.

ANSWER: This disclosure has been updated to state the following:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur.

Certain Relationships and Related Transactions, page 32

9. We note your response to prior comment 30. Please provide us with your analysis supporting your view that Mr. Weinhaupl is not a promoter. In this regard, we note your disclosure on page 25 that Mr. Weinhaupl is your founder and specifically refer you to paragraph (1)(i) of the definition of promoter in Securities Act Rule 405. Alternatively, revise your disclosure to provide the information required by Item 404(c) of Regulation S-K.

ANSWER: The disclosure on page 25 has been amended to refer to Mr. Weinhaupl as our CEO.

### Financial Statements

### General

10. We note you removed the separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011, in response to our prior comment 31. However, we also note there is no reference to such financial statements in the index on page 33 and you do not include any information for that period in the Notes to the financial statements. Please revise the Notes to include any appropriate disclosures for such period. In addition, please revise the index to include reference to each of the respective financial statements as of December 31, 2011 and for the period from inception (July 12, 2011) to December 31, 2011. Alternatively, remove all references to the dates and refer only to the respective financial statements and the related pages.

ANSWER: The Financial Statements have been amended.

11. Revise the column header for December 31, 2011 in both the Statement of Operations and Statement of Cash Flows to refer to the period from inception (July 12, 2011) to December 31, 2011.

ANSWER: The Statement of Operations and Statement of Cash Flows has been amended to reflect the correct dates.

### Statement of Cash Flows, page 37

12. The net increase (decrease) in cash and equivalents for the year ended December 31, 2012 should be \$40,048 and cash and cash equivalents at beginning of period should be \$0. Please revise accordingly. In addition, ensure that the amounts for the period from July 12, 2011 (inception) to December 31, 2012 and July 12, 2011 (inception) to March 31, 2013 are properly corrected as well.

ANSWER: The Statements of Cash Flows have been updated.

Notes to Financial Statements

Note 5 Subsequent Events, page 40

13. We note this additional disclosure. Please revise to state, as requested in our prior comment 35, the date through which subsequent events have been evaluated and state whether that date is the date the financial statements were issued or the date the financial statements were available for issuance pursuant to ASC 855-10-50-1. Similar revisions should be made to the Note 6 on page 45.

ANSWER: In accordance with ASC 855, management evaluated the subsequent events through the date of June 30, 2013, the date the financial statements were issued, and there are no subsequent events to disclose.

March 31, 2013 Financial Statements

Statement of Operations, page 42

14. Your statement of operations for the period from July 12, 2011 (Inception) to March 31, 2013 does not foot. Please revise accordingly.

ANSWER: The statement of operations has been amended to reconcile this discrepancy.

Part II

Exhibit 5.1

15. Given the company's name change, please have the legality opinion updated to reflect the company's new name.

ANSWER: The legality opinion has been amended to reflect the company's new name.

### Exhibit 23

16. The revised consent refers to the report of the independent registered public accounting firm, dated February 8, 2012, except for the company name change which is as of June 5, 2013. The date of such report on page 34 is February 8, 2013, except for the company name change which is as of June 5, 2013. Please revise accordingly.

ANSWER: The consent has been updated.

17. Also, we note that you continue to reference specific financial statements in the consent of your independent registered public accounting firm. As stated in our prior comment 36, to the extent that you make reference to specific financial statements in the consent, please ensure that you refer to all of the audited financial statements. In this regard, revise to refer to the balance sheets for both December 31, 2012 and 2011 and the statement of operations, stockholders' equity and cash flows for the year ended December 31, 2012; the period from July 12, 2011 (date of inception) to December 31, 2011; and the period from July 12, 2011 (date of inception) to December 31, 2012. Alternatively, as we previously indicated, you may choose to refer to the report date only.

ANSWER: The consent has been updated.

Thank you.

# NEVADA STATE BUSINESS LICENSE

### SCRIPTION WORK SOLUTIONS INC

### Nevada Business Identification # NV20111458864

Expiration Date: July 31, 2013

In accordance with Title 7 of Nevada Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed fees, the above anmed is hereby granted a Nevada State Business License for business activities conducted within the State of Nevada.


This license shall be considered valid until the expiration date listed above unless suspended or revoked in accordance with Title 7 of Nevada Revised Statutes.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on May 24, 2013.

ROSS MILLER

Secretary of State

You may verify this certificate online at http://www.nvsos.gov/







**ROSS MILLER** Secretary of State 204 North Carson Street, Suite 4 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov

# Articles of Incorporation (PURSUANT TO NRS CHAPTER 78)

Filed in the office of	Document Number	
	20110512408-24	
· da Ma	Filing Date and Time	
Ross Miller	07/12/2011 1:34 PM	
Secretary of State	Entity Number	
State of Nevada	E0392262011-0	

(This document was filed electronically.)

USE BLACK INK ONLY - DO	) NOT HIGHLIGHT		ABOVE SPACE IS FOR O	OFFICE USE OF
1. Name of Corporation:	TRANSTECH SOLUTIONS INC.			
2. Registered Agent for Service of Process: (check only one box)	Commercial Registered Agent: INCS1 Name Noncommercial Registered Agent (name and address below)	OR Offi	ce or Position with Entity ame and address below)	
	Name of Noncommercial Registered Agent OR	Name of Title of Office or Ot		***************************************
	Street Address	City	Nevada	ip Code
	Olifet Addless	Ony	Nevada	ip odde
	Mailing Address (if different from street address)	City	Z	ip Code
3. Authorized Stock: (number of shares corporation is authorized to issue)	Number of shares with par value: 75000000	Par value per share: \$ 0.001	Number of shares without par value:	0
4. Names and Addresses of the Board of	1) CHRIS WEINHAUPL Name	CALGARY	AB	

Directors/Trustees: (each Director/Trustee	Street Address	City	State	Zip Code
must be a natural person	2)		•••••	··········
at least 18 years of age; attach additional page if	Name			
more than two directors/trustees)	Street Address	City	State	Zip Code
5. Purpose: (optional; see instructions)	The purpose of the corporation shall be:			
A. M				
6. Name, Address and Signature of	CHRIS WEINHAUPL	X CHRIS WEINHA	UPL	
and Signature of incorporator: (attach	CHRIS WEINHAUPL	CHRIS WEINHA Incorporator Signature	UPL	
and Signature of Incorporator: (attach additional page if more			UPL AB	
and Signature of incorporator: (attach		Incorporator Signature		Zip Code
and Signature of Incorporator: (attach additional page if more	Name	Incorporator Signature  CALGARY  City	AB State	Zip Code
and Signature of incorporator: (attach additional page if more than one incorporator)  7. Certificate of	Name Accress	Incorporator Signature  CALGARY  City	AB State	

This form must be accompanied by appropriate fees.

Nevada Secretary of State NRS 78 Articles Revised: 4-10-09

Tel: 206.274.4598

Fax: 206.493.2777

e-mail: info@deanlawcorp.com

July 31, 2013

#### Via EDGAR

Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Ladies and Gentlemen:

### Re: Scription Work Solutions Inc. (the "Company")

We have acted as special counsel for the Company for the limited purpose of rendering this opinion in connection with the filing of the Registration Statement on Form S-1 with the Securities and Exchange Commission. In our capacity as special counsel to the Company, we have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company, and other documents we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents. Please be advised that, we have reached the following conclusions regarding the offering:

- 1. The Company is a duly and legally organized and existing Nevada State Corporation, with its registered office and principal place of business located in Las Vegas, Nevada. The Articles of Incorporation and corporate registration fees were submitted to the Nevada Secretary of State's office and filed with the office on July 12, 2011. The Company's existence and form is valid and legal pursuant to Nevada law.
- 2. The Company is a fully and duly incorporated Nevada corporate entity. The Company has one class of Common Stock at this time. Neither the Articles of Incorporation, Bylaws, nor amendments thereto, nor subsequent resolutions change the non-assessable characteristics of the Company's common shares of stock. The Common Stock previously issued by the Company is in legal form and in compliance with the laws of the State of Nevada, its Constitution and reported judicial decisions interpreting those laws and when such stock was issued it was duly authorized, fully paid for and non-assessable.
- 3. To our knowledge, the Company is not a party to any legal proceedings nor are there any judgments against the Company, nor are there any actions or suits filed or threatened against it or its officers and directors, in their capacities as such, other than as set forth in the registration statement. We know of no disputes involving the Company and the Company has no claim, actions or inquiries from any federal, state or other government agency, other than as set forth in the registration statement. We know of no claims against the Company or any reputed claims against it at this time, other than as set forth in the registration statement.
- 4. The Company's outstanding shares are all common shares. There are no liquidation preference rights held by any of the Shareholders upon voluntary or involuntary liquidation of the Company.
- 5. The directors and officers of the Company are indemnified against all costs, expenses, judgments and liabilities, including

attorney's fees, reasonably incurred by or imposed upon them or any of them in connection with or resulting from any action, suit or proceedings, civil or general, in which the officer or director is or may be made a party by reason of his being or having been such a director or officer. This indemnification is not exclusive of other rights to which such director or officer may be entitled as a matter of law.


- 6. The Company's Articles of Incorporation presently provide the authority to the Company to issue 75,000,000 shares of common stock, with a par value of \$0.001 per share.
- 7. Under the applicable law of the State of Nevada (including statutory, regulatory and case law), the 20,0000,000 shares of common stock of the Company being registered pursuant to the Registration Statement for resale by the selling shareholders were duly authorized by all necessary corporate action on the part of the Company and are validly issued, fully paid and nonassessable and, when sold as contemplated in the Registration Statement, will continue to be validly issued, fully paid and nonassessable.

We consent to filing this opinion as an exhibit to the Registration statement and also consent to the reference of our name in the prospectus which forms a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Yours very truly,

/s/ Dean Law Corp.

DEAN LAW CORP.



## CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) of our report dated February 8, 2012, except the Company name change which is as of June 5, 2013, relating to the financial statements for the period from July 12, 2011 (inception) to December 31, 2012, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut June 27, 2013



# **UNITED STATES OF AMERICA**

SECURITIES AND EXCHANGE COMMISSION

# **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 4 to Form S-1, registration statement, received in this Commission on October 7, 2013, under the name of Scription Work Solutions Inc. (Formerly known as: Transtech Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Digitally signed by Mills, Larry
DN: dc=GOV, dc=SEC, dc=AD,
ou=Common, ou=Metro DC, ou=OSO.
ou=Employee, cn=Mills, Larry, email=MillsL@SEC.GOV Date: 2015.09.28 15:14:56 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director. Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1

Amendment No. 4

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# Scription Work Solutions Inc.

(Formerly known as: Transtech Solutions Inc.) (Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation or organization)

(Primary Standard Industrial Classification Code Number)

41-2281519 (I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp. 601 Union Street, Suite 4200 Seattle, Washington 98101

Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public:

as soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer." "accelerated filer." and "smaller reporting company in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer 
Accelerated filer 
Non-accelerated filer 
Smaller reporting company

(Do not check if a smaller reporting company)

## **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(1)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$27.28

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated \_\_\_\_\_, 2013

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

Scirption Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

# 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2013.

**Explanatory Note** 

This Amendment No.4 on Form S-1/A (this "Amendment") amends the Registration Statement on Form S-1 for the quarter ended June 30, 2013 which the Registrant previously filed with the Securities and Exchange Commission on October 7, 2013 (the "Original Filing"). The Registrant is filing this Amendment to include the Auditor Consent file which failed to properly upload to EDGAR with the main document files on the EDGARized version of the Original Filing.

Except as set forth above, the Original Filing has not been amended, updated or otherwise modified. Other events occurring after the filing of the Form S-1/A or other disclosures necessary to reflect subsequent events have been addressed in our reports filed with the Securities and Exchange Commission subsequent to the filing of this Form S-1.

# TABLE OF CONTENTS

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

#### PROSPECTUS SUMMARY

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" f/k/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

#### Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of

our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

# **SUMMARY OF THIS OFFERING**

The Issuer Scription Work Solutions Inc. f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per

share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the Offering The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no

longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Securities Issued And to be

Issued

50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

Use of Proceeds We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for

the Selling Stockholders.

# **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

	As of Dec 31, 2012 (Audited)	
Balance Sheet		
Total Assets	\$ 40,048	
Total Liabilities	\$ C	
Stockholders' Equity	\$ 40,048	
	Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)	
Income Statement		
Revenue	\$ •	
Total Operating Expenses	\$ 10,052	
Net Loss	\$ (10,052)	

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions. Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to our operation. This employment may also impact his flexibility.

#### Risks Relating To Our Common Stock

## Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

# If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

# We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk of being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both in excess of \$10 million and a class of equity securities (other than exempted securities) held of record by either (i) 2,000 persons, or (ii) 500 persons who are not accredited investors. For these purposes, the "held of record" definition in Section 12(g)(5) does not include securities held by persons who received the securities pursuant to an employee compensation plan in transactions exempt from the registration requirements under Section 5 of the Securities Act of 1933, as amended ("Securities Act"). This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

#### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

#### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

# PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

# **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

## Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### **State Securities Laws**

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

# **Selling Shareholders**

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

		Total Number Of Shares To	1	
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned
Name Of Selling	Shares Owned Prior	r For Selling Shareholders	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	
Domingo Mahusay			N.13	X1''
Quinatagcan	2,200,000	2,200,000	Nil	Nil
John Michael Bornasal	., . ,	_,,	N.121	N.111
Esmeralda	2,200,000	2,200,000	Nil	Nil
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Heman de la Pena	2,200,000	2,200.000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomov	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000	Nil	Nil
Jose Jay N. Briton	100,000	100,000	Nil	Nil
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil
Cherry Grace N. Briton	100,000	100,000	Nil	Nil
Arlene M. Morato	100,000	100,000	Nil	Nil
Ernesto Bejeno	100,000	100,000	Nil	Nil
Total	20,000,000	20,000,000	Nil	Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

# **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

# **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

#### INFORMATION WITH RESPECT TO REGISTRANT

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

#### **Description of Business:**

#### Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

# **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### Market Needs

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of nonessential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### Market Growth

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

Competition

The competition takes two general forms:

- 1. General transcription service- these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- Specialized medical transcription- there are a number of exclusive medical transcription service providers. The
  market is controlled by larger companies that have established their brand over the years. Many of the smaller
  companies that provide are being driven out of the industry due to the larger more reputable companies being able
  to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

#### Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

#### Plan of Operations

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our CEO, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### Services

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

- Next Day Turnaround: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.
- Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.
- 98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.
- 24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.
- Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to
  all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live
  environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be
  promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all
  transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical
  Transcription Standards.
- Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.
- HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPPAA was a result of congressional healthcare reform proponents to reform healthcare. The HIPAA legislation has four primary objectives.
  - 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical conditions
  - 2. Reduce healthcare fraud and abuse
  - 3. Enforce standards for health information
  - 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organizations insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical

transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

Platform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

Hire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

Beta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

Acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Total		\$180,000

#### Management

#### Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

#### **COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

#### **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

#### **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

#### Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

#### **Outstanding Equity Awards since Inception:**

		OPTION AWA	RDS				STOCK	AWARDS	S
		•						Equity Incentive	Equity Incentive Plan
							Market	Plan	Awards:
							Value	Awards:	Market
			Equity			Number	of		or Payout
			Incentive			of	Shares	of	Value of
			Plan			Shares	or	Unearned	Unearned
			Awards:			or Units	Units	Shares,	Shares,
			Number of			of	of	Units or	Units or
	Number of		Securities			Stock	Stock	Other	Other
	Securities		Underlying			that	that	Rights	Rights
	Underlying		Unexercised	Option		have	have	that have	that have
	Unexercised	Number of Securities	Unearned	Exercise	Option	not	not	not	not
	Options (#)	Underlying Unexercised	Options	Price	Expiration	Vested	Vested	Vested	Vested
Name	Exercisable	Options (#) Unexercisable	(#)	(\$)	Date	(#)	(\$)	(\$)	(\$)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)
ChristopherWeinhaupl	0	0	0	0	0	0	0	0	0

#### **Long-Term Incentive Plans**

We currently have no Long-Term Incentive Plans.

#### **Director Compensation**

None.

#### Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

#### Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

#### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at March 28, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of March 28, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

#### **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	34
Balance Sheet as of December 31, 2012	3:
Statement of Cash Flows as of December 31, 2012	30
Statement of Operations as of December 31, 2012	3.
Statement of Stockholders' Equity as of December 31, 2012	. 38
Notes to Financials	39
Balance Sheet as of March 31, 2013	4
Statement of Cash Flows as of March 31, 2013	. 43
Statement of Operations as of March 31, 2013	4:
Notes to Financials	44

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc. (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

Total liabilities and stockholder's equity

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

BALANCE SHEETS			
Asset Current Assets		Dec-31 2012 (audited)	Dec-31 2011 (audited)
Current Assets	Cash	40,048	0
Total Asset		40,048	Ō
	Accounts Payable		
Shareholder's Equity	1		
• •	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued		
	and outstanding Additional paid-in-capital Deficit accumulated during the development	50,100 0	10,000 0
	stage	(10,052)	(10,000)
Total Stockholder's Equity		40,048	0
		40 0 40	Λ.

40,048

## SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.)

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

#### **STATEMENT OF OPERATIONS**

Expenses	General and Administration Incorporations Fees Professional Fees Net (loss) from Operation before Taxes	December 31, 2012 (audited) 61 0 0 -61	For the Period From July 12, 2011 (inception) to December 31, 2011 (audited) 5 124 9,871	For the Period From July 12, 2011 (inception) to December 31, 2012 66 124 9,871
Other Income		9	0	9
Provision for Income Taxes		0	0	0
Net (loss)		-52	-10,000	-10,052
Basic and Diluted Loss per Common Share			0	0
Weighted Outstanding Shares			50,100,000	50,100,000

See Notes to Financial Statements

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

#### STATEMENT OF CASH FLOWS

		December 31, 2012 (audited)	July 12, 2011 (inception)	For the m Period From July 12, 2011 (inception) er to December 31, 2012
Operating Activities		(uuuntuu)	(uuuiteu)	
. •	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities		-52	-10,000	-10,052
Financing Activities			•	
	Loans from Director	0	0	0
	Sale of common stock Net cash provided by financing	40,100	10,000	50,100
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		40,048	0	-52
Cash and equivalents at beginning of the period		0	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0 .	0

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

#### STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception
(July 12, 2011) to December 31, 201

Description   Shares   Amount   Capital   Stage   Total	(July 12, 2011) to December 31, 2012	Common	Stock	Additional Paid in	(Deficit) Accumulated During the	
Common stock issued for cash (\$0.001/share)       10,000,000 10,000 0 0 0 10,000 0 0 0 10,000 1	Description	Shares	Amount	Capital	Development Stage	Totals
Net (loss) for the period         0         0         0         (10,000)         10,000           Balance as of December 31, 2011         10,000,000         10,000         0         (10,000)         0           Common stock issued for cash (\$0.001/share)         40,100,000         40,100         0         0         40,100           Net (loss) for the period         0         0         0         -52         -52	Balance as of July 12, 2011	0	\$	\$	\$	\$
Balance as of December 31, 2011       10,000,000       10,000       0       (10,000)       0         Common stock issued for cash (\$0.001/share)       40,100,000       40,100       0       0       40,1         Net (loss) for the period       0       0       0       -52       -52	Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0	0	10,000
Common stock issued for cash (\$0.001/share) 40,100,000 40,100 0 0 40,1 Net (loss) for the period 0 0 0 -52 -52	Net (loss) for the period	0	0	0	(10,000)	10,000
Net (loss) for the period 0 0 -52 -52	Balance as of December 31, 2011	10,000,000	10,000	0	(10,000)	0
		, ,		·	-	40,100
			<u>`</u> _			40,048

Scription Work Solutions Inc. (f/k/a: Transtech Solutions Inc.) (A Development Stage Company) Notes to the Financial Statements December 31, 2012 (Audited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Solutions Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

#### c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

#### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

#### g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

#### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

#### j) Fiscal Periods

The Company's fiscal year end is December 31.

#### k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

#### 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of December 31, 2012 the date the financial statements were issued, and there are no subsequent events to disclose.

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

BALANCE SHEET		As of June 30, 2013	As of December 31, 2012
		(unaudited)	Audited
Asset Current Assets	Cash	33,880	40,048
Total Asset		33,880	40,048
Liabilities and Stockholders' Equity			
Current Liabilities	Accounts Payable		
Long Term Liabilities Total Liabilities		0	0 0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 share authorized;		
	50,100,000 shares issued and outstanding Additional paid-in-capital Deficit Accumulated During Development Stage	50,100	50,100
	(Deficit)	(16,220)	(10,052)
Total Stockholder's Equity Total liabilities and stockholder's equity See Notes to Financial Statements		33,880 33,880	40,048 <b>40,048</b>

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

See Notes to Financial Statements

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

### STATEMENT OF CASH FLOWS STATEMENT OF OPERATIONS

		For the Three Months ended June 30, 2013	For the Three Months ended June 30, 2012	For the Six Months Ended June 30, 2013	For the Six Months ended June 30, 2012	July 12, 2011 (Inception) to June 30, 2013
Expenses SG&A	General and Administration Incorporation Fees Professional Fees Bank Charges and Interest Other Income	0 0 875 (3) 0	0 0 0 0	(7) 0 6,175 0	0 0 0 0	66 124 16,046 (6) (9)
Net (loss) from Operation before Taxes Net (loss)		(872) (872)	0 0	(6,168) (6,168)	0	(16,230) (16,221)
Basic and Diluted Loss per Common Share Weighted Outstanding Shares		0 50,100,000	0 50,100,000	50,100,000	0 50,100,000	o
			For the Six Months ended June 30, 2013	For the Six Months ended June 30, 2012	l (Ince	12, 2011 ption) to 30, 2013
Operating Activities  Net cash (used) for operating activities	Net (loss)		(6,168) (6,168)			6,220) 6 <b>,220)</b>
Financing Activities	Loans from Director Sale of common stock Net cash provided by finar activities	ncing	0 0	:		0 0,100 0,100
Net increase (decrease) in cash and equivalents Cash and equivalents at beginning of the period Cash and equivalents at end of the period			(6,168) 40,048 33,880			3,880 0 3,880
Supplemental cash flow information Cash paid for: Interest Taxes Non-Cash Activities			0 0 0 0	0 0 0		0 0 0 0

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of March 31, 2013 the Company has \$34,751.45 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

#### c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

#### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

#### g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

#### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

#### j) Fiscal Periods

The Company's fiscal year end is December 31.

#### k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on March 31, 2013.

#### 5. INCOME TAXES

For the quarter ended March 31, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2013, the Company had approximately \$15,349 of federal and state net operating losses.

#### 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of June 30, 2013 the date the financial statements were issued, and there are no subsequent events to disclose.

#### 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

#### **Information Not Required In the Prospectus**

#### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT
SEC Registration Fee*	\$27.28
Accounting Fees and Expenses*	\$15,000
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72
Total*	\$20,000

<sup>\*</sup> Estimated Figures

#### **Indemnification of Directors and Officers**

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
- (3) a transaction from which the director derived an improper personal profit; and
- (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law;
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

#### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit	
Number	scription
3.1	Articles of Incorporation of Scription Work Solutions, Inc.
3.2	Bylaws of Scription Work Solutions, Inc.
4.1	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered
23.1	Auditor Consent
23.2	Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

#### **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

#### **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on October 7, 2013.

SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director October 7, 2013

October 7, 2013

#### Via EDGAR

Ivan Griswold
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No.3 to Registration Statement on Form S-1
Filed June 28, 2013
File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. Your comments are reprinted below along with our response and, if applicable, our proposed changes to the Registration Statement:

#### General

1. It appears that you have sought to change your company's name from Transtech Solutions, Inc. to Scription Work Solutions, Inc. However, it does not appear that you have completed the name change in EDGAR. You may contact EDGAR Filer Support if you require assistance in this regard. Further, it appears that a provider of medical transcription software, eScription, which you reference in your document, shares a substantially similar name. Please tell us what consideration you have given to including risk factor disclosure addressing the risks associated with having a name that is substantially similar to one of your competitors.

ANSWER: We have completed the name change in EDGAR. eScription has updated their software's name to The Dragon Medical 360 | eScription as per their website. Furthermore, their company name is Nuance, the reference above refers to names of software they offer. This has created enough of a distinction to not add a risk factor.

2. We note that you filed a current report on Form 8-K on June 6, 2013 to announce that you amended your articles of incorporation to effect a name change. Please note that until your registration statement is declared effective, you are not yet a reporting company under the Exchange Act. Accordingly, Exchange Act reports, including current reports on Form 8-K, are not yet required to be filed. Please file your amended articles of incorporation reflecting your name change as an exhibit to your amended registration statement.

ANSWER: We have filed our amended articles of incorporation reflecting our name change as an exhibit to our amended registration statement.

- "Mr. Weinhaupl, the sole employee, officer and director...," page 12
- 3. Please revise this risk factor to disclose the number of hours per week Mr. Weinhaupl expects to devote to your business. It appears that you should also disclose that, in addition to his involvement with his other businesses, Mr. Weinhaupl is currently employed as Senior Network Support at Enterprise Contact Centers, which may impact his flexibility.

ANSWER: The following has been added to the risk factor:

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to our operation. This employment may also impact his flexibility.

- "We have less than 300 record holders following the completion of the...," page 14
- 4. Please revise to clarify the subheading of this risk factor. In addition, you state that certain disclosure obligations will not apply to you unless you have both 500 or more security holders and greater than \$10 million in assets. Please

amend this disclosure in light of recent amendments to Section 12(g) of the Securities Exchange Act.

ANSWER: The risk factor has been amended in to reflect recent updates to Section 12(g) of the Securities Exchange Act.

Information with Respect the Registrant

Plan of Operations, page 25

5. We note your additional disclosure on page 27 where you state, using the currently available capital resources, the minimum period of time that you will be able to conduct your planned operations is approximately twelve months. However, we also note your disclosures on page 12 where you indicate that you estimate current available financial resources will sustain your operations only through the next few months. Please further revise these disclosures to address the apparent inconsistencies.

ANSWER: The disclosure on page 27 has been updated to be consistent with the disclosure on page 12. The disclosure appears as follows:

Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

#### Products and Services, page 26

6. Your response to prior comment 20 notwithstanding, your discussion in this section requires additional revisions. Although this section is titled "Products and Services," it is unclear how the term "products" is applicable to your business as it appears that you intend to offer solely transcription services. In addition, your descriptions of the Physician Portal appear to suggest that the portal is currently operational. Please revise as appropriate.

ANSWER: We have updated the heading of this section to "Services". Reference to physician Portal has been amended to the following:

Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

7. We note your disclosure that your company's services will be fully compliant with the Health Insurance Portability and Accountability Act of 1996. Please clarify how the Act impacts your services and expand your disclosure to describe what is required in order for you to be HIPAA compliant. Refer to Item 101(h)(4)(ix) of Regulation S-K.

ANSWER: We have updated the disclosure to the following:

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPPAA was a result of congressional healthcare reform proponents to reform healthcare. The HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical conditions
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organizations insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of

the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Directors, Executive Officers, Promoters and Control Persons, page 27

8. You state that Christopher Weinhaupl has been "an accomplished serial entrepreneur" over the last 15 years. Please reasonably substantiate this characterization in your document or revise your disclosure as necessary.

ANSWER: This disclosure has been updated to state the following:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur.

Certain Relationships and Related Transactions, page 32

9. We note your response to prior comment 30. Please provide us with your analysis supporting your view that Mr. Weinhaupl is not a promoter. In this regard, we note your disclosure on page 25 that Mr. Weinhaupl is your founder and specifically refer you to paragraph (1)(i) of the definition of promoter in Securities Act Rule 405. Alternatively, revise your disclosure to provide the information required by Item 404(c) of Regulation S-K.

ANSWER: The disclosure on page 25 has been amended to refer to Mr. Weinhaupl as our CEO.

#### **Financial Statements**

General

10. We note you removed the separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011, in response to our prior comment 31. However, we also note there is no reference to such financial statements in the index on page 33 and you do not include any information for that period in the Notes to the financial statements. Please revise the Notes to include any appropriate disclosures for such period. In addition, please revise the index to include reference to each of the respective financial statements as of December 31, 2011 and for the period from inception (July 12, 2011) to December 31, 2011. Alternatively, remove all references to the dates and refer only to the respective financial statements and the related pages.

ANSWER: The Financial Statements have been amended.

11. Revise the column header for December 31, 2011 in both the Statement of Operations and Statement of Cash Flows to refer to the period from inception (July 12, 2011) to December 31, 2011.

ANSWER: The Statement of Operations and Statement of Cash Flows has been amended to reflect the correct dates.

Statement of Cash Flows, page 37

12. The net increase (decrease) in cash and equivalents for the year ended December 31, 2012 should be \$40,048 and cash and cash equivalents at beginning of period should be \$0. Please revise accordingly. In addition, ensure that the amounts for the period from July 12, 2011 (inception) to December 31, 2012 and July 12, 2011 (inception) to March 31, 2013 are properly corrected as well.

ANSWER: The Statements of Cash Flows have been updated.

Notes to Financial Statements

Note 5 Subsequent Events, page 40

13. We note this additional disclosure. Please revise to state, as requested in our prior comment 35, the date through which subsequent events have been evaluated and state whether that date is the date the financial statements were issued or the date the financial statements were available for issuance pursuant to ASC 855-10-50-1. Similar revisions should be made to the Note 6 on page 45.

ANSWER: In accordance with ASC 855, management evaluated the subsequent events through the date of June 30, 2013, the date the financial statements were issued, and there are no subsequent events to disclose.

March 31, 2013 Financial Statements

Statement of Operations, page 42

14. Your statement of operations for the period from July 12, 2011 (Inception) to March 31, 2013 does not foot. Please revise accordingly.

ANSWER: The statement of operations has been amended to reconcile this discrepancy.

Part II

Exhibit 5.1

15. Given the company's name change, please have the legality opinion updated to reflect the company's new name.

ANSWER: The legality opinion has been amended to reflect the company's new name.

#### Exhibit 23

16. The revised consent refers to the report of the independent registered public accounting firm, dated February 8, 2012, except for the company name change which is as of June 5, 2013. The date of such report on page 34 is February 8, 2013, except for the company name change which is as of June 5, 2013. Please revise accordingly.

ANSWER: The consent has been updated.

17. Also, we note that you continue to reference specific financial statements in the consent of your independent registered public accounting firm. As stated in our prior comment 36, to the extent that you make reference to specific financial statements in the consent, please ensure that you refer to all of the audited financial statements. In this regard, revise to refer to the balance sheets for both December 31, 2012 and 2011 and the statement of operations, stockholders' equity and cash flows for the year ended December 31, 2012; the period from July 12, 2011 (date of inception) to December 31, 2011; and the period from July 12, 2011 (date of inception) to December 31, 2012. Alternatively, as we previously indicated, you may choose to refer to the report date only.

ANSWER: The consent has been updated.

Thank you.

#### NEVADA STATE BUSINESS LICENSE

#### SCRIPTION WORK SOLUTIONS INC

#### Nevada Business Identification # NV20111458864

**Expiration Date: July 31, 2013** 

In accordance with Title 7 of Nevada Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed fees, the above anmed is hereby granted a Nevada State Business License for business activities conducted within the State of Nevada.


This license shall be considered valid until the expiration date listed above unless suspended or revoked in accordance with Title 7 of Nevada Revised Statutes.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on May 24, 2013.

ROSS MILLER

Secretary of State

You may verify this certificate online at http://www.nvsos.gov/







USE BLACK INK ONLY - DO NOT HIGHLIGHT

ROSS MILLER Secretary of State 204 North Carson Street, Suite 4 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov

# Articles of Incorporation (PURSUANT TO NRS CHAPTER 78)

Filed in the office of	Document Number
	20110512408-24
· ca Mea	Filing Date and Time
Ross Miller	07/12/2011 1:34 PM
Secretary of State	Entity Number
State of Nevada	E0392262011-0

(This document was filed electronically.) ABOVE SPACE IS FOR OFFICE USE ONLY

1. Name of Corporation:	TRANSTECH SOLUTIONS INC.				
2. Registered Agent for Service of Process: (check only one box)	Commercial Registered Agent: INCS Name Noncommercial Registered Agent (name and address below)	OR Offi	ice or Position with Entity ame and address below)		
	Name of Noncommercial Registered Agent OR Name of Title of Office or Other Position with Entity				
			Nevada		
	Street Address	City	Zip Code		
			Nevada		
	Mailing Address (if different from street address)	City	Zip Code		
3. Authorized Stock: (number of shares corporation is authorized to issue)	Number of shares with par value: 75000000	Par value per share: \$ 0.001	Number of shares without par value: 0		
4. Names and Addresses of the Board of	1) CHRIS WEINHAUPL Name	CALGADY	AD L		

Directors/Trustees:		::			<b></b> i
(each Director/Trustee must be a natural person at least 18 years of age; attach additional page if more than two directors/trustees)	Sireer Address	City	State	Zip Code	
	2)				
	Name				;
	Street Address	City	State	Zip Code	
5. Purpose: (optional;	The purpose of the corporation shall be:			**	
see instructions)					
6. Name, Address		3.7			
and Signature of Incorporator: (attach	CHRIS WEINHAUPL	X CHRIS WEINHA	AUPL		
	Name	Incorporator Signature		_	
additional page if more than one incorporator)		CALGARY	AB		,
	Address	City	State	Zip Code	
7. Certificate of	I hereby accept appointment as Registere	ed Agent for the above named	Entity.		
Acceptance of					
Appointment of	X INCSMART.BIZ, INC.		7/12/2	2011	
Registered Agent:	Authorized Signature of Registered Agent or On	Behalf of Registered Agent Entity	Date		

This form must be accompanied by appropriate fees.

Nevada Secretary of State NRS 78 Articles Revised: 4-10-09

Tel: 206.274.4598 Fax: 206.493.2777

e-mail: info@deanlawcorp.com

July 31, 2013

#### Via EDGAR

Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Ladies and Gentlemen:

#### Re: Scription Work Solutions Inc. (the "Company")

We have acted as special counsel for the Company for the limited purpose of rendering this opinion in connection with the filing of the Registration Statement on Form S-1 with the Securities and Exchange Commission. In our capacity as special counsel to the Company, we have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company, and other documents we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents. Please be advised that, we have reached the following conclusions regarding the offering:

- 1. The Company is a duly and legally organized and existing Nevada State Corporation, with its registered office and principal place of business located in Las Vegas, Nevada. The Articles of Incorporation and corporate registration fees were submitted to the Nevada Secretary of State's office and filed with the office on July 12, 2011. The Company's existence and form is valid and legal pursuant to Nevada law.
- 2. The Company is a fully and duly incorporated Nevada corporate entity. The Company has one class of Common Stock at this time. Neither the Articles of Incorporation, Bylaws, nor amendments thereto, nor subsequent resolutions change the non-assessable characteristics of the Company's common shares of stock. The Common Stock previously issued by the Company is in legal form and in compliance with the laws of the State of Nevada, its Constitution and reported judicial decisions interpreting those laws and when such stock was issued it was duly authorized, fully paid for and non-assessable.
- 3. To our knowledge, the Company is not a party to any legal proceedings nor are there any judgments against the Company, nor are there any actions or suits filed or threatened against it or its officers and directors, in their capacities as such, other than as set forth in the registration statement. We know of no disputes involving the Company and the Company has no claim, actions or inquiries from any federal, state or other government agency, other than as set forth in the registration statement. We know of no claims against the Company or any reputed claims against it at this time, other than as set forth in the registration statement.
- 4. The Company's outstanding shares are all common shares. There are no liquidation preference rights held by any of the Shareholders upon voluntary or involuntary liquidation of the Company.
- 5. The directors and officers of the Company are indemnified against all costs, expenses, judgments and liabilities, including

attorney's fees, reasonably incurred by or imposed upon them or any of them in connection with or resulting from any action, suit or proceedings, civil or general, in which the officer or director is or may be made a party by reason of his being or having been such a director or officer. This indemnification is not exclusive of other rights to which such director or officer may be entitled as a matter of law.

- 6. The Company's Articles of Incorporation presently provide the authority to the Company to issue 75,000,000 shares of common stock, with a par value of \$0.001 per share.
- 7. Under the applicable law of the State of Nevada (including statutory, regulatory and case law), the 20,0000,000 shares of common stock of the Company being registered pursuant to the Registration Statement for resale by the selling shareholders were duly authorized by all necessary corporate action on the part of the Company and are validly issued, fully paid and nonassessable and, when sold as contemplated in the Registration Statement, will continue to be validly issued, fully paid and nonassessable.

We consent to filing this opinion as an exhibit to the Registration statement and also consent to the reference of our name in the prospectus which forms a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Yours very truly,

/s/ Dean Law Corp.

DEAN LAW CORP.

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) of our report dated February 8, 2012, except the Company name change which is as of June 5, 2013, relating to the financial statements for the period from July 12, 2011 (inception) to December 31, 2012, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut June 27, 2013

# CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Inc of our report dated August 28, 2013, relating to the financial statements of the six months ended June 30, 2013.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut October 2, 2013



# UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

# **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 5 to Form S-1, registration statement, received in this Commission on November 1, 2013, under the name of Scription Work Solutions Inc. (Formerly known as: Transtech Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Mills, Larry

Digitally signed by Mills, Larry
DN: dc=GOV, dc=SEC, dc=AD,
ou=Common, ou=Metro DC, ou=OSO,
ou=Employee, cn=Mills, Larry,
email=MillsL@SEC.GOV
Date: 2015.09.28 15:16:21 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

But J. File

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1

# Amendment No. 5

# REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# **Scription Work Solutions Inc.**

(Formerly known as: Transtech Solutions Inc.) (Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization) 7374
(Primary Standard Industrial Classification Code Number)

41-2281519 (I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

With a copy to:

Dean Law Corp. 601 Union Street, Suite 4200 Seattle, Washington 98101

Telephone: (206) 274-4598 Facsimile: (206) 493-2777

Approximate date of proposed sale to the public: as soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer □ Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☑
(Do not check if a smaller reporting company)

#### **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(1)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$25.76

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated \_\_\_\_\_, 2013

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

Scirption Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

#### 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2013.

# **Explanatory Note**

This Amendment No.4 on Form S-1/A (this "Amendment") amends the Registration Statement on Form S-1 for the quarter ended June 30, 2013 which the Registrant previously filed with the Securities and Exchange Commission on October 7, 2013 (the "Original Filing"). The Registrant is filing this Amendment to include the Auditor Consent file which failed to properly upload to EDGAR with the main document files on the EDGARized version of the Original Filing.

Except as set forth above, the Original Filing has not been amended, updated or otherwise modified. Other events occurring after the filing of the Form S-1/A or other disclosures necessary to reflect subsequent events have been addressed in our reports filed with the Securities and Exchange Commission subsequent to the filing of this Form S-1.

# TABLE OF CONTENTS

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

#### PROSPECTUS SUMMARY

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" f/k/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

#### Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. Christopher Weinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be

subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

### **SUMMARY OF THIS OFFERING**

The Issuer Scription Work Solutions Inc, f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per Per Share Price

share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the

Offering

The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Issued

Securities Issued And to be 50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

**Use of Proceeds** We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed.

FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for the

Selling Stockholders.

# **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

		As of Dec 31, 2012 (Audited)
Balance Sheet		
Total Assets	\$	40,048
Total Liabilities	<b>\$</b>	0
Stockholders' Equity	\$	40,048
		Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)
Income Statement		
Revenue	\$	-
Total Operating Expenses	\$	10,052
Net Loss	\$	(10,052)

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions.

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to or operation. This employment may also impact his flexibility.

#### Risks Relating To Our Common Stock

# Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk of being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both in excess of \$10 million and a class of equity securities (other than exempted securities) held of record by either (i) 2,000 persons, or (ii) 500 persons who are not accredited investors. For these purposes, the "held of record" definition in Section 12(g)(g) does not include securities held by persons who received the securities pursuant to an employee compensation plan in transaction exempt from the registration requirements under Section 5 of the Securities Act of 1933, as amended ("Securities Act"). This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

#### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

#### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### **Dilution**

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

#### PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

# **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

#### Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### State Securities Laws

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

# **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

# **Selling Shareholders**

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

<del>-</del>		Total Number Of Shares To	)	
		Be Offered	<b>Total Shares to Be Owned</b>	Percentage of Shares owned
Name Of Selling		r For Selling Shareholders	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000	1411	
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000		
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000		Nil
Jose Jay N. Briton	100,000	100,000		Nil
Daryl Nhon N. Briton	100,000	100,000		Nil
Cherry Grace N. Briton	100,000	100,000		Nil
Arlene M. Morato	100,000	100,000		Nil
Ernesto Bejeno	100,000	100,000		Nil
cincato Dejeno	100,000	100,000	1411	INII .
Total	20,000,000	20,000,000	Nil	Nil .

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### **Common Stock**

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

#### **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

#### **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

#### **INFORMATION WITH RESPECT TO REGISTRANT**

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

# **Description of Business:**

#### Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

#### **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### **Market Needs**

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of non-essential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

Competition

The competition takes two general forms:

- General transcription service- these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- 2. Specialized medical transcription- there are a number of exclusive medical transcription service providers. The market is controlled by larger companies that have established their brand over the years. Many of the smaller companies that provide are being driven out of the industry due to the larger more reputable companies being able to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

### Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

#### **Plan of Operations**

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our CEO, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### **Services**

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

Next Day Turnaround: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.

**Physician Portal:** We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.

24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.

Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical Transcription Standards.

Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPAA was a result of congressional healthcare reform proponents to reform healthcare. HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical condition
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organization insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

latform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

lire additional staff — When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

eta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Public Offering and Registration Fees	10-12 months	\$15,000
Total		\$200,000

#### Management

# Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur. Mr. Weinhaupl's active roles are contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

# **COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

#### **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

#### **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

## Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

# **Outstanding Equity Awards since Inception:**

	OPTION AWARDS				STOCK	AWARDS	3		
Name (a)	Number of Securities Underlying Unexercised Options (#) Exercisable (b)	Number of Securities Underlying Unexercised Options (#) Unexercisable (c)	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) (d)	Option Exercise Price (\$) (c)	Option Expiration Date (f)	Number of Shares or Units of Stock that have not Vested (#) (g)	Market Value of Shares or Units of Stock that have not Vested (\$) (h)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have not Vested (\$) (i)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that have not Vested (\$) (j)
ChristopherWeinhaupl	0		0	0	0	0	0	0	0

### Long-Term Incentive Plans

We currently have no Long-Term Incentive Plans.

#### **Director Compensation**

None.

#### Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

# SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at October 31, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of October 31, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

#### **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	34
Balance Sheet as of December 31, 2012	35
Statement of Operations as of December 31, 2012	36
Statement of Cash Flows as of December 31, 2012	31
Statement of Stockholders' Equity as of December 31, 2012	38
Notes to Financials	39
Balance Sheet as of June 30, 2013	43
Statement of Operations as of June 30, 2013 Statement of Cash Flows as of June 30, 2013	42 43
Notes to Financials	44

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

BALANCE SHEET		As of June 30, 2013	As of December 31, 2012
		(unaudited)	Audited
Asset Current Assets Total Asset	Cash	33,880 <b>33,880</b>	40,048 <b>40,</b> 048
Liabilities and Stockholders' Equity			,
Current Liabilities	Accounts Payable		
Long Term Liabilities Total Liabilities		0	. 0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued and outstanding Additional paid-in-capital	50,100	50,100
	Deficit Accumulated During Development Stage (Deficit)	(16,220)	(10,052)
Total Stockholder's Equity Total liabilities and stockholder's equity See Notes to Financial Statements		33,880 33,880	40,048 <b>40,048</b>

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

#### STATEMENT OF OPERATIONS

		For the Three Months ended June 30, 2013	For the Three Months ended June 30, 2012	For the Six Months Ended June 30, 2013	For the Six Months ended June 30, 2012	July 12, 2011 (Inception) to June 30, 2013
Expenses						
	General and					
	Administration	0	0	(7)	0	66
	Incorporation Fees	0	0	0	0	124
	Professional Fees	875	0	6,175	0	16,046
	Bank Charges and Interest	(3)	0	0	0	(6)
	Other Income	0	0	0	0	(9)
Net (loss) from Operation before Taxes		(872)	0	(6,168)	0	(16,230)
Net (loss)		(872)	0	(6,168)	0	(16,221)
Basic and Diluted Loss per Common Share Weighted Outstanding Shares		0 50,100,000	0 50,100,000	50,100,000	0 50,100,000	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF JUNE 30, 2013

# **STATEMENT OF CASH FLOWS**

		For the Six Months ended June 30, 2013	For the Six Months ended June 30, 2012	July 12, 2011 (Inception) to June 30, 2013
Operating Activities				
	Net (loss)	(6,168)	-	(16,220)
Net cash (used) for operating activities		(6,168)	-	(16,220)
Financing Activities				
•	Loans from Director	0	-	0
	Sale of common stock	0	-	50,100
	Net cash provided by financing			
	activities	0	-	50,100
Net increase (decrease) in cash and equivalents,		(6,168)		33,880
Cash and equivalents at beginning of the period		40,048	-	Ō
Cash and equivalents at end of the period		33,880	-	. 33,880
Supplemental cash flow information		0		0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0

#### SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS

**AS OF JUNE 30, 2013** 

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of March 31, 2013 the Company has \$34,751.45 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

#### c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

#### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

#### g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

#### h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

#### i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

#### j) Fiscal Periods

The Company's fiscal year end is December 31.

#### k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on March 31, 2013.

#### 5. INCOME TAXES

For the quarter ended March 31, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2013, the Company had approximately \$15,349 of federal and state net operating losses.

#### 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of June 30, 2013 the date the financial statements were issued, and there are no subsequent events to disclose.

# 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

#### Information Not Required In the Prospectus

#### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT
SEC Registration Fee*	\$27.28
Accounting Fees and Expenses*	\$15,000
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72
Total*	\$20,000

#### \* Estimated Figures

#### Indemnification of Directors and Officers

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
  - (3) a transaction from which the director derived an improper personal profit; and
  - (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

#### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit Number	scription
3.1	Articles of Incorporation of Scription Work Solutions, Inc.
3.2	Bylaws of Scription Work Solutions, Inc.
4.1	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered
23.1	Auditor Consent
23.2	Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

#### Undertakings:

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

#### The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

#### Signatures

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on October 31, 2013.

SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director October 31, 2013

October 31, 2013

#### Via EDGAR

Ivan Griswold United States Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No. 4 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013, June 28, 2013, October 7, 2013,

October 7, 2013

File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. Your comments are reprinted below along with our response and, if applicable, our proposed changes to the Registration Statement:

#### General

1. It appears that you have sought to change your company's name from Transtech Solutions, Inc. to Scription Work Solutions, Inc. However, it does not appear that you have completed the name change in EDGAR. You may contact EDGAR Filer Support if you require assistance in this regard. Further, it appears that a provider of medical transcription software, eScription, which you reference in your document, shares a substantially similar name. Please tell us what consideration you have given to including risk factor disclosure addressing the risks associated with having a name that is substantially similar to one of your competitors.

ANSWER: We have completed the name change in EDGAR. eScription has updated their software's name to The Dragon Medical 360 | eScription as per their website. Furthermore, their company name is Nuance, the reference above refers to names of software they offer. This has created enough of a distinction to not add a risk factor.

2. We note that you filed a current report on Form 8-K on June 6, 2013 to announce that you amended your articles of incorporation to effect a name change. Please note that until your registration statement is declared effective, you are not yet a reporting company under the Exchange Act. Accordingly, Exchange Act reports, including current reports on Form 8-K, are not yet required to be filed. Please file your amended articles of incorporation reflecting your name change as an exhibit to your amended registration statement.

ANSWER: We have filed our amended articles of incorporation reflecting our name change as an exhibit to our amended registration statement.

"Mr. Weinhaupl, the sole employee, officer and director...," page 12

3. Please revise this risk factor to disclose the number of hours per week Mr. Weinhaupl expects to devote to your business. It appears that you should also disclose that, in addition to his involvement with his other businesses, Mr. Weinhaupl is currently employed as Senior Network Support at Enterprise Contact Centers, which may impact his flexibility.

ANSWER: The following has been added to the risk factor:

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to our operation. This employment may also impact his flexibility.

- "We have less than 300 record holders following the completion of the...," page 14
- 4. Please revise to clarify the subheading of this risk factor. In addition, you state that certain disclosure obligations will not apply to you unless you have both 500 or more security holders and greater than \$10 million in assets. Please amend this disclosure in light of recent amendments to Section 12(g) of the Securities Exchange Act.

ANSWER: The risk factor has been amended in to reflect recent updates to Section 12(g) of the Securities Exchange Act.

Information with Respect the Registrant

Plan of Operations, page 25

5. We note your additional disclosure on page 27 where you state, using the currently available capital resources, the minimum period of time that you will be able to conduct your planned operations is approximately twelve months. However, we also note your disclosures on page 12 where you indicate that you estimate current available financial resources will sustain your operations only through the next few months. Please further revise these disclosures to address the apparent inconsistencies.

ANSWER: The disclosure on page 27 has been updated to be consistent with the disclosure on page 12. The disclosure appears as follows:

Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Products and Services, page 26

6. Your response to prior comment 20 notwithstanding, your discussion in this section requires additional revisions. Although this section is titled "Products and Services," it is unclear how the term "products" is applicable to your business as it appears that you intend to offer solely transcription services. In addition, your descriptions of the Physician Portal appear to suggest that the portal is currently operational. Please revise as appropriate.

ANSWER: We have updated the heading of this section to "Services". Reference to physician Portal has been amended to the following:

Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

7. We note your disclosure that your company's services will be fully compliant with the Health Insurance Portability and Accountability Act of 1996. Please clarify how the Act impacts your services and expand your disclosure to describe what is required in order for you to be HIPAA compliant. Refer to Item 101(h)(4)(ix) of Regulation S-K.

ANSWER: We have updated the disclosure to the following:

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPPAA was a result of congressional healthcare reform proponents to reform healthcare. The HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical conditions
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organizations insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Directors, Executive Officers, Promoters and Control Persons, page 27

8. You state that Christopher Weinhaupl has been "an accomplished serial entrepreneur" over the last 15 years. Please reasonably substantiate this characterization in your document or revise your disclosure as necessary.

ANSWER: This disclosure has been updated to state the following:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur.

Certain Relationships and Related Transactions, page 32

9. We note your response to prior comment 30. Please provide us with your analysis supporting your view that Mr. Weinhaupl is not a promoter. In this regard, we note your disclosure on page 25 that Mr. Weinhaupl is your founder and specifically refer you to paragraph (1)(i) of the definition of promoter in Securities Act Rule 405. Alternatively, revise your disclosure to provide the information required by Item 404(c) of Regulation S-K.

ANSWER: The disclosure on page 25 has been amended to refer to Mr. Weinhaupl as our CEO.

#### Financial Statements

#### General

10. We note you removed the separate set of financial statements for the period from inception (July 12, 2011) to December 31, 2011, in response to our prior comment 31. However, we also note there is no reference to such financial statements in the index on page 33 and you do not include any information for that period in the Notes to the financial statements. Please revise the Notes to include any appropriate disclosures for such period. In addition, please revise the index to include reference to each of the respective financial statements as of December 31, 2011 and for the period from inception (July 12, 2011) to December 31, 2011. Alternatively, remove all references to the dates and refer only to the respective financial statements and the related pages.

ANSWER: The Financial Statements have been amended.

11. Revise the column header for December 31, 2011 in both the Statement of Operations and Statement of Cash Flows to refer to the period from inception (July 12, 2011) to December 31, 2011.

ANSWER: The Statement of Operations and Statement of Cash Flows has been amended to reflect the correct dates.

Statement of Cash Flows, page 37

12. The net increase (decrease) in cash and equivalents for the year ended December 31, 2012 should be \$40,048 and cash and cash equivalents at beginning of period should be \$0. Please revise accordingly. In addition, ensure that the amounts for the period from July 12, 2011 (inception) to December 31, 2012 and July 12, 2011 (inception) to March 31, 2013 are properly corrected as well.

ANSWER: The Statements of Cash Flows have been updated.

Notes to Financial Statements

Note 5 Subsequent Events, page 40

13. We note this additional disclosure. Please revise to state, as requested in our prior comment 35, the date through which subsequent events have been evaluated and state whether that date is the date the financial statements were issued or the date the financial statements were available for issuance pursuant to ASC 855-10-50-1. Similar revisions should be made to the Note 6 on page 45.

ANSWER: In accordance with ASC 855, management evaluated the subsequent events through the date of June 30,

2013, the date the financial statements were issued, and there are no subsequent events to disclose.

March 31, 2013 Financial Statements

Statement of Operations, page 42

14. Your statement of operations for the period from July 12, 2011 (Inception) to March 31, 2013 does not foot. Please revise accordingly.

ANSWER: The statement of operations has been amended to reconcile this discrepancy.

Part II

Exhibit 5.1

15. Given the company's name change, please have the legality opinion updated to reflect the company's new name.

ANSWER: The legality opinion has been amended to reflect the company's new name.

#### Exhibit 23

16. The revised consent refers to the report of the independent registered public accounting firm, dated February 8, 2012, except for the company name change which is as of June 5, 2013. The date of such report on page 34 is February 8, 2013, except for the company name change which is as of June 5, 2013. Please revise accordingly.

ANSWER: The consent has been updated.

17. Also, we note that you continue to reference specific financial statements in the consent of your independent registered public accounting firm. As stated in our prior comment 36, to the extent that you make reference to specific financial statements in the consent, please ensure that you refer to all of the audited financial statements. In this regard, revise to refer to the balance sheets for both December 31, 2012 and 2011 and the statement of operations, stockholders' equity and cash flows for the year ended December 31, 2012; the period from July 12, 2011 (date of inception) to December 31, 2011; and the period from July 12, 2011 (date of inception) to December 31, 2012. Alternatively, as we previously indicated, you may choose to refer to the report date only.

ANSWER: The consent has been updated.

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No. 5 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013, June 28, 2013, October 7, 2013,

October 7, 2013, October 30, 2013 File No. 333-187609

We specifically note that you did not correct the consent of your independent registered public accounting firm as previously requested. In addition, you should include a recently dated consent related to the audited financial statements. In this regard, it is unclear why you included a consent dated October 2, 2013 referring to a report dated August 28, 2013 that is not even included in the Form S-1 filing and which relates to unaudited financial statements.

ANSWER: We have corrected the consent of our independent registered public accounting firm, and a recently dated consent related to the the audited financial statements have been included.

Thank you. Chris Weinhaupl

## NEVADA STATE BUSINESS LICENSE

#### SCRIPTION WORK SOLUTIONS INC

#### Nevada Business Identification # NV20111458864

Expiration Date: July 31, 2013

In accordance with Title 7 of Nevada Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed fees, the above named is hereby granted a Nevada State Business License for business activities conducted within the State of Nevada.


This license shall be considered valid until the expiration date listed above unless suspended or revoked in accordance with Title 7 of Nevada Revised Statutes.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on May 24, 2013.

ROSS MILLER

Secretary of State

You may verify this certificate online at http://www.nvsos.gov/







USE BLACK INK ONLY - DO NOT HIGHLIGHT

**ROSS MILLER** Secretary of State 204 North Carson Street, Suite 4 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov

# Articles of Incorporation (PURSUANT TO NRS CHAPTER 78)

Filed in the office of	Document Number	_
	20110512408-24	
· con Man	Filing Date and Time	
Ross Miller	07/12/2011 1:34 PM	
Secretary of State	Entity Number	-
State of Nevada	E0392262011-0	

(This document was filed electronically.) ABOVE SPACE IS FOR OFFICE USE ONLY

1. Name of Corporation:	TRANSTECH SOLUTIONS INC.		
2. Registered Agent for Service of Process: (check only one box)	Commercial Registered Agent: INCS Name Noncommercial Registered Agent (name and address below)	OR ☐ Offi	ice or Position with Entity ame and address below)
	Name of Noncommercial Registered Agent OR	Name of Title of Office or Of	
	Street Address	City	Nevada Zip Code
			Nevada
	Mailing Address (if different from street address)	City	Zip Code
3. Authorized Stock: (number of shares corporation is authorized to issue)	Number of shares with par value: 75000000	Par value per share: \$ 0.001	Number of shares without par value:
4. Names and Addresses of the Board of	1) CHRIS WEINHAUPL Name	CALGARY	AB

Directors/Trustees:	1: , , , , , , , , , , , , , , , , , , ,		4 4 4	
(each Director/Trustee	Street Address	City	State	Zip Code
must be a natural person	2)			
at least 18 years of age;	Name			······
attach additional page if more than two				
directors/trustees)	Street Address	City	State	Zip Code
5. Purpose: (optional;	The purpose of the corporation shall be:			
see instructions)				
6. Name, Address				
and Signature of	CHRIS WEINHAUPL	X CHRIS WEINHA	UPL	
Incorporator: (attach	Name	Incorporator Signature		
additional page if more than one incorporator)	4	CALGARY	AB	
	Address	City	State	Zip Code
7. Certificate of	I hereby accept appointment as Regis	stered Agent for the above named b	Entity.	
Acceptance of				
Appointment of	X INCSMART.BIZ, INC.		7/12/2	2011
Registered Agent:	Authorized Signature of Registered Agent or On Behalf of Registered Agent Entity			······································

This form must be accompanied by appropriate fees.

Nevada Secretary of State NRS 78 Articles Revised: 4-10-09

Tel: 206.274.4598 Fax: 206.493.2777

e-mail: info@deanlawcorp.com

July 31, 2013

#### Via EDGAR

Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Ladies and Gentlemen:

### Re: Scription Work Solutions Inc. (the "Company")

We have acted as special counsel for the Company for the limited purpose of rendering this opinion in connection with the filing of the Registration Statement on Form S-1 with the Securities and Exchange Commission. In our capacity as special counsel to the Company, we have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company, and other documents we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents. Please be advised that, we have reached the following conclusions regarding the offering:

- The Company is a duly and legally organized and existing Nevada State Corporation, with its registered office and principal
  place of business located in Las Vegas, Nevada. The Articles of Incorporation and corporate registration fees were
  submitted to the Nevada Secretary of State's office and filed with the office on July 12, 2011. The Company's existence and
  form is valid and legal pursuant to Nevada law.
- 2. The Company is a fully and duly incorporated Nevada corporate entity. The Company has one class of Common Stock at this time. Neither the Articles of Incorporation, Bylaws, nor amendments thereto, nor subsequent resolutions change the non-assessable characteristics of the Company's common shares of stock. The Common Stock previously issued by the Company is in legal form and in compliance with the laws of the State of Nevada, its Constitution and reported judicial decisions interpreting those laws and when such stock was issued it was duly authorized, fully paid for and non-assessable.
- 3. To our knowledge, the Company is not a party to any legal proceedings nor are there any judgments against the Company, nor are there any actions or suits filed or threatened against it or its officers and directors, in their capacities as such, other than as set forth in the registration statement. We know of no disputes involving the Company and the Company has no claim, actions or inquiries from any federal, state or other government agency, other than as set forth in the registration statement. We know of no claims against the Company or any reputed claims against it at this time, other than as set forth in the registration statement.
- 4. The Company's outstanding shares are all common shares. There are no liquidation preference rights held by any of the Shareholders upon voluntary or involuntary liquidation of the Company.
- 5. The directors and officers of the Company are indemnified against all costs, expenses, judgments and liabilities, including

attorney's fees, reasonably incurred by or imposed upon them or any of them in connection with or resulting from any action, suit or proceedings, civil or general, in which the officer or director is or may be made a party by reason of his being or having been such a director or officer. This indemnification is not exclusive of other rights to which such director or officer may be entitled as a matter of law.


- 6. The Company's Articles of Incorporation presently provide the authority to the Company to issue 75,000,000 shares of common stock, with a par value of \$0.001 per share.
- 7. Under the applicable law of the State of Nevada (including statutory, regulatory and case law), the 20,0000,000 shares of common stock of the Company being registered pursuant to the Registration Statement for resale by the selling shareholders were duly authorized by all necessary corporate action on the part of the Company and are validly issued, fully paid and nonassessable and, when sold as contemplated in the Registration Statement, will continue to be validly issued, fully paid and nonassessable.

We consent to filing this opinion as an exhibit to the Registration statement and also consent to the reference of our name in the prospectus which forms a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Yours very truly,

/s/ Dean Law Corp.

DEAN LAW CORP.



#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc. (fka: Transtech Solutions Inc.) of our report dated February 8, 2013, except the Company name change which is as of June 5, 2013, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut October 30, 2013



# UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

# **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 6 to Form S-1, registration statement, received in this Commission on November 25, 2013, under the name of Scription Work Solutions, Inc. (Formerly known as: Transtech Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Digitally signed by Mills, Larry DN: dc=GOV, dc=SEC, dc=AD, Mills, Larry ou=Common, ou=menus acry, ou=Employee, cn=Mills, Larry, email=MillsL@SEC.GOV ou=Common, ou=Metro DC, ou=OSO, Date: 2015.09.28 15:18:04 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1 Amendment No. 6

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# **Scription Work Solutions Inc.**

(Formerly known as: Transtech Solutions Inc.)
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization)

(Primary Standard Industrial Classification Code Number)

41-2281519 (I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Approximate date of proposed sale to the public: as soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer □ Accelerated filer □ Non-accelerated filer □ Smaller reporting company Ø
(Do not check if a smaller reporting company)

#### **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(1)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$25.76

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated \_\_\_\_\_, 2013

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

Scription Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

#### 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2013.

### TABLE OF CONTENTS

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

#### **PROSPECTUS SUMMARY**

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" f/k/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

#### Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more:
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be

subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

#### **SUMMARY OF THIS OFFERING**

The Issuer Scription Work Solutions Inc, f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per

share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the

Offering

The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two years from the effective date of this registration statement.

Issued

Securities Issued And to be 50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

**Use of Proceeds** We will not receive any proceeds from the sale of the common stock by the selling shareholders.

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for the

Selling Stockholders.

# **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

	As of Dec 31, 2012 (Audited)
Balance Sheet	
Total Assets	\$ 40,048
Total Liabilities	\$ •
Stockholders' Equity	\$ 40,048
	Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)
Income Statement	
Revenue	\$
Total Operating Expenses	\$ 10,05
Net Loss	\$ (10,052

ż,

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions.

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to or operation. This employment may also impact his flexibility.

# Risks Relating To Our Common Stock

# Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

# If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

# We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk of being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both in excess of \$10 million and a class of equity securities (other than exempted securities) held of record by either (i) 2,000 persons, or (ii) 500 persons who are not accredited investors. For these purposes, the "held of record" definition in Section 12(g)(g) does not include securities held by persons who received the securities pursuant to an employee compensation plan in transaction exempt from the registration requirements under Section 5 of the Securities Act of 1933, as amended ("Securities Act"). This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

# Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

# PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

#### Timing of Sales

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

# Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### **State Securities Laws**

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

### Selling Shareholders

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

		Total Number Of Shares To	0	
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned
Name Of Selling	<b>Shares Owned Prior</b>	For Selling Shareholders	Upon	Upon
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000	NII	NII
John Michael Bornasal			NPI	NU
Esmeralda	2,200,000	2,200,000	Nil	Nil
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	600,000	600,000	Nil	Nil
Norma Parreno	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000	Nil	Nil
Jose Jay N. Briton	100,000	100,000	Nil	Nil
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil
Cherry Grace N. Briton	100,000	100,000	Nil	Nil
Arlene M. Morato	100,000	100,000	Nil	Nil
Ernesto Bejeno	100,000	100,000	Nil	Nil
Total	20,000,000	20,000,000	Nil	Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

# **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

## **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

#### **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

# **INFORMATION WITH RESPECT TO REGISTRANT**

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

# **Description of Business:**

# Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

### **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### Market Needs

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of nonessential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

Competition

The competition takes two general forms:

- 1. **General transcription service-** these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- 2. Specialized medical transcription- there are a number of exclusive medical transcription service providers. The market is controlled by larger companies that have established their brand over the years. Many of the smaller companies that provide are being driven out of the industry due to the larger more reputable companies being able to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

# Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

# Plan of Operations

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our CEO, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### Services

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

**Next Day Turnaround**: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.

Physician Portal: We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.

24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.

Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical Transcription Standards.

Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPAA was a result of congressional healthcare reform proponents to reform healthcare. HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical condition
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organization insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

latform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

lire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

leta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Public Offering and Registration Fees	10-12 months	\$ 20,000
Total		\$200,000

#### Management

# Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur. Mr. Weinhaupl's active roles are

contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Since 2010, Christopher Weinhaupl has held ownership and founder of Canadapack a North American cross boarder Logistics Company. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses.

# COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

# **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

# **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

# **Legal Proceedings**

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

# **Outstanding Equity Awards since Inception:**

		OPTION AWA	ARDS				STOCK	AWARDS	3
								Equity	Equity Incentive
·			Equity			Number of	Market Value of	Incentive Plan Awards: Number	Plan Awards: Market or Payout
			Incentive Plan Awards:			Shares or Units of	Shares or Units	of Uncarned Shares,	Value of Unearned Shares,
	Number of Securities Underlying		Number of Securities Underlying Unexercised	Option		Stock that have	of Stock that have	Units or Other Rights that have	Units or Other Rights that have
	Unexercised Options (#)	Number of Securities Underlying Unexercised	Unearned	Exercise	Option Expiration	not Vested	not Vested	not	not Vested
Name	Exercisable	Options (#) Unexercisable	Options (#)	(\$)	Date	(#)	(\$)	Vested (\$)	(\$)
(a) ChristopherWeinhaupl	(b)	(c)	(d)	(e)	<u>(f)</u>	·(g)	(h) 0	(i) 0	(j)
Christopherweinnaupi	0	0	0	0	0	υ	U	U	0

# **Long-Term Incentive Plans**

We currently have no Long-Term Incentive Plans.

# **Director Compensation**

None.

# Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

# SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at October 31, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of October 31, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50,100,000	100%

(1)

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

# CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

Mr. Weinhaupl has been the sole officer and director of the company since inception and has founded the company, thus he is a promoter as defined in Rule 405 of Regulation C. Mr. Weinhaupl has not received nor is scheduled to receive anything of value either directly or indirectly from the Company.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	34
Balance Sheet as of December 31, 2012	35
Statement of Operations as of December 31, 2012	36
Statement of Cash Flows as of December 31, 2012	37
Statement of Stockholders' Equity as of December 31, 2012	38
Notes to Financials	39
Balance Sheet as of September 30, 2013	41
Statement of Operations as of September 30, 2013 Statement of Cash Flows as of September 30, 2013	42 43
Notes to Financials	44

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc. (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

BALANCE SHEETS			
		Dec-31	Dec-31
		2012	2011
Asset		(audited)	(audited)
Current Assets	Cash	40,048	0
Total Asset	Casii	40,048	0
r Otal France		40,040	v
	Accounts Payable		
• • • • • • • • • • • • • • • • • • • •	•		
Shareholder's Equity	0 0 1 0000		
	Common Stock, \$0.001		
	par value, 75,000,000 shares authorized;		
	50,100,000 shares issued		
	and outstanding	50,100	10,000
	Additional paid-in-capital	0	0
	Deficit accumulated		
	during the development	(10.050)	(10.000)
	stage	(10,052)	(10,000)
Total Stockholder's Equity		40,048	0
Total liabilities and stockholder's equity		40,048	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF OPERATIONS

Expenses	General and	December 31, 2012 (audited)	For the Period From July 12, 2011 (inception) to December 3 2011 (audited)	For the Period From July 12, 2011 (inception) 1, to December 31, 2012
	Administration	61	5	66
	Incorporations Fees	0	124	124
	Professional Fees	0	9,871	9,871
	Net (loss) from			
	Operation before Taxes	-61	-10,000	-10,061
Other Income		9	0	9
Provision for Income Taxes		0	0	0
Net (loss)		-52	-10,000	-10,052
Basic and Diluted Loss per Common Share			0	0
Dasie and Diraced Loss per Common Share			U	U

See Notes to Financial Statements

Weighted Outstanding Shares

50,100,000

50,100,000

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF CASH FLOWS

STATE OF CASH LOWS				
			For the	For the
			Period	Period
			From	From
			July 12,	July 12,
			2011	2011
				) (inception)
			to	to
		December	December	December
		31, 2012	31, 2011	31, 2012
		(audited)	(audited)	5., 20.2
Operating Activities		(audited)	(audited)	
Operating Activities	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities	1401 (1033)	-52	-10,000	-10,052
Net easif (used) for operating activities		-32	-10,000	-10,032
Financing Activities				
	Loans from Director	0	0	0
	Sale of common stock	40,100	10,000	50,100
	Net cash provided by financing	•	ŕ	•
	activities	40,100	10,000	50,100
Net increase (decrease) in cash and equivalents		40,048	0	-52
Cash and equivalents at beginning of the period		0	0	40,100
Cash and equivalents at end of the period		40,048	Õ	40,048
cash and equivalents at end of the period		40,040	V	40,046
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
		•	•	-
Non-Cash Activities		0	0	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception (July 12, 2011) to December 31, 2012

(July 12, 2011) to December 31, 2012	Common	Stock	Addition Paid in		(Deficit) Accumulated During the Development	
Description	Shares	Amount	Capita	l	Stage	Totals
Balance as of July 12, 2011	0	\$	\$		\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0		0	10,000
Net (loss) for the period	0	_0	0		(10,000)	10,000
Balance as of December 31, 2011	10,000,000	10,000	0		(10,000)	0
Common stock issued for cash (\$0.001/share) Net (loss) for the period	40,100 0	),000	40,100 0	0	0 -52	40,100 -52
Balance as of December 31, 2012	50,100	),000	50,100	0	(10,052)	40,048

Scription Work Solutions Inc. (f/k/a: Transtech Solutions Inc.) (A Development Stage Company) Notes to the Financial Statements December 31, 2012 (Audited)

# 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Solutions Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

# h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

# 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

# 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

# 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of December 31, 2012 the date the financial statements were issued, and there are no subsequent events to disclose.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

|--|

BALANCE SHEET		As of September 30, 2013	As of December 31, 2012	
		(unaudited)	Audited	
Asset Current Assets	Cash	31,683	40,048	
Total Asset		31,683	40,048	
Liabilities and Stockholders' Equity				
Current Liabilities	Accounts Payable			
Accounts Payable and Long Accrued Liabilities		0	0	
Loan from Shareholders		0	0	
Total Liabilities		0	0	
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized;			
	50,100,000 shares issued and outstanding Additional paid-in-capital Deficit Accumulated During Development Stag	50,100	50,100	
	(Deficit)	(18,417)	(10,052)	
Total Stockholder's Equity Total liabilities and stockholder's equity See Notes to Financial Statements		31,683 <b>31,683</b>	40,048 40,048	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

# STATEMENT OF OPERATIONS

		For the Three Months ended September 30, 2013	For the Three Months ended September 30, 2012	For the Nine Months Ended September 30, 2013	For the Nine Months ended September 30, 2012	July 12, 2011 (Inception) to September 30, 2013
Expenses	6					
	General and Administration	1,176	43	1,179	49	1,240
	Incorporation Fees	0	0	0	0	124
	Professional Fees	1,025	0	7,200	0	17,076
	Other Income	(4)	(1)	(14)	(1)	(23)
Net (loss) from Operation before Taxes		(2,197)	(42)	(8,365)	(48)	(18,417)
Net (loss)		(2,197)	(42)	(8,365)	(48)	(18,417)
Basic and Diluted Loss per Common Share		0	0		0	0
Weighted Outstanding Shares		50,100,000	50,100,000	50,100,000	50,100,000	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

# **STATEMENT OF CASH FLOWS**

		For the Nine Months ended September 30, 2013	For the Nine Months ended September 30, 2012	July 12, 2011 (Inception) to September 30, 2013
Operating Activitles  Net cash (used) for operating activities	Net (loss)	(8,365) (8,365)	(48) (48)	(18,417) (18,417)
Financing Activities	Loans from Director Sale of common stock Net cash provided by financing activities	0 0	0 20,100 0	0 50,100 50,100
Net increase (decrease) in cash and equivalents Cash and equivalents at beginning of the period Cash and equivalents at end of the period		(8,365) 40,048 31,683	20,052 0 0	31,683 0 <b>31,683</b>
Supplemental cash flow information Cash paid for: Interest Taxes Non-Cash Activities		0 0 0 0	0 0 0	0 0 0 0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) NOTES TO FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of September 30, 2013 the Company has \$31,683 in cash.

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

# a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

# b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

# f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

# h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

# k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between inception (July 12, 2011) to December 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. During the period between January 2012 and December 2012, the Company issued an additional 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at September 30, 2013.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on September 31, 2013.

#### 5. INCOME TAXES

For the quarter ended September 30, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2013, the Company had approximately \$17,242 of federal and state net operating losses.

#### 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

## 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

#### Information Not Required In the Prospectus

#### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT		
SEC Registration Fee*	\$27.28		
Accounting Fees and Expenses*	\$15,000		
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72		
Total*	\$20,000		

#### \* Estimated Figures

#### Indemnification of Directors and Officers

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
  - (3) a transaction from which the director derived an improper personal profit; and
  - (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

#### **Recent Sales of Unregistered Securities**

During the period from August 2011 and September 2012, the Company issued 30,100,000 shares of common stock for cash at \$0.001 per share or for a value of \$30,100. We relied on Regulation S of the Securities Act of 1933 for these issuances. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

#### **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

# Exhibit Number 3.1 Articles of Incorporation of Scription Work Solutions, Inc. 3.2 Bylaws of Scription Work Solutions, Inc. 4.1 Form of Subscription Agreement 5.1 Opinion of Dean Law Corp, re: the legality of the shares being registered

- 23.1 Auditor Consent
- 23.2 Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

#### **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

#### The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

#### **Signatures**

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-1 and authorized this registration statement to be signed on our behalf by the undersigned, on November 25, 2013.

SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

**SIGNATURE** 

CAPACITY IN WHICH SIGNED

DATE

/s/ Christopher Weinhaupl Christopher Weinhaupl President, Chief Executive Officer, Secretary, Treasurer, Principal Accounting Officer, Principal Financial Officer and Director November 25, 2013

#### Via EDGAR

Ivan Griswold United States Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No.6 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013, June 28, 2013, October 7, 2013,

October 7, 2013, October 30, 2013 File No. 333-187609

#### General

1. Please update your financial statements in accordance with Rule 8-08(b) of Regulation S-X.

ANSWER: The financial statements have been updated.

2. We note your response to prior comment 2; however, it appears that the document filed as Exhibit 31 is not the amended articles of incorporation filed with the Form 8-K on June 5, 2013. Please file the amended articles of incorporation reflecting your name change with your next amendment as Exhibit 3.1.

ANSWER: The amended Exhibit 3.1 has been added.

3. It appears that your business license filed as Exhibit 31 expired on July 31, 2013. Please advise.

ANSWER: The Business License was renewed on July 31, 2013. Please refer to Exhibit 3.1. You may verify the document at http://nvsos.gov

4. We are unable to locate disclosure regarding recent sales of unregistered securities. Please include the information required by Item 15 of Form S-1 and Item 701 of Regulation S-K or advise.

ANSWER: Item 15 of Form S-1 and Item 701 of Regulation S-K has been added.

Plan of Operations, page 25

5. It appears that your revised disclosure on page 27 estimating offering expenses of \$15,000 is inconsistent with your disclosure on page 46 estimating offering expenses of \$20,000. Please revise to reconcile this apparent inconsistency.

ANSWER: The disclosure has been amended to reconcile the inconsistency.

Directors, Executive Officers, Promoters and Control Persons, page 27

6. We note your revisions in response to prior comment 8 and your disclosure that "Mr. Weinhaupl has forged and built a number of startup firms in diverse industries from services to product sales." We note further that the sole reference to Mr. Weinhaupl's role as a founder relates to his experience at Canadapack. Please revise your disclosure to substantiate this statement or consider removing it.

ANSWER: The disclosure has been amended.

Certain Relationships and Related Transactions, page 32

7. We note that in response to prior comment 9 you have removed the reference from page 25 identifying your CEO as founder. This revision does not appear to be responsive to our comment, which we reissue. Given that it appears that Mr. Weinhaupl has been the sole officer and director of the company since inception and has been described by you as founding the company, he is a promoter as defined in Rule 405 of Regulation C. Please revise your disclosure to identify him as such and provide disclosure responsive to Item 404(c) of Regulation S-K.

ANSWER: The following has been added to the disclosure:

Mr. Weinhaupl has been the sole officer and director of the company since inception and has founded the company, thus he is a promoter as defined in Rule 405 of Regulation C. Mr. Weinhaupl has not received nor is scheduled to receive anything of value either directly or indirectly from the Company.

Exhibit Index, page 47 Exhibit 5.1

8. Your counsel indicates that it has "acted as special counsel for the Company for the limited purpose of rendering this opinion in connection with the filing of the Registration Statement...." In light of the fact that counsel is listed on the cover page of the document, please have counsel revise the statement to clearly reflect the nature and scope of the legal engagement, or tell us why the existing description is accurate.

ANSWER: The contact information for Dean Law Corp has been removed from the cover page of the Registration Statement, and the current statement is now accurate.

Thank you. Chris Weinhaupl

# SCRIPTION WORK SOLUTIONS INC Nevada Business Identification # NV20111458864

# Expiration Date: July 31, 2014

In accordance with Title 7 of Menda Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed New Law and payment of appropriate prescribed New Law advantages License for business activities conducted within the State of Newsda.


This license shall be considered volid until the expiration date listed above unless suspended or revoked in accordance with Tale 7 of Nevada Revised Statutes.

This document is not transferable and is not issued in lieu of any locally-required business license, pernit or registration.

13 WITMEW WHEBERE I have boronto set my



You may verify this certificate online at http://www.nvsos.gov/





ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website: www.nvsos.gov



\*090201\*

Filed in the office of

Document Number 20130319577-08

da Me

Filing Date and Time

Ross Miller Secretary of State

State of Nevada

05/13/2013 5:43 AM

Entity Number

E0392262011-0

## **Certificate of Amendment**

(PURSUANT TO NRS 78,385 AND 78,390)

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

# Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1. Name of corporation:

TRANSTECH SOLUTIONS INC

2. The articles have been amended as follows: (provide article numbers, if available)

THE NAME OF THE CORPORATION IS BEING AMENDED TO:

SCRIPTION WORK SOLUTIONS INC

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes as agriculture.


articles of incorporation* have voted in favor of the amendment is:	harmonia marian consideration for consideration	provisions 60%	or the
4. Effective date and time of filing: (optional) Date:	Time:		
(must not be later than 9	O days after the	certificate is fi	led)
5. Signature: (required)			
1/1/2/1			
X / M Wysl	**		
Signature of Officer	9		

"If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate fees.

Nevade Secretary of State Amend Profit-After Revised: 8-31-11



#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) of our report dated February 8, 2013, except the Company name change which is as of June 5, 2013, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut November 25, 2013



### **UNITED STATES OF AMERICA**

SECURITIES AND EXCHANGE COMMISSION

#### **ATTESTATION**

I HEREBY ATTEST

that:

Attached is a copy of Amendment No. 7 to Form S-1, registration statement, received in this Commission on January 21, 2014, under the name of Scription Work Solutions Inc. (Formerly known as: Transtech Solutions, Inc.), File No. 333-187609, pursuant to the provisions of the Securities Act of 1933.

on file in this Commission

09/28/2015

Date

Mills, Larry ou=Common, ou=Metro DC, ou ou=Common, ou=Metro DC, ou ou=Employee, cn=Mills, Larry, ou=Employee, cn=Mills, Larry, on=All selections of the common output of the comm

Digitally signed by Mills, Larry
DN: dc=GOV, dc=SEC, dc=AD,
ou=Common, ou=Metro DC, ou=OSO,
ou=Employee, cn=Mills, Larry,
email=MillsL@SEC.GOV
Date: 2015.09.28 15:19:56 -04'00'

Larry Mills, Management and Program Analyst

It is hereby certified that the Secretary of the U.S. Securities and Exchange Commission, Washington, DC, which Commission was created by the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) is official custodian of the records and files of said Commission and was such official custodian at the time of executing the above attestation, and that he/she, and persons holding the positions of Deputy Secretary, Assistant Director, Records Officer, Branch Chief of Records Management, and the Program Analyst for the Records Officer, or anyone of them, are authorized to execute the above attestation.

For the Commission

Secretary

## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM S-1 Amendment No. 7

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

#### **Scription Work Solutions Inc.**

(Formerly known as: Transtech Solutions Inc.)
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization)

(Primary Standard Industrial Classification Code Number)

(I.R.S. Employer Identification Number)

843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107 1 (866) 998-6920

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Approximate date of proposed sale to the public: as soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company: in Rule 12b-2 of the Exchange Act (Check one):  Large accelerated filer
(Do not check if a smaller reporting company)

#### **CALCULATION OF REGISTRATION FEE**

		Maximum	Maximum	
		Offering	Aggregate	Amount of
Title of Each Class	Amount to be	Price Per	Offering Price	Registration
of Securities to be Registered	Registered	Share	(I)	Fee (1)
Common Stock, \$0.01 par value per share	20,000,000	\$0.01	\$200,000	\$25.76

(1) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) under the Securities Act.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to completion, dated \_\_\_\_\_, 2014

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.

#### PRELIMINARY PROSPECTUS

Scription Work Solutions Inc. (F/K/A: TRANSTECH SOLUTIONS, INC.) 843 N Rainbow Blvd, Unit 1175 Las Vegas, NV 89107

#### 20,000,000 SHARES OF COMMON STOCK

The selling shareholders named in this prospectus are offering all of the shares of common stock offered through this prospectus for a period of up to two years from the effective date.

Our common stock is presently not traded on any market or securities exchange.

THE PURCHASE OF THE SECURITIES OFFERED THROUGH THIS PROSPECTUS INVOLVES A HIGH DEGREE OF RISK. See section entitled "Risk Factors" on pages 8 to 14 of this prospectus.

The information in this prospectus is not complete and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering. We will not receive any proceeds from the offering. We intend to apply for quotation on the OTCBB, but there is no guarantee that we will be accepted for quotation or will engage a market maker to file an application on our behalf. There is no assurance of when, if ever, our stock will be listed on an exchange. The absence of a public market for our common stock makes our shares highly illiquid. It will be difficult to sell the common stock of our company.

We are currently in the development stage and have nominal operations and minimal assets, which makes us a "shell company" as defined in Rule 12b-2 of the Exchange Act.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

We are not a blank check company and have no plans or intention to engage in a business combination with another entity. Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations. We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

The Date of this prospectus is \_\_\_\_\_\_, 2014.

#### TABLE OF CONTENTS

	Page
Prospectus Summary	5
The Offering	8
Risk Factors	10
Determination of Offering Price	15
Use of Proceeds	15
Dilution	15
Plan of Distribution; Terms of the Offering	17
Description of Securities	21
Interests of Named Experts and Counsel	22
Description of Business	23
Plan of Operations	26
Management	28
Outstanding Equity Awards since Inception	30
Security Ownership of Beneficial Owners and Management	31
Certain Relationships and Related Transactions	32
Commission Position on Indemnification for Securities Act Liabilities	33
Index to Financial Statements	F-1

#### **PROSPECTUS SUMMARY**

Prospective investors are urged to read this prospectus in its entirety.

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements, before making an investment decision. The terms "Scription Work Solutions Inc" f/k/a "Transtech Solutions Inc" "we," "us" and "our" as used in this prospectus refer to Scription Work Solutions Inc.

#### Company Overview

Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. (the "Company") was incorporated in the State of Nevada on July 12, 2011. We are a development stage company that plans to engage in the sale of medical transcription services. We intend to purchase a web-based platform that will give us the ability to reach potential customers. ChristopherWeinhaupl, who is currently our sole officer and director, founded our Company. Our headquarters are located at 843 N Rainbow Blvd, Unit 1175, Las Vegas, NV 89107.

Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists. Scription Work Solutions intends to purchase one of many transcription platforms available on the market such as Dragon Medical Software or eScription, which our medical transcriptionists will use for physicians in hospitals, clinics and diagnostic laboratories in the United States. Since inception, our operations have primarily consisted of the formation of our company, completion of our business plan, and the acquisition of funding. We have not commenced in purchasing transcription software as we have not yet raised the minimum funds necessary to commence operations. A market-ready transcription platform will not be available for 10-12 months after we have raised the necessary funds.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. If we are unable to obtain the level of financing, our business may fail.

We are endeavoring to be a reporting company with the SEC as we believe doing so will provide us with greater opportunities to access and acquire the additional capital that we require for our growth and to further implement our business plan. In addition, becoming a reporting issuer may provide us with more financing alternatives, due to the transparency provided by the public reporting requirements.

Since inception, our operations have consisted of incorporating our Company and formulating our business plan. The Company intends to begin substantive operations within 10-12 months after we obtain our necessary funding requirements. The initial plan of operations calls for the Company to begin marketing our transcription services to potential business clients. We believe that if we are able to raise the full amount of funds contemplated herein, we would be able to launch our Company and properly market our transcription services. We will design a full marketing strategy to gain brand awareness, and ultimately obtain a large medical transcription client base.

Although our sole officer and director has only recently become interested in the medical transcription business, and does not have any professional training or technical credentials in the development and maintenance of such a company, he has experience running a business. We plan to purchase a medical transcription platform and hire qualified marketing and sales personnel staff if we are successful in raising capital. We do not have any verbal or written agreements regarding the retention of any qualified personnel to date.

Although the Company has no market for its common stock, management believes that the Company will meet all requirements to be quoted on the OTC market, and even though the Company's common stock will likely will be a penny stock, becoming a reporting company will provide us with enhanced visibility and give us a greater possibility to provide liquidity to our shareholders.

We are currently a development stage company and to date we have recorded no revenue. Accordingly, our independent registered public accountants have issued a comment regarding our ability to continue as a going concern (please refer to the footnotes to the financial statements). Until such time that we are able to establish a consistent flow of revenues from our operations which is sufficient to sustain our operating needs, management intends to rely primarily upon debt financing to supplement cash flows, if any, generated by our services. We will seek out such financing as necessary to allow the Company to continue to grow our business operations, and to cover such cost, including professional fees, associated with being a reporting Company with the Securities and Exchange Commission ("SEC"); we estimate such costs to be approximately \$200,000 for 12 months following this Offering. The Company has included such costs to become a publicly reporting company in its targeted expenses for working capital expenses and intends to seek out reasonable loans from friends, family and business acquaintances if it becomes necessary. At this point we have been funded by our sole officer, family, friends and business acquaintances.

We are an Emerging Growth Company as defined in the Jumpstart Our Business Startups Act.

We shall continue to be deemed an emerging growth company until the earliest of:

- (A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of \$1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;
- (B) the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective registration statement under this title;
- (C) the date on which such issuer has, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or
- (D) the date on which such issuer is deemed to be a 'large accelerated filer', as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto.

As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.

As an emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.

We have irrevocably opted out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in business. As such we may have to cease operations and you could lose your investment. We currently have no commitments to raise the minimum funds necessary to become a revenue generating company over the next twelve months.

As of effectiveness of our registration statement of which this prospectus is a part, the Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934.

We will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our registration statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our registration statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted; however, that filing obligation will generally apply even if our reporting obligations have been suspended automatically under section 15(d) of the Exchange Act prior to the due date for the Form 10-K. After that fiscal year and provided the Company has less than 300 shareholders, the Company is not required to file these reports. If the reports are not filed, the investors will have reduced visibility as to the Company and its financial condition.

In addition, as a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements, and our common stock will not be subject to the protection of the ongoing private regulations. Additionally, the Company will be subject to only limited portions of the tender offer rules, and our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings in our Company, and will not be

subject to the short-swing profit recovery provisions of the Exchange Act. Further, more than five percent (5%) holders of classes of our equity securities will not be required to report information about their ownership positions in the securities. This means that your access to information regarding our business will be limited.

As a reporting company under the Exchange Act, we are required to comply with the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC after the consummation of this Offering. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. We will be unable to issue securities in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore, failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business and share price and could limit our ability to report our financial results accurately and timely

#### **SUMMARY OF THIS OFFERING**

The Issuer Scription Work Solutions Inc, f/k/a Transtech Solutions Inc.

Securities being offered Up to 20,000,000 shares of Common Stock

Offering Type The selling shareholders will sell our shares at a fixed price of \$0.01 per share.

Per Share Price The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per

share. We will pay all expenses of registering the securities, estimated at approximately \$20,000.

Termination of the

Offering

The offering will conclude when all of the 20,000,000 shares of common stock have been sold, the shares no longer need to be registered to be sold due to the operation of Rule 144 or we decide at any time to terminate the registration of the shares at our sole discretion. In any event, the offering shall be terminated no later than two

years from the effective date of this registration statement.

Issued

Securities Issued And to be 50,100,000 shares of our common stock are issued and outstanding as of the date of this prospectus. All of

20,000,000 shares will be sold by existing shareholder

We will not receive any proceeds from the sale of the common stock by the selling shareholders. Use of Proceeds

Market for the Common

Stock

There is currently no public market for the shares of our common stock. There can be no assurance that a market maker will agree to file the necessary documents with FINRA to allow our shares of common stock to be traded on

the OTCBB, nor can there be any assurance that such an application for quotation will be approved if filed. FINRA operates the OTCBB. We have agreed to bear the expenses relating to the registration of the shares for the

Selling Stockholders.

#### **Summary Financial Information**

The following audited financial information summarizes the more complete historical financial information at the end of this prospectus.

	As of Dec 31, 2012 (Audited)		
Balance Sheet			
Total Assets	\$	40,048	
Total Liabilities	\$	0	
Stockholders' Equity	\$	40,048	
		Period from July 12, 2011 (date of inception) to Dec 31, 2012 (Audited)	
Income Statement			
Revenue	\$	-	
Total Operating Expenses	\$	10,052	
Net Loss	\$	(10,052)	

#### **RISK FACTORS**

In addition to the other information provided in this Prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Our lack of operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. You are unable to determine whether we will ever become profitable, which increases your investment risk.

We were incorporated on July 12, 2011. We have no operating history. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that, even if we successfully implement our business plan, we will ever generate revenues or profits, which makes it difficult to evaluate our business. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Because of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues, or expenses. If we make poor operational decisions in implementing our business plan, we may never generate revenues or become profitable or incur losses, which may result in a decline in our stock price.

Because we will need additional capital to implement our business plan and may not be able to obtain sufficient capital, we may be forced to limit the scope of our operations, and our revenues may be reduced.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

We will require financing to achieve our current business strategy and our inability to obtain such financing could prohibit us from executing our business plan and cause us to slow down our expansion or cease our operations.

We will need to raise a minimum of \$200,000 over the next twelve months through public or private debt or sale of equity to execute our business plan to become a revenue generating company. Such financing may not be available as needed. Even if such financing is available, it may be on terms that are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences or other terms. If we are unable to obtain this financing on reasonable terms, we would be unable to hire the additional employees needed to execute our business plan and we would be forced to delay or scale back our plans for expansion. This would delay our ability to get our operations to profitability and could force us to cease operations. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results or financial condition.

Moreover, in addition to monies needed to commence operations over the next twelve months, we anticipate requiring additional funds in order to execute any future plans for growth. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. There can be no assurance that we will be able to obtain financing if or when it is needed on terms we deem acceptable.

Our lack of an established brand name and relative lack of resources could negatively impact our ability to effectively compete in the medical transcription industry, which could reduce the value of your investment.

We do not have an established brand name or reputation in the business of providing medical transcription services. We also have a relative lack of resources to conduct our business operations. Thus, we may have difficulty effectively competing with companies that have greater name recognition and financial resources than we do. Our inability to promote and/or protect our brand name may have an adverse effect on our ability to compete effectively in the market.

Because our auditors have issued a going concern opinion, there is substantial uncertainty we will continue operations in which case you could lose your investment.

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months as we lack an operating history. The financial statements do not include any adjustments that might result from the uncertainty about our ability to commence in business. As such we may have to cease operations and you could lose your investment. If we do not commence our operations, secure financing, and related activities or if we do not secure funding to implement our business plan, we estimate current available financial resources will sustain our operations only through the next few months, and then only if continued funding by the management of the company.

If we do not make a profit, we may have to suspend or cease operations.

Because we are small and do not have much capital, we must limit our marketing to the existing business relationships of our CEO, Mr. Christopher Weinhaupl. Because we will be limiting our marketing activities, we may not be able to attract enough clients to operate profitably. If we cannot operate profitably, we may have to suspend or cease our operations.

We are dependent on our CEO, Mr. Christopher Weinhaupl, to guide our initial operations and implement our plan of operations. If we lose such services we will have to change our business plan/direction or cease operations.

Our success will depend on the ability and resources of our CEO & President. If we lose the services of our CEO, we will be forced to either change our business plan and direction or cease operations. We have no written employment agreement with our CEO. We have not obtained any key man life insurance relating to our CEO. If we lose such services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Mr. Christopher Weinhaupl's services could reduce our revenues. We have no written employment agreement or covenant not to compete with Mr. Christopher Weinhaupl.

Mr. Weinhaupl, the sole employee, officer and director, is committing a limited amount of time to the management of the company.

Mr. Weinhaupl's involvement with his other businesses currently occupies most of his time and schedule. Certain tasks for Scription Work Solutions may not be completed in a timely fashion due to travel and other commitments. The Company has given consideration to conflicts of interest that may arise based on Mr. Weinhaupl's commitment to his other businesses. However, as the owner, Mr. Weinhaupl is fortunate to have a very flexible work environment and schedule; thus we believe he can fulfill his responsibilities both during the week and on the weekend, allowing him prioritize his schedule to devote time as needed to the Scription Work Solutions.

Due to Mr. Weinhaupl's current employment as Senior Network Support at Enterprise Contact Centers, he can currently devote approximately 20 hours per week to or operation. This employment may also impact his flexibility.

#### Risks Relating To Our Common Stock

Because there is no public trading market for our common stock, you may not be able to resell your stock.

There is currently no public trading market for our common stock. Therefore there is no central place, such as a stock exchange or electronic trading system, to resell your shares. If you do want to resell your shares, you will have to locate a buyer and negotiate your own sale in compliance with applicable federal and state securities laws.

There is no assurance of a public market or that our common stock will ever trade on a recognized exchange or quotation system. Therefore, you may be unable to liquidate your investment in our stock.

There is no established public trading market for our common stock. Our shares are not and have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, which operates the OTCBB, to create such listing or quotation, nor can there be any assurance that such an application would be approved if filed, or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

If our common stock is quoted on the OTC Bulletin Board which may have an unfavorable impact on our stock price and liquidity.

We anticipate that our common stock will be quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

We may be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.

The SEC has adopted regulations which generally define so-called "penny stocks" to be an equity security that has a market price less than \$5.00 per share or an exercise price of less than \$5.00 per share, subject to certain exemptions. If our common stock becomes a "penny stock," we may become subject to Rule 15g-9 under the Exchange Act, or the "Penny Stock Rule." This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors" (generally, individuals with a net worth in excess of \$1,000,000 or annual incomes exceeding \$200,000, or \$300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market.

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

Because we do not have an audit or compensation committee, shareholders will have to rely on the board of directors, which is not independent, to perform these functions.

We do not have an audit or compensation committee comprised of independent directors. These functions are performed by the board of directors as a whole. The sole member of the board of directors is not independent. Thus, there is a potential conflict in that board members who are management will participate in discussions concerning management compensation and audit issues that may affect management decisions.

Our management has limited experience in managing the day to day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.

Our CEO Christopher Weinhaupl is responsible for our operations and SEC reporting. The requirements of operating as a small public company are new to him. This will require us to obtain outside assistance from legal, accounting, investor relations or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements and compliance under the Sarbanes-Oxley Act of 2002. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.

We have less than 300 record holders following the completion of the offering, and pose the risk of being suspended.

The Company will not become a fully reporting company, but rather, will be subject to the reporting requirements of Section 15(d) of the Securities Exchange Act of 1934. As of the effectiveness of our Registration Statement of which this prospectus is a part, we will be required to file periodic reports with the SEC which will be immediately available to the public for inspection and copying. Except during the year that our Registration Statement becomes effective, these reporting obligations may be automatically suspended under Section 15(d) if we have less than 300 shareholders. If this occurs after the year in which our Registration Statement becomes effective, we will no longer be obligated to file periodic reports with the SEC and your access to our business information would then be even more restricted. After this Registration Statement on Form S-1 becomes effective, we will be required to deliver periodic reports to security holders. However, we will not be required to furnish proxy statements to security holders and our directors, officers and principal beneficial owners will not be required to report their beneficial ownership of securities to the SEC pursuant to Section 16 of the Securities Exchange Act of 1934 until we have both in excess of \$10 million and a class of equity securities (other than exempted securities) held of record by either (i) 2,000 persons, or (ii) 500 persons who are not accredited investors. For these purposes, the "held of record" definition in Section 12(g)(g) does not include securities held by persons who received the securities pursuant to an employee compensation plan in transaction exempt from the registration requirements under Section 5 of the Securities Act of 1933, as amended ("Securities Act"). This means that your access to information regarding our business will be limited.

We are a shell company as defined in Securities Act Rule 405, and may not have available to us the Securities Act Rule 144 for purposes of meeting the safe harbor requirement.

The unavailability of Securities Act Rule 144 from the definition of underwriter, may negatively affect liquidity of our shares and on our ability to attract additional capital to implement our business plan or sustain operations. Therefore, negatively affecting our cash flow and business plan moving forward.

We may be exposed to potential risks resulting from new requirements under section 404 of the Sarbanes-Oxley Act of 2002.

In addition to the costs of compliance with having our shares listed on the OTCBB, there are substantial penalties that could be imposed upon us if we fail to comply with all regulatory requirements. In particular, under Section 404 of the Sarbanes-Oxley Act of 2002, as a smaller reporting company, our management will be required to provide a report on the effectiveness of our internal controls over financial reporting, beginning with our second annual report, and we will not be required to provide an auditor's attestation regarding such report. We have not assessed the effectiveness of our disclosure controls and procedures or our internal controls over financial reporting, and we expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements. Additionally, investors should be aware of the risk that management may assess and render the Company's internal controls ineffective, which could have a material adverse effect on the Company's financial condition or result of operations."

#### Forward Looking Statements.

Some of the statements in this Prospectus are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with this offering.

#### Use of Proceeds

The selling stockholders are selling shares of common stock covered in the prospectus for their own account. We will not receive any of the proceeds from the resale of these shares. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.

#### **Determination of Offering Price**

The selling stockholders may offer their shares through public or private transactions at a fixed price of \$0.01 per share. We determined the price of our public offering by arbitrarily adding a \$0.009 per share premium to the last sale price of our common stock to investors. The price does not bear any relationship to our assets, book value, earnings, or other established criteria for valuing a privately held company.

#### Dilution

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders.

#### PLAN OF DISTRIBUTION; TERMS OF THE OFFERING

#### **Timing of Sales**

The selling stockholders may offer and sell the shares covered by this prospectus at various times. The selling stockholders will act independently of Scription Work Solutions Inc, f/k/a Transtech Solutions in making decisions with respect to the timing, manner and size of each sale.

The selling shareholders, who are underwriters, will sell our shares at a fixed price of \$0.01 per share for the duration of the offering."

#### Offering Price

The selling stockholders, who are underwriters, will sell their shares at the fixed price until our shares are quoted on the OTC Bulletin Board and thereafter at prevailing market prices or privately negotiated prices. Our common stock is not currently listed on any national exchange or electronic quotation system. To date, no actions have been taken to list our shares on any national exchange or electronic quotation system. If our common stock becomes publicly traded, then the sales price to the public will vary according to the selling decisions of each selling stockholder and the market for our stock at the time of resale.

#### Manner of Sale

The selling stockholders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling stockholder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling stockholder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the-counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If our selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

#### Sales Pursuant to Rule 144

Currently, we are a "shell company" as defined in Rule 12b-2 of the Exchange Act, as amended and Rule 144 is not available for the resale of securities issued by any issuer that is or has been at any time previously a shell company unless the following conditions have been met:

- the issuer of the securities that was formerly a shell company has ceased to be a shell company;
- the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
- the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
- at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

#### Regulation M

We have advised the selling security holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling security holders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution. Accordingly, the selling stockholder is not permitted to cover short sales by purchasing shares while the distribution is taking place. Regulation M also governs bids and purchases made in order to stabilize the price of a security in connection with a distribution of the security. In addition, we will make copies of this prospectus available to the selling security holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.

#### State Securities Laws

Under the securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

#### **Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. These expenses are estimated to be \$20,000, including, but not limited to, legal, accounting, printing and mailing fees. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

#### Selling Shareholders

The selling shareholders named in this prospectus are offering all of the 20,000,000 shares of common stock offered for resale through this prospectus. The 20,000,000 shares that were previously issued were acquired from us in private placements that were exempt from registration provided under Regulation S of the Securities Act of 1933. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

The following table provides as of the date of this prospectus, information regarding the beneficial ownership of our common stock held by each of the selling shareholders, including:

the number of shares owned by each prior to this offering;

the total number of shares that are to be offered for each;

the total number of shares that will be owned by each upon completion of the offering; and

the percentage owned by each upon completion of the offering.

Total Number Of Shares To				
		Be Offered	Total Shares to Be Owned	Percentage of Shares owned
Name Of Selling		For Selling Shareholders	Upon Completion Of This Offering	Upon Completion of This Offering
Shareholder	To This Offering	Account	Completion Of This Offering	Completion of This Offering
Domingo Mahusay			Nil	Nil
Quinatagcan	2,200,000	2,200,000		
John Michael Bornasal			Nil	Nil
Esmeralda	2,200,000	2,200,000		
John Paul Bornasal	2,200,000	2,200,000	Nil	Nil
Hernan de la Pena	2,200,000	2,200,000	Nil	Nil
Analy P. Mamburao	1,000,000	1,000,000	Nil	Nil
Normelito B. Alfante	2,200,000	2,200,000	Nil	Nil
Jose L. Mamburao Jr	1,000,000	1,000,000	Nil	Nil
Jacqueline P. Parreno	600,000	600,000	Nil	Nil
Sarah Carmona	600,000	600,000	Nil	Nil
Jonell P. Suganob	600,000	600,000	Nil	Nil
Junneri Canata Cangas	600,000	600,000	Nil	Nil
Cherry Mae P. Pauya	600,000	600,000	Nil	Nil
Leonel Canata Francisco	•	600,000	Nil	Nil
Norma Раггепо	600,000	600,000	Nil	Nil
Czarina Mae Torres Justo	600,000	600,000	Nil	Nil
Michael Tuazon Oris	200,000	200,000	Nil	Nil
Elmar A. Pomoy	200,000	200,000	Nil	Nil
Jonell M. Dimafelix	100,000	100,000	Nil	Nil
Evangeline N. Carvajal	100,000	100,000	Nil	Nil
Richard O. Cinco	100,000	100,000	Nil	Nil
Roman M. Eleonor	100,000	100,000	Nil	Nil
Jesrel Dagaang Birad	100,000	100,000	Nil	Nil
Jericko M. Erodias	100,000	100,000	Nil	Nil
Dinah Parreno	100,000	100,000	Nil	Nil
Edelberto P. Genon Jr	100,000	100,000	Nil	Nil
Enric B. Alarca	100,000	100,000	Nil	Nil
Josephine P. Laroa	100,000	100,000	Nil	Nil
Mirafe Fiel Alferez	100,000	100,000	Nil	Nil
Kell B. Esguerra	100,000	100,000	Nil	Nil
Melvina P. Alib	100,000	100,000	Nil	Nil
Jose Jay N. Briton	100,000	100,000	Nil	Nil
Daryl Nhon N. Briton	100,000	100,000	Nil	Nil
Cherry Grace N. Briton	100,000	100,000	Nil	Nil
Arlene M. Morato	100,000	100,000	Nil	Nil
Ernesto Bejeno	100,000	100,000	Nil	Nil
· Fotal	20,000,000	20,000,000	Nil	Nil

The named party beneficially owns and has sole voting and investment power over all shares or rights to these shares. The numbers in this table assume that none of the selling shareholders sells shares of common stock not being offered in this prospectus or purchases additional shares of common stock, and assumes that all shares offered are sold. The percentages are based on 20,000,000 shares of common stock outstanding on the date of this prospectus.

Other than disclosed above, none of the selling shareholders:

- 1. has had a material relationship with us other than as a shareholder at any time within the past three years;
- 2. has ever been one of our officers or directors;
- 3. is a broker-dealer; or broker-dealer's affiliate.

#### **Description of Securities**

#### General

The following description as a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws as they relate to our capital structure. The Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this Prospectus is a part.

#### Common Stock

We have 75,000,000 authorized shares of common stock with \$.001 par value. As of December 31, 2012, there were 50,100,000 shares of our common stock issued and outstanding. All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements and other factors.

Holders of our common stock have no pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control. There are no conversion, pre-emptive or other subscription rights or privileges with respect to any shares.

#### Preferred Stock

We are not authorized to issue any shares of preferred stock.

#### **Dividend Policy**

We have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

#### **Share Purchase Warrants and Options**

We do not presently have any options or warrants authorized or any securities that may be convertible into common stock. However, our board of directors may later determine to authorize options and warrants for our Company.

#### **Interests of Named Experts and Counsel**

The legality of the shares offered under this registration statement is being passed upon by Dean Law Corp.

The financial statements included in this prospectus and the registration statement have been audited by Kenne Ruan, CPA to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

#### INFORMATION WITH RESPECT TO REGISTRANT

THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ TOGETHER WITH THE CONSOLIDATED FINANCIAL STATEMENTS OF SCRIPTION WORK SOLUTIONS INC F/K/A TRANSTECH SOLUTIONS, INC. AND THE NOTES TO CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN THIS REGISTRATION STATEMENT. THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING OUR OPERATING RESULTS, FINANCIAL CONDITIONS AND LIQUIDITY AND CASH-FLOW SINCE INCEPTION.

#### **Description of Business:**

#### Organization:

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. was incorporated to the laws of the State of Nevada on July 12, 2011. We are a development stage company that has limited operating history and has earned no revenues.

Since our inception, we have devoted our activities to developing our business plan, determining the market for our services, developing a marketing plan, as well as capital formation. Our day-to-day operations consist of working on these to ensure effective, efficient and timely completion.

There is substantial doubt about our ability to continue, as a going concern, over the next twelve months.

#### **Business**

Scription Work Solutions Inc, f/k/a Transtech Solutions Inc. is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. The company intends to cater to the healthcare sector by providing timely, highly accurate medical transcriptions of dictated patient reports. Scription Work Solutions Inc, f/k/a Transtech aims to incorporate outsourcing operations overseas to take advantage of lower cost of labor, pending our sales effort. We believe this technology will allow an efficient way to manage transcription services on a web-based platform.

The main market sectors we aspire to penetrate are as follows:

- Offices of physicians
- Hospitals
- Medical and diagnostic laboratories

We expect Scription Work Solutions Inc, f/k/a Transtech's core service offerings to consist of medical record transcription services for the following:

- Office visits
- Surgery notes
- Lab results
- Admissions
- Assessments

#### **Industry Overview**

The Bureau of Labor Statistics reports that employment of medical transcriptionists is expected to grow 6 percent from 2010 to 2020. According to BLS, this growth rate is slower than average for all occupations. We anticipate the volume of healthcare services to continue to increase, resulting in a growing number of medical tests and procedures, all of which will require transcription. In our opinion, an aging population contributing to an increased number of healthcare visits, combined with a continued emphasis of accessible documentation, is anticipated to stimulate the need for medical transcriptionists. In other words, increasing numbers of medical transcriptionists will be needed to amend patients' records, edit for grammar, and identify discrepancies in electronic records.

Contracting out transcription work overseas and advancements in speech recognition technology are not expected to significantly reduce the need for well-trained medical transcriptionists in the US. Outsourcing transcription work abroad—to countries such as India, Pakistan, Philippines, and the Caribbean—has grown more popular as transmitting confidential health information over the Internet has become more secure; however, we believe the demand for overseas transcription services is expected only to supplement the demand for well-trained domestic medical transcriptionists. Speech-recognition technology allows physicians and other health professionals to dictate medical reports to a computer that immediately creates an electronic document. In spite of the advances in this technology, the software has been slow to grasp and analyze the human voice and the English language, and the medical vernacular with all its diversity. As a result, we expect there will continue to be a need for skilled medical transcriptionists to identify and appropriately edit the inevitable errors created by speech recognition systems, and to create a final document.

While the tools used by medical transcriptionists have dramatically changed to digital devices, the fundamental nature of the practice has not. The BLS reports that in spite of advances in technology, there will continue to be a need for skilled medical transcriptionists.

#### Market Research

The medical transcription business is a growing industry that is struggling to fulfill the demand created by physicians. We predict the drive to increase the quality of transcription services will result in insurance companies increasing their demand for qualified medical transcriptionists. We believe this is a highly fragmented and competitive industry that will continue to grow over the years, as demand is typically driven by quality of service, timely delivery and competitive pricing.

There are two general categories of customers that regularly need medical transcription services. There are physicians and psychologists who practice alone. The practitioners have the need for transcriptionists because they are typically too small to warrant their own in-house employee. The second group consists of hospitals, clinics, and other doctors who have an in-house solution, who at times are in need of supplemental services. There service requests are sporadic in nature and often require express services.

#### Market Needs

Scription Work Solutions Inc, f/k/a Transtech intends to provide its customers with a reliable, flexible, medically-trained transcription service. We believe the following benefits are important to our future customers:

- Medical Background: This is important due to the specialized language within the medical profession.
- Convenience: The ability to offer the service at the doctor's convenience is a significant advantage.
- Accuracy: Documents need to be accurate to guard against malpractice threats.

#### **Market Trends**

The market trend for industries that utilize transcription services is decreasing overhead through the outsourcing of nonessential activities. We believe that this market trend will result in an increased demand for providers of outsourced transcription solutions so that they can focus on their core business competencies.

#### **Market Growth**

As physician's practices are under increasing pressure to develop efficiencies (this pressure is primarily coming from the insurance companies which have significantly reduced their allowable reimbursement amounts), practices will be shedding non-essential employees and replacing them with outsourced service providers.

Competition

The competition takes two general forms:

- 1. **General transcription service-** these are transcription services that offer medical services in addition to general service offerings. These firms typically have someone who had been trained in medical transcription, but does not do medical exclusively.
- Specialized medical transcription- there are a number of exclusive medical transcription service providers. The
  market is controlled by larger companies that have established their brand over the years. Many of the smaller
  companies that provide are being driven out of the industry due to the larger more reputable companies being able
  to provide cheaper and faster services.

The buying patterns for medical transcriptionists are typically based on the type of relationship the physician or hospital has with the transcriptionist. If the physician does not have an in-house solution then they ideally will have a long-tem relationship with a service provider. If the physician or hospital has in-house transcriptionists, then their relationships with the transcriptionist services are based on the sporadic service calls, filling a need when their service provider is unable.

# Scription Work Solutions' Competitive Advantage

New technology such as voice recognition transcription software have been disruptive force in the medical transcription industry. Although voice technology has been shown to be accurate in medical transcription, we believe hospitals and medical clinics have been slow to adopt the new technology due to their preference for a live transcriptionist with whom they can interact.

Despite current industry changes, we believe there is opportunity for our company in this market. We believe we can occupy the space left in the industry where the small shops were pushed out with newer and more efficient transcription technology and methods available now. Although we do not believe we can compete with the volume of the larger players in the transcription industry, we assume a smaller shop like ours, utilizing the web, can provide competitive services with lower overhead. By adopting global outsourcing and providing our medical transcriptionists and clients a web-based platform to communicate, we believe we can provide time-efficient services at a competitive price.

# The Company - Who We Are; Mission Statement

We are a Nevada corporation and were formed on July 12, 2011. Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists

At Scription Work Solutions Inc. our mission it to provide state of the art transcription services, with a primary focus on building custom er trust by ensuring a high level of confidentiality. Our goal is to ensure that customer's associate simplicity and efficiency in reliable next day turn around services when they think of our brand. Customer satisfaction and loyalty is the backbone of our business. Our primary business objective is to maximize earnings and cash flow by constant marketing efforts to increase our client base.

# **Plan of Operations**

Since inception, our operations have primarily consisted of the organization of our business and the development of our business plan. Our business plan includes a two-phase plan that details the purchase of a medical transcription platform. Currently we are still in Phase 1 of our plan which includes the following:

Formation of our Company

Completion of our business plan; and

The acquisition of additional funding

Phase 1 have been completed, with the exception of raising additional funding. To date, our CEO, Christopher Weinhaupl, has conducted all operations. As such, upon incorporating our Company, Mr. Weinhaupl was named as the Company's sole officer and director. Operations and expenditures have included the incorporation of Scription Work Solutions Inc, f/k/a Transtech Solutions, Inc. under the laws of the State of Nevada, and the formation of an extensive business plan in which we have mapped out all of the initial services that we plan to offer to our clients. Phase 1 will culminate with the completion of this Offering, which will hopefully allow us to raise capital through public or private debt or sale of equity and see us through Phase 2. Phase 2 involves purchasing a medical transcription platform and we do not intend on entering Phase 2 until the Company raises additional funding either through public or private debt or sale of equity.

#### Services

Scription Work Solutions Inc, f/k/a Transtech plans to provide medical transcription services for the medical community. We expect to transcribe office visits, surgery notes, lab results, admissions, assessment, and discharge summaries. Our future customers may simply and efficiently use phone dictation or send voice files via the Internet.

**Next Day Turnaround**: Scription Work Solutions Inc, f/k/a Transtech plans to offer 24 hour turnaround time on all dictation received by 6:00pm Central Time. If this isn't fast enough, we intend to also provide STAT transcription services with turnaround in less than 4 hours.

**Physician Portal:** We plan to use a portal where physicians can review and correct the transcribed report using standard Word functionality and any changes will be saved to the server and will be accessed or distributed to all users. The physician will sign the document with a single mouse click upon which the report will be electronically stamped and marked as final.

98% Accuracy: Physicians demand high quality medical transcription that is verifiable and accurate. All transcripts will be graded by proof-readers based on the American Association of Medical Transcription standards. Scription Work Solutions Inc, f/k/a Transtech plans to guarantee 98% accuracy or better or files are provided free.

24 Hour Data Access: Scription Work Solutions Inc, f/k/a Transtech plans to provide 24/7 access to data. The company's servers will offer redundant power backups as well as complete backup Internet backbone to assure that data is always accessible.

Quality Assurance: Scription Work Solutions Inc, f/k/a Transtech projects to provide 4 to 6 months of training to all transcriptionists that join Transtech. Once training is complete, transcriptionists will be placed in a live environment where all their work is scrutinized for accuracy. Only after 2 to 3 years will transcriptionists be promoted to Assistant Quality Assurance positions in the Quality Assurance Department. We plan for all transcriptions to be guaranteed for 98% accuracy or better based on American Association of Medical Transcription Standards.

Easy File Transfers: Scription Work Solutions Inc, f/k/a Transtech's interface will be architected with usability for the computer illiterate as well as the tech savvy user. A minimal interface will allow future clients to copy their dictations from their recorders and send it to Scription Work Solutions Inc, f/k/a Transtech's servers with just 3 clicks of a mouse.

HIPAA Compliant: Scription Work Solutions' medical transcription services will be fully compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA). HIPAA was a result of congressional healthcare reform proponents to reform healthcare. HIPAA legislation has four primary objectives.

- 1. Assure health insurance portability by eliminating job-lock due to pre-existing medical condition
- 2. Reduce healthcare fraud and abuse
- 3. Enforce standards for health information
- 4. Guarantee security and privacy of health information

Of the four primary objectives, the fourth objective has the most impact on medical transcription.

The rule requires that healthcare organization insurers and payors that have been using any electronic means of storing patient data and performing claims submission must comply with HIPAA legislation. Since medical transcription deals with electronic means of handling and storing patient data, our services will ensure the security and confidentiality of the patient's Protected Health Information (PHI), and maintain an audit trail of all individuals who have had access to a PHI.

Assuming we are able to successfully raise funding from public or private debt or sale of equity, we will begin the second part of our business plan. In order to initiate Phase 2 of our operations, we will have to raise enough money to purchase the medical transcription platform. While we are researching the medical transcription platform to purchase, we will begin initial preparations for the launch of our platform and website.

latform purchase – We plan to purchase our medical transcription platform. The purchase of our platform and development of our website will entail the bulk of Phase 2. We plan to allocate \$65,000 to purchase the medical transcription software. At this time we will also allocate \$10,000 to purchase servers and hosting for our planned website and platform.

lire additional staff – When our platform has been purchased, we will begin hiring additional staff to prepare for our launch. We plan to hire one full-time marketing representatives to begin work on a marketing plan for our launch. We will allocate \$30,000 for the salary of the marketing representative, and up to \$50,000 on marketing materials. We will use the marketing ideas of our President, Christopher Weinhaupl, as set forth in our "Marketing" section. However, we will look to our new employees to come up with new and innovative ways to promote our Company.

leta testing – Once our platform is fully deployed, and our sales and marketing teams are in place, we will begin beta testing our website and transcription platform.

acquisition of clients— When we are ready to offer our medical transcription services to the public, we intend to launch a marketing campaign ourselves in order to promote our services to potential clients. This will complete Phase 2 of our development.

In order to complete Phase 2 of our business plan, we will rely on the management skills of our President. He will have to work closely with our sales and marketing team to make sure that there is constant communication between each. The sales of our services will be directly related to the work that our marketing team is providing. In the months that follow our launch, the work of our website developers will be critical as well. We hope to be in a phase of rapid growth, and our staff will be working hard to provide constant updates to our site, and fix any bugs that may occur. Our President will have to work hard to keep all components of our business on track.

With our currently available capital resources, we will be able to conduct phase one of our planned operations, which includes the formation of our company and the completion of our business plan. We will need to raise additional capital in order to commence phase two of our planned operations, which is to purchase the transcription platform and begin our sales and marketing efforts. Using currently available capital resources, the minimum period of time that we will be able to conduct our planned operations is approximately the next few months, and then only if continued funding by the management of the company.

Description	Time period	Estimated maximum expenses
Working Capital	10-12 months	\$10,000
Website Hosting and Servers	10-12 months	\$10,000
Platform Purchase	10-12 months	\$65,000
Marketing Representatives	10-12 months	\$30,000
Marketing Materials	10-12 months	\$50,000
Admin / Professional Fees	10-12 months	\$15,000
Public Offering and Registration Fees	10-12 months	\$ 20 ,000
Total		\$200,000

## Management

#### Directors, Executive Officers, Promoters and Control Persons

The Board of Directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our directors and executive officers are as follows:

Christopher Weinhaupl, 43, has numerous years of experience as an entrepreneur. Mr. Weinhaupl's active roles are

contributing to the Technology and Business Development of new market technologies. Mr. Weinhaupl looks for opportunities where Technology is a major disruptive factor in a mature market segment.

Canadapack a North American cross boarder Logistics Company. Mr. Weinhaupl was apart of data and web based business development, along with managing their marketing team. He was responsible for overseeing day to day operations. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. Mr. Weinhaupl' continues to oversee the marketing and development of this company's corporate brand imaging. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact Centers, providing technology support for North American businesses. Mr. Weinhaupl holds academic diplomas in International Marketing an International Finance. His organizational skills, marketing skills on building a brand, and his experience working in the medical industry with "mypharmacare" will assist Scription Work Solutions Inc. and help grow the business.

# COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Name	Age	Position
Mr. Christopher Weinhaupl	43	CEO, President & Director

Our Articles of Incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by Nevada law and that none of our directors will be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

- for any breach of the director's duty of loyalty to the Company or its stockholders;
- for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of the law;
- under Nevada General Corporation Law for the unlawful payment of dividends; or
- for any transaction from which the director derives an improper personal benefit.

These provisions require us to indemnify our directors and officers unless restricted by Nevada law and eliminate our rights and those of our stockholders to recover monetary damages from a director for breach of his fiduciary duty of care as a director except in the situations described above. The limitations summarized above, however, do not affect our ability or that of our stockholders to seek non-monetary remedies, such as an injunction or rescission, against a director for breach of his or his fiduciary duty.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

# **Employees**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely of Mr. Weinhaupl to manage all aspects of our business. We plan to use both in-house and freelance medical transcriptionists, who are trained and licensed, to perform the transcription work on our platform and servers.

Name	Department	Function	Salary	Contractors
ChristopherWeinhaupl	Admin	Business Development / Information Technology	None	N/A

## **Employees and Consultants**

As of the date of this filing, the Company has no full time employees other than our sole officer and director, Mr. Weinhaupl. We currently rely on Mr. Weinhaupl, to manage all aspects of our business. Mr. Weinhaupl has committed to devote up to 30 hours per week to our Company. We plan to use third-party developers to assist in the production of our proposed website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of management to meet the Company's then current needs.

## Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

#### **Outstanding Equity Awards since Inception:**

	OPTION AWARDS				STOCK	AWARDS	8		
Name (a)	Number of Securities Underlying Unexercised Options (#) Exercisable (b)	Number of Securities Underlying Unexercised Options (#) Unexercisable (c)	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) (d)	Option Exercise Price (\$) (e)	Option Expiration Date (f)	Number of Shares or Units of Stock that have not Vested (#) (g)	Market Value of Shares or Units of Stock that have not Vested (\$) (h)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have not Vested (\$) (i)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that have not Vested (\$) (j)
ChristopherWeinhaupl	0	0	0	0	0	0	0	0	0

#### **Long-Term Incentive Plans**

We currently have no Long-Term Incentive Plans.

#### **Director Compensation**

None.

## Director Independence

Our board of directors is currently composed of one member, Christopher Weinhaupl, who does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management.

# Security Holders Recommendations to Board of Directors

We welcome comments and questions from our shareholders. Shareholders can direct communications to our Chief Executive Officer, Christopher Weinhaupl, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to individually respond to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with the SEC so that all shareholders have access to information about us at the same time. Mr. Weinhaupl collects and evaluates all shareholder communications. All communications addressed to our director and executive officer will be reviewed by Mr. Weinhaupl unless the communication is clearly frivolous.

# SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information at October 31, 2013, with respect to the beneficial ownership of shares of Common Stock by (i) each person known to us who owns beneficially more than 5% of the outstanding shares of Common Stock (based upon reports which have been filed and other information known to us), (ii) each of our Directors, (iii) each of our Executive Officers and (iv) all of our Executive Officers and Directors as a group. Unless otherwise indicated, each stockholder has sole voting and investment power with respect to the shares shown. As of October 31, 2013, we had 50,100,000 shares of Common Stock issued and outstanding.

Title of class	Name and address of beneficial owner	Amount and Nature of Beneficial Ownership	Percentage of Common Stock (1)
Common Stock	ChristopherWeinhaupl 47 Sundown Green SE Calgary, AB	30,100,000	60%
	Total	50.100.000	100%

Under Rule 13d-3 promulgated under the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

We are not aware of any arrangements that could result in a change of control.

# **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

As a result, Mr. Weinhaupl owns 60% of the issued and outstanding common shares of the Company.

Other than the foregoing, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party since the beginning of our last fiscal year, or in any proposed transaction to which we propose to be a party:

- (A) any of our director(s) or executive officer(s);
- (B) any nominee for election as one of our directors;
- (C) any person who is known by us to beneficially own, directly or indirectly, shares carrying more than 5% of the voting rights attached to our Common Stock; or
- (D) any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any of the foregoing persons named in paragraph (A), (B) or (C) above.

Mr. Weinhaupl has been the sole officer and director of the company since inception and has founded the company, thus he is a promoter as defined in Rule 405 of Regulation C. Mr. Weinhaupl has not received nor is scheduled to receive anything of value either directly or indirectly from the Company.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012

Report of Independent Registered Public Accounting Firm	34
Balance Sheet as of December 31, 2012	35
Statement of Operations as of December 31, 2012	36
Statement of Cash Flows as of December 31, 2012	37
Statement of Stockholders' Equity as of December 31, 2012	38
Notes to Financials	39
Balance Sheet as of September 30, 2013	41
Statement of Operations as of September 30, 2013 Statement of Cash Flows as of September 30, 2013	42 43
Notes to Financials	44

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Scription Work Solutions Inc.
(f/k/a: Transtech Solutions Inc.)
(A Development Stage Company)

#### Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders Scription Work Solutions Inc (fka: Transtech Solutions Inc) (A Development Stage Company)

We have audited the accompanying balance sheets of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) (A development stage company) as of December 31, 2012 and 2011, and the related statements of operations, stockholders' equity and cash flows for the year ended December 31, 2012, the period from July 12, 2011(date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial positions of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the year ended December 31, 2012, the period from July 12, 2011 (date of inception) to December 31, 2011, and the period from July 12, 2011 (date of inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut February 8, 2013, except for the Company name change which is as of June 5, 2013

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

Asset Current Assets Total Asset	Cash	Dec-31 2012 (audited) 40,048 40,048	Dec-31 2011 (audited) 0
	Accounts Payable		
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized; 50,100,000 shares issued and outstanding Additional paid-in-capital Deficit accumulated during the development stage	50,100 0 (10,052)	10,000 0 (10,000)
Total Stockholder's Equity Total liabilities and stockholder's equity		40,048 <b>40,048</b>	0 <b>0</b>

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# **STATEMENT OF OPERATIONS**

		December 31, 2012	For the Period From July 12, 2011 (inception) to December 3 2011	For the Period From July 12, 2011 (inception) 1, to December 31, 2012
Expenses		(audited)	(audited)	
	General and			
	Administration	61	5	66
	Incorporations Fees	0	124	124
	Professional Fees	0	9,871	9,871
	Net (loss) from			
	Operation before Taxes	-61	-10,000	-10,061
		_		_
Other Income		9	0	9
Provision for Income Taxes		0	0	0
Net (loss)		-52	-10,000	-10,052

Basic and Diluted Loss per Common Share00Weighted Outstanding Shares50,100,00050,100,000

See Notes to Financial Statements

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF CASH FLOWS

		December	to	For the Period From July 12, 2011 ) (inception) to December
• •		31, 2012	31, 2011	31, 2012
Operating Activities		(audited)	(audited)	
Operating Activities	Net (loss)	-52	-10,000	-10,052
Net cash (used) for operating activities	1101 (1003)	-52	-10,000	-10,052
, ,			,	,
Financing Activities				
	Loans from Director	0	0	0
	Sale of common stock	40,100	10,000	50,100
	Net cash provided by financing activities	40,100	10,000	50,100
	activities	40,100	10,000	30,100
Net increase (decrease) in cash and equivalents		40,048	0	-52
Cash and equivalents at beginning of the period		0	0	40,100
Cash and equivalents at end of the period		40,048	0	40,048
Supplemental cash flow information		0	0	0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
		-		-
Non-Cash Activities		0	0 -	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF DECEMBER 31, 2012 (AUDITED)

# STATEMENT OF SHAREHOLDER EQUITY

From the Period From Inception
(July 12, 2011) to December 31, 2012

(July 12, 2011) to December 31, 2012	Common	Stock	Additie Paid in		(Deficit) Accumulated During the	
Description	Shares	Amount	Capita	1	Development Stage	Totals
Balance as of July 12, 2011	. 0	\$	\$		\$	\$
Common stock issued for cash (\$0.001/share)	10,000,000	10,000	0		0	10,000
Net (loss) for the period	0	0	0		(10,000)	10,000
Balance as of December 31, 2011	10,000,000	10,000	0		(10,000)	0
Common stock issued for cash (\$0.001/share)	40,100	,000	40,100	0	0	40,100
Net (loss) for the period	0		0	0	-52	-52
Balance as of December 31, 2012	50,100	,000	50,100	0	(10,052)	40,048

Scription Work Solutions Inc. (f/k/a: Transtech Solutions Inc.) (A Development Stage Company) Notes to the Financial Statements December 31, 2012 (Audited)

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Solutions Inc. ("the Company") (f/k/a: Transtech Solutions Inc.) was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of December 31, 2012 the Company has \$40,048.09 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

## a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

#### b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

## c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

# d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

## e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

## f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

## h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

# j) Fiscal Periods

The Company's fiscal year end is December 31.

## k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between January 2012 and December 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.001 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at December 31, 2012.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on December 31, 2012.

#### 5. INCOME TAXES

For the year ended December 31, 2012 and from January 2012 to December 31, 2012, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2012, the Company had approximately \$52 of federal and state net operating losses.

## 5. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of December 31, 2012 the date the financial statements were issued, and there are no subsequent events to disclose.

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

BA	LANC	Έ:	SHE	EΤ

BALANCE SHEET		As of September 30, 2013	As of December 31, 2012
		(unaudited)	Audited
Asset Current Assets	Cash	31,683	40,048
Total Asset		31,683	40,048
Liabilities and Stockholders' Equity			
Current Liabilities	Accounts Payable		
Accounts Payable and Long Accrued Liabilities		0	0
Loan from Shareholders Total Uabilities		0	0
Shareholder's Equity	Common Stock, \$0.001 par value, 75,000,000 shares authorized;		
	50,100,000 shares issued and outstanding Additional paid-in-capital Deficit Accumulated During Development Stag		50,100
	(Deficit)	(18,417)	(10,052)
Total Stockholder's Equity Total Ilabilities and stockholder's equity See Notes to Financial Statements		31,683 <b>31,683</b>	40,048 <b>40,048</b>

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

# STATEMENT OF OPERATIONS

		For the Three	For the Three	For the Nine	For the Nine	July 12, 2011
		Months ended September 30,	Months ended	Months Ended September 30,	Months ended September 30,	(Inception) to September
		2013	September 30, 2012	2013	2012	30, 2013
Expenses						
	General and Administration	1,176	43	1,179	49	1,240
	Incorporation Fees	0	0	0	0	124
	Professional Fees	1,025	0	7,200	0	17,076
	Other Income	(4)	(1)	(14)	(1)	(23)
Net (loss) from Operation before Taxes		(2,197)	(42)	(8,365)	(48)	(18,417)
Net (loss)		(2,197)	(42)	(8,365)	(48)	(18,417)
Basic and Diluted Loss per Common Share		0	0		0	0
Weighted Outstanding Shares		50,100,000	50,100,000	50,100,000	50,100,000	

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

# **STATEMENT OF CASH FLOWS**

		For the Nine Months ended September 30, 2013	For the Nine Months ended September 30, 2012	July 12, 2011 (Inception) to September 30, 2013
Operating Activities				
No. 2 and Associated	Net (loss)	(8,365)	(48)	(18,417)
Net cash (used) for operating activities		(8,365)	(48)	(18,417)
Financing Activities				
•	Loans from Director	0	0	0
	Sale of common stock	0	20,100	50,100
	Net cash provided by financing			
	activities	0	0	50,100
Net increase (decrease) in cash and equivalents		(8,365)	20,052	31,683
Cash and equivalents at beginning of the period		40,048	o	0
Cash and equivalents at end of the period		31,683	0	31,683
Supplemental cash flow information		0		0
Cash paid for:		0	0	0
Interest		0	0	0
Taxes		0	0	0
Non-Cash Activities		0	0	0

# SCRIPTION WORK SOLUTIONS INC. (f/k/a: TRANSTECH SOLUTIONS INC.) (A DEVELOPMENT STAGE COMPANY) NOTES TO FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013

#### 1. ORGANIZATION AND BUSINESS OPERATIONS

Scription Work Inc. ("the Company") was incorporated under the laws of the State of Nevada, U.S. on July 12, 2011. The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities." The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. As of September 30, 2013 the Company has \$31,683 in cash.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

## a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

## b) Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and or private placement of common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

# c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

#### d) Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

# e) Foreign Currency Translation

The Company's functional currency and its reporting currency is the United States dollar.

#### f) Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

# g) Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC Topic 718 which requires the Company to recognize expense related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded

vesting basis over the vesting period of the award. To date, the Company has not adopted a stock option plan and has not granted any stock options.

## h) Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

# i) Basic and Diluted Net Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

## j) Fiscal Periods

The Company's fiscal year end is December 31.

## k) Recent Accounting Pronouncements

The Company has evaluated the recent accounting pronouncements through ASU 2011-06 and believes that none of them will have a material effect on the company's financial statements.

#### 3. COMMON STOCK

The authorized capital of the Company is 75,000,000 common shares with a par value of \$ 0.001 per share.

During the period between inception (July 12, 2011) to December 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. During the period between January 2012 and December 2012, the Company issued an additional 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl. The Company relied on Section 4(2) of the Securities Act for this issuance.

During the period between January 2012 and December 2012, Company issued 20,000,000 shares of common stock under the private placements agreement to various investors at \$0.01 per share. Company received a total of \$20,000 net of offering proceeds.

There were no further issuances of stock as at September 30, 2013.

#### 4. RELATED PARTY TRANSACTIONS

Mr. Christopher Weinhaupl has not advanced funds to the Company to pay any costs incurred by it. These funds are unsecured, non-interest bearing and due on demand. The balance due Mr. Christopher Weinhaupl was \$0 as on September 31, 2013.

#### 5. INCOME TAXES

For the quarter ended September 30, 2013, the Company incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2013, the Company had approximately \$17,242 of federal and state net operating losses.

## 6. SUBSEQUENT EVENTS

In accordance with ASC 855, management evaluated the subsequent events through the date of this report and there are no subsequent events to disclose.

## 20,000,000 SHARES COMMON STOCK

#### **PROSPECTUS**

#### DEALER PROSPECTUS DELIVERY OBLIGATION

Until (180 days after the effective date), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

#### Part II

## Information Not Required In the Prospectus

#### Other Expenses of Issuance and Distribution

The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being offered by this Prospectus. Items marked with an asterisk (\*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.

ITEM	AMOUNT
SEC Registration Fee*	\$27.28
Accounting Fees and Expenses*	\$15,000
Printing, Edgar, Postage, Transfer Agent & Misc.*	\$4,972.72
Total*	\$20,000

# \* Estimated Figures

## **Indemnification of Directors and Officers**

Our sole officer and Director is indemnified as provided by the Nevada Revised Statutes and our bylaws.

Under the NRS, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company's articles of incorporation that is not the case with our articles of incorporation. Excepted from that immunity are:

- (1) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest;
- (2) a violation of criminal law (unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful);
  - (3) a transaction from which the director derived an improper personal profit; and
  - (4) willful misconduct.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent not prohibited by Nevada law; provided, however, that we may modify the extent of such indemnification by individual contracts with our directors and officers; and, provided, further, that we shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless:

- (1) such indemnification is expressly required to be made by law;
- (2) the proceeding was authorized by our Board of Directors;
- (3) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested us under Nevada law; or
- (4) such indemnification is required to be made pursuant to the bylaws.

Our bylaws provide that we will advance all expenses incurred to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was our director or officer, or is or was serving at our request as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request. The Company's obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Corporation.

# **Recent Sales of Unregistered Securities**

During the period from August 2011 and September 2012, the Company issued 30,100,000 shares of common stock for cash at \$0.001 per share or for a value of \$30,100. We relied on Regulation S of the Securities Act of 1933 for these issuances. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sale of the securities was completed in an "offshore transaction," as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. Each investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

On August 26, 2011, the Company issued 10,000,000 shares of common stock at a price of \$0.001 per share for a value of \$10,000 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

On September 4, 2012, the Company issued 20,100,000 shares of common stock at a price of \$0.001 per share for a value of \$20,100 to Christopher Weinhaupl, its President. The Company relied on Section 4(2) of the Securities Act for this issuance.

## **Exhibits**

The following is a list of exhibits filed as part of this Registration Statement. Where so indicated by footnote, exhibits which were previously filed are incorporated herein by reference. Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Exhibit Number	scription
3.1	Articles of Incorporation of Scription Work Solutions, Inc.
3.2	Bylaws of Scription Work Solutions, Inc.
4.1	Form of Subscription Agreement
5.1	Opinion of Dean Law Corp, re: the legality of the shares being registered

- 23.1 Auditor Consent
- 23.2 Consent of Dean Law Corp (included in Exhibit 5.1)

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

#### **Undertakings:**

Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

#### The undersigned registrant hereby undertakes:

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
- iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
- ii.If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

# **Signatures**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Las Vegas, State of Nevada, on January 21, 2014.

# SCRIPTION WORK SOLUTIONS Inc., formerly known as TRANSTECH SOLUTIONS Inc.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

By: /s/ Christopher Weinhaupl
Christopher Weinhaupl
President, Chief Executive Officer,
Secretary, Treasurer, Principal
Accounting Officer, Chief
Financial Officer and Director

DATE January 21, 2014

#### Via EDGAR

Ivan Griswold United States Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549

Dear Mr. Griswold:

Re: Scription Work Solutions, Inc. (the "Company")
Amendment No. 7 to Registration Statement on Form S-1
Filed March 29, 2013, May 10, 2013, June 28, 2013, October 7, 2013,

October 7, 2013, November 1, 2013, November 25, 2013 File No. 333-187609

I am President and C.E.O. of the Company and am writing this letter on behalf of the Company. As per our telephone conversation last week, I have addressed your comments below along with our response and, if applicable, our proposed changes to the Registration Statement:

1. In our disclosure of Management in Directors, Executive Officers, Promoters and Control Persons you asked for clarification in for the use of the word "disruptive" in Mr. Weinhaupl's past or present work experience. It was then suggested that S-1 filings are inclusive of company mission statements, distinct management skills and corporate milestones.

ANSWER The use of the word disruptive in Mr Weinhaupl's management background is used to describe his business nature when seeking out new opportunities. The word is inclusive of his current opportunity within the medical transcription industry, which he believes to be a lucrative industry that continues to grow. Mr. Weinhaupl seeks out ventures that he believes advancement in technology and logistics development serve as a strategic differentiation in business growth.

The following disclosures have been added to the filing:

# The Company - Who We Are; Mission Statement

We are a Nevada corporation and were formed on July 12, 2011. Medical transcription is converting confidential patient information from various sources such as voice recordings or medical notes into electronic text documents by medical transcriptionists.

At Scription Work Solutions Inc. our mission it to provide state of the art transcription services, with a primary focus on building customer trust by ensuring a high level of confidentiality. Our goal is to ensure that customer's associate simplicity and efficiency in reliable next day turn around services when they think of our brand. Customer satisfaction and loyalty is the backbone of our business. Our primary business objective is to maximize earnings and cash flow by constant marketing efforts to increase our client base.


Since 2010, Christopher Weinhaupl has held ownership and was a founder of Canadapack a North American cross boarder Logistics Company. Mr. Weinhaupl was apart of data and web based business development, along with managing their marketing team. He was responsible for overseeing day to day operations. From 2001 to present, Mr. Weinhaupl has been a Senior Partner at "mypharmacard", a payment processor solution for web based Pharma companies. Mr. Weinhaupl continues to oversee the marketing and development of this company's corporate brand imaging. From 2005 to present, Mr. Weinhaupl has held a position as Senior Network Support at Enterprise Contact

Centers, providing technology support for North American businesses. Mr. Weinhaupl holds academic diplomas in International Marketing an International Finance. His organizational skills, marketing skills on building a brand, and his experience working in the medical industry with "mypharmacare" will assist Scription Work Solutions Inc. and help grow the business.

2. On page 49, the Signature page should be phrased as precisely as it is on the SEC's S-1 file format. http://www.sec.gov/about/forms/forms-1.pdf

ANSWER: This disclosure has been revised to reflect your recommended changes.

Thank you. Chris Weinhaupl



# CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the filing documentation on Form S-1 of Scription Work Solutions Inc (fka: Transtech Solutions Inc.) of our report dated February 8, 2013, except the Company name change which is as of June 5, 2013, and to the reference to our firm under the caption "Experts" included in this registration statement.

/s/ Kenne Ruan, CPA, P.C.

Woodbridge, Connecticut January 21, 2014

COMPOSITE EXHIBIT D	

From: Amrit Hayer

Sent: Wednesday, March 27, 2013 11:52 AM

To: fdean@deanlawcorp.com Subject: Re: Transtech S1

COMPOSITE EXHIBIT D

Hi Faiyez can you please send over the consent, we are going to file soon.

Thanks

Sent from my iPhone

On 2013-03-26, at 6:28 PM, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote:

No problem, I will get that to you tomorrow morning. Do you have an EDGAR Agent to convert the document.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8

Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Date: Tue, 26 Mar 2013 18:24:17 -0700

To: <fdean@deanlawcorp.com>

Subject: RE: Transtech S1

Hi Faiyez,

I have attached the auditors consent. Please reply with your consent and we are going to self file this on our own. Please date your consent for March 27th.

Thanks, Amrit

From: fdean@deanlawcorp.com

То:

Subject: RE: Transtech S1

Date: Mon, 25 Mar 2013 12:09:06 -0700

Let me know once you have auditor's consent to file.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image002.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Sent: Thursday, March 21, 2013 8:24 PM

To: fdean@deanlawcorp.com

Subject: RE: Transtech S1 Payment proof for shareholders. Thanks, From: fdean@deanlawcorp.com To: amrithayer@hotmail.com Subject: RE: Transtech S1 Date: Thu, 21 Mar 2013 09:17:34 -0700 Before I can provide the legal opinion, I need copies of the director's resolution issuing the shares to the shareholders, as well as proof of payment for the shareholders. Regards, Faiyaz Dean Attorney-at-Law\* (\*licensed in BC and Washington) <image004.jpg> Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8

Tel: 604.628.4838

Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Sent: Wednesday, March 20, 2013 9:23 PM

To: fdean@deanlawcorp.com Subject: Transtech S1

Sent time:

03/26/2013 10:18:18

To:

fdean@deanlawcorp.com

Subject:

Re: Transtech S1

We have software to edgerize the documents.

**Thanks** 

Sent from my iPhone

On 2013-03-26, at 6:28 PM, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote:

No problem, I will get that to you tomorrow morning. Do you have an EDGAR Agent to convert the document. Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Date: Tue, 26 Mar 2013 18:24:17 -0700

To: <fdean@deanlawcorp.com>
Subject: RE: Transtech S1

Hi Faiyez,

I have attached the auditors consent. Please reply with your consent and we are going to self file this on our own. Please date your consent for March 27th.

Thanks, Amrit

From: fdean@deanlawcorp.com

Amrit Hayer

Sent time:

03/21/2013 11:12:37

To:

fdean@deanlawcorp.com

Subject:

RE: Transtech S1

Attachments:

TT Meeting of Director - Share issuace Shareholders 2012.doc TT Meeting of Director - Share issuace to Chris Weinhaupl

2012.doc TT Meeting of Director - Share issuace to Chris Weinhaupl 2011.doc

Hi Faiyaz,

Please see attached directors resolutions and I will send proof of payment for shareholders in the following emails.

Thanks, Amrit

From: fdean@deanlawcorp.com

To:

Subject: RE: Transtech S1

Date: Thu, 21 Mar 2013 09:17:34 -0700

Before I can provide the legal opinion, I need copies of the director's resolution issuing the shares to the shareholders, as well as proof of payment for the shareholders.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



### Dean Law Corp. (Vancouver)

555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

#### Dean Law Corp. (Seattle)

601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Sent: Wednesday, March 20, 2013 9:23 PM

To: fdean@deanlawcorp.com Subject: Transtech S1

Hi Faiyez,

Our accountant is ready to issue an audit report for the Transtech S1. We have also made revisions as you suggested.

Amrit Hayer

Sent time:

03/21/2013 12:23:01

To:

fdean@deanlawcorp.com

Subject:

Transtech S1

Attachments:

TransTech Solutions S1 ver3.doc

Hi Faiyez,

Our accountant is ready to issue an audit report for the Transtech S1. We have also made revisions as you suggested.

Please see attached and let us know if we are good to move forward.

Thanks,

Amrit

Faiyaz Dean <fdean@deanlawcorp.com>

Sent time:

04/30/2013 01:17:48

To:

Paul Kwon

Subject:

RE: Transtech S1A1

Hi Paul,

Since your group prepared the S-1 on your own, I just wanted to confirm with you that any time I spend working on the comments will be billed hourly? Is that your understanding?

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Paul Kwon

Sent: April 29, 2013 7:34 PM

To: Faiyaz Dean Cc: Andy Jagpal

Subject: Transtech S1A1

Hi Faiyaz,

Attached are the Transtech S1A1 and our answers to the comment letter.

Please review the S1A1 and the comment responses, especially the ones highlighted in yellow, and advise whether our responses are adequate.

Thank you.

Paul Kwon

Sent time:

04/30/2013 05:47:19

To:

Faiyaz Dean <fdean@deanlawcorp.com>

Subject:

Re: Transtech S1A1

Hi Faiyaz,

Yes, please send me an invoice for the time that you will be spending to review the S1A1 and the comment letter responses.

We are in the process of changing the company name from Transtech Solutions Inc to Scription Work Solutions Inc. When the name change has been completed with the Nevada SoS, I think we will have to file something on EDGAR advising of the name change. Is this something that we add to the S1 amendment that we are filing? Or is there a separate filing for company name changes?

Thank you.

Paul

On 2013. 4. 30., at 오전 10:17, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote:

Hi Paul,

Since your group prepared the S-1 on your own, I just wanted to confirm with you that any time I spend working on the comments will be billed hourly? Is that your understanding?

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image001.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101

Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Paul Kwon

Sent: April 29, 2013 7:34 PM

To: Faiyaz Dean Cc: Andy Jagpal

Subject: Transtech S1A1

Hi Faiyaz,

Attached are the Transtech S1A1 and our answers to the comment letter.

Please review the S1A1 and the comment responses, especially the ones highlighted in yellow, and advise whether our responses are adequate.
Thank you.
Paul
Paul
Paul
Paul .
Paul
Paul
Paul Tenter to the control of the co

Paul Kwon

Sent time:

05/08/2013 02:54:03

To:

Faiyaz Dean <fdean@deanlawcorp.com>

Subject:

Re: Transtech S1A1

Attachments:

TT S1A1 Changes Tracked Q8-Q10 Q37.doc

Hi Faiyaz,

We only require a review of Q8-Q10 and Q37 of the comment letter.

Attached is the S1A1 with the changes tracked only pertaining to those questions. We did all the changes on htm, and it would take several hours to track all changes made for the 38 questions to word.

If you really need the changes made to the entire S1A1 tracked, then I can get it to you later tonight.

Thank you.

Paul

On Wed, May 8, 2013 at 11:18 AM, Faiyaz Dean <fdean@deanlawcorp.com > wrote:

Hi Paul,

You never sent me the redlined copy of the S-1? I will need that to review the responses to the comments.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777 Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Paul Kwon
Sent: May 8, 2013 8:15 AM

To: Faiyaz Dean

Subject: Re: Transtech S1A1

Hi Faiyaz,

Have you had a chance to read over our responses for questions 8, 9, 10, and 37 in Transtech's S1A1 Comment Letter Response?

Thank you. Paul

On Tue, May 7, 2013 at 3:04 PM, Paul Kwon

wrote:

Hi Faiyaz.

Thank you for the information. I will give you a call about this later this week.

Please let me know when you have had a chance to review the four Transtech S1A1 comment letter questions.

We are hoping to file our comment response by the end of this week.

Thank you.

Paul

On Tue, May 7, 2013 at 11:59 AM, Faiyaz Dean < fdean@deanlawcorp.com > wrote:

Hi Paul,

The quickest, easiest and most cost effective way would be a stock split. Feel free to call or email to discuss.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101

Tel: <u>206.274.4598</u> Fax: <u>206.493.2777</u>

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From:

Date: Tue, 7 May 2013 00:20:40 +0000

To: Faiyaz Dean<fdean@deanlawcorp.com>

ReplyTo:

Subject: Re: Transtech S1A1

Hi Faiyaz,

Quick question.

For Transtech, we currently have 30.1mil shares to the President and 20mil shares to the shareholders.

If we want to increase the number of shares for both the President and the shareholders, what is the best way to do it? Would it be to register the additional shares via another S1 or a stock split?

Thank you.

Paul

Sent from my BlackBerry® smartphone powered by Mobilicity

From: "Faiyaz Dean" < fdean@deanlawcorp.com>

Date: Wed, 1 May 2013 12:04:32 -0700

To:

Subject: RE: Transtech S1A1

Hi Paul.

The changes need to be redlined on the word document using word's track function feature.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604 628 4838

Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From:

Sent: May 1, 2013 11:51 AM

To: Faiyaz Dean

Subject: Re: Transtech S1A1

Hi Faiyaz,

Thank you for the heads up.

On the html version of our filing, the changes and revisions are highlighted. I will locate the revisions on our html file and highlight it on the word copy that I will send you later today.

Thank you

Paul

Sent from my BlackBerry® smartphone powered by Mobilicity

From: "Faiyaz Dean" < fdean@deanlawcorp.com>

Date: Wed, 1 May 2013 10:34:19 -0700

To: 'Paul Kwon'

Cc: 'Andy Jagpal'<aijagpal@alliancevancouver.com>

Subject: RE: Transtech S1A1

Hi Paul,

You need to redline all changes to the S-1 on the amendments so that the SEC is able to pick up the changes. Please redlined and send back to me or if you'd like, e-mail me a copy of the document that was filed and I can do a compare and pick up the changes.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Paul Kwon

Sent: April 29, 2013 7:34 PM

To: Faiyaz Dean Cc: Andy Jagpal

Subject: Transtech S1A1

Hi Faiyaz,

Attached are the Transtech S1A1 and our answers to the comment letter.

Please review the S1A1 and the comment responses, especially the ones highlighted in yellow, and advise whether our responses are adequate.

Thank you.

Sent time:

04/17/2013 12:33:42

To:

Faiyaz Dean <fdean@deanlawcorp.com>; Andy Jagpal <ajagpal@alliancevancouver.com>

Subject:

Re: TransTech Name Letter

Hi Faiyaz,

Did you have a chance to look over the attached letter that I sent you?

The legal letter has set an April 19th deadline to comply so we should act on this quickly.

Please let me know.

Thank you

Paul

Sent from my BlackBerry smartphone powered by Mobilicity

From: Paul Kwon

Date: Mon, 15 Apr 2013 09:09:20 -0700

To: Faiyaz Dean<fdean@deanlawcorp.com>; Andy Jagpal<ajagpal@alliancevancouver.com>

Subject: TransTech Name Letter

Hi Faiyaz,

I hope you had a good weekend.

Attached is a letter we received from a Texas company with the same name as us demanding that we change our name.

Please review and advise on how we should proceed.

Thank you.

Vancouver, BC V7X 1M8 Tel: <u>604.628.4838</u> Fax: <u>604.630.3099</u>

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101

Tel: <u>206.274.4598</u> Fax: <u>206.493.2777</u>

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Paul Kwor

**Sent:** April 29, 2013 7:34 PM

To: Faiyaz Dean Cc: Andy Jagpal

Subject: Transtech S1A1

Hi Faiyaz,

Attached are the Transtech S1A1 and our answers to the comment letter.

Please review the S1A1 and the comment responses, especially the ones highlighted in yellow, and advise whether our responses are adequate.

Thank you.

Sent time:

06/05/2013 04:54:48

To:

Faiyaz Dean <fdean@deanlawcorp.com>

Subject:

Update

#### Hi Faiyaz,

I just wanted to give you a heads up that with Transtech, we have completed with Nevada the corpor ate name change to Scription Work Solutions, Inc. The 8-K for the name change was filed today.

If you hear any updates regarding Flow Tech's DTC or Enviro Cleanse's 15C, please let me know.

Thank you

Paul

Sent from my BlackBerry® smartphone powered by Mobilicity

Paul Kwon

Sent time:

11/15/2013 07:51:34

To:

Faiyaz Dean <fdean@deanlawcorp.com>

Subject:

Fwd: SEC Comment Letter: Scription Work Solutions Inc Inc S-1-A 2013-11-15 Letter

Attachments:

Scription Work Solutions Inc Inc S-1-A 2013-11-15 Letter[CLEAN].pdf

Hi Faiyaz,

Please respond to Comment 8 of the most recent comment letter.

Thank you. Paul

----- Forwarded message -----

From: Griswold, Ivan < Griswoldl@sec.gov>

Date: Fri. Nov 15, 2013 at 2:44 PM

Subject: SEC Comment Letter: Scription Work Solutions Inc Inc S-1-A 2013-11-15 Letter

To: "fdean@deanlawcorp.com" <fdean@deanlawcorp.com>, "chrisw@transtechsolutionsinc.com"

<chrisw@transtechsolutionsinc.com>

Please find attached a letter relating to the filing referenced therein. Do not respond to this electronic communication unless you have received it incorrectly. If you have any questions, please contact the person(s) identified at the end of the attached letter.

Division of Corporation Finance
U.S. Securities & Exchange Commission
100 F Street, NE
Washington, D.C. 20549
www.sec.gov

This communication and its attachment(s) contain sensitive, nonpublic information generated by the SEC or by a private entity. Such information is exempt from public disclosure under applicable law. If you are not the intended recipient of this communication (or a person responsible for delivering it to the intended recipient), do not review, copy, disclose, or disseminate this communication or its attachment(s). Immediately notify the sender of this communication by email or phone that you have received it in error, and delete the communication and attachment(s) without making or retaining any copies, electronic or otherwise. Thank you for your cooperation.

Sent time:

04/02/2013 05:33:11

To:

Faiyaz Dean <fdean@deanlawcorp.com>

Cc:

Amrit Hayer

Subject:

Re: Transtech S1

Hi Faiyaz,

Please be advised that the S1 was filed last week for Transtech.

Are you required to provide the Transtech email seperately to the SEC?

Thank you

Paul

Sent from my BlackBerry® smartphone powered by Mobilicity

From: Paul Kwon

Date: Tue, 2 Apr 2013 11:09:59 -0700

To: Faiyaz Dean<fdean@deanlawcorp.com>

Cc: Amrit Hayer

Subject: Re: Transtech S1

chrisw@transtechsolutionsinc.com

On 2013. 4. 2., at 오전 11:03, "Faiyaz Dean" <fdean@deanlawcorp.com> wrote:

What is the e-mail for the company? I need to provide it to the SEC for the comment letter.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image001.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Faiyaz Dean <fdean@deanlawcorp.com>

Sent time:

04/15/2013 03:58:34

To:

Cc:

Amrit Hayer

Subject:

RE: Transtech S1

Hey guys,

Just got a call from the SEC and they noticed a spacing issue with the President's name. There aren't any spaces between his first and last names. This will need to be resolved in the next amendment.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)



Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From:

Sent: April 2, 2013 2:33 PM

To: Faiyaz Dean Cc: Amrit Hayer Subject: Re: Transtech S1 Hi Faiyaz, Please be advised that the S1 was filed last week for Transtech. Are you required to provide the Transtech email seperately to the SEC? Thank you Paul Sent from my BlackBerry® smartphone powered by Mobilicity From: Paul Kwon Date: Tue, 2 Apr 2013 11:09:59 -0700 To: Faiyaz Dean<fdean@deanlawcorp.com> Cc: Amrit Hayer Subject: Re: Transtech S1 chrisw@transtechsolutionsinc.com On 2013. 4. 2., at 오전 11:03, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote: What is the e-mail for the company? I need to provide it to the SEC for the comment letter. Regards, Faiyaz Dean Attorney-at-Law\* (\*licensed in BC and Washington) <image001.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777 Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Sent: March-27-13 1:20 PM

To: Faiyaz Dean

Subject: Re: Transtech S1

Thanks!

Sent from my iPhone

On 2013-03-27, at 1:11 PM, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote:

Please see attached.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image003.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Sent: Wednesday, March 27, 2013 11:52 AM

To: fdean@deanlawcorp.com Subject: Re: Transtech S1

Hi Faiyez can you please send over the consent, we are going to file soon.

Thanks

Sent from my iPhone

On 2013-03-26, at 6:28 PM, "Faiyaz Dean" < fdean@deanlawcorp.com > wrote:

No problem, I will get that to you tomorrow morning. Do you have an EDGAR Agent to convert the document.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838

Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101

Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer

Date: Tue, 26 Mar 2013 18:24:17 -0700

To: <fdean@deanlawcorp.com>

Subject: RE: Transtech S1

Hi Faiyez,

I have attached the auditors consent. Please reply with your consent and we are going to self file this on our own. Please date your consent for March 27th.

Thanks, Amrit

From: fdean@deanlawcorp.com

To:

Subject: RE: Transtech S1

Date: Mon, 25 Mar 2013 12:09:06 -0700

Let me know once you have auditor's consent to file.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image002.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838

Fax: 604.630.3099

Dean Law Corp. (Seattle)

601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598

Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer
Sent: Thursday, March 21, 2013 8:24 PM
To: fdean@deanlawcorp.com
Subject: RE: Transtech S1

Payment proof for shareholders.

Thanks,

From: fdean@deanlawcorp.com
To: Subject: RE: Transtech S1

Date: Thu, 21 Mar 2013 09:17:34 -0700

Before I can provide the legal opinion, I need copies of the director's resolution issuing the shares to the shareholders, as well as proof of payment for the shareholders.

Regards,

Faiyaz Dean Attorney-at-Law\*

(\*licensed in BC and Washington)

<image004.jpg>

Dean Law Corp. (Vancouver) 555 Burrard Street, Suite 900 Vancouver, BC V7X 1M8 Tel: 604.628.4838 Fax: 604.630.3099

Dean Law Corp. (Seattle) 601 Union Street, Suite 4200 Seattle, Washington 98101 Tel: 206.274.4598 Fax: 206.493.2777

Web: www.deanlawcorp.com

Disclaimer - This email and any files transmitted with it are confidential and contain privileged information. You must not present this message to another party without gaining permission from the sender. If you are not the intended recipient you must not copy, distribute or use this email or the information contained in it for any purpose other than to notify us. If you have received this message in error, please notify the sender immediately, and delete this email from your system.

From: Amrit Hayer
Sent: Wednesday, March 20, 2013 9:23 PM
To: fdean@deanlawcorp.com
Subject: Transtech S1

Hi Faiyez,

Our accountant is ready to issue an audit report for the Transtech S1. We have also made revisions as you suggested.

Please see attached and let us know if we are good to move forward.


Thanks,

Amrit


<Exhibit 5.1 - Transtech.doc>

**COMPOSITE EXHIBIT E** 


## COMPOSITE EXHIBIT E





FOIA Confidential Treatment Requested



.-







.

# **EXHIBIT F**

Page 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
In the Matter of:
) File No. FL-03857-F GENUFOOD ENERGY ENZYMES CORP. )
WITNESS: Christopher Weinhaupl
PAGES: 1 through 163
PLACE: Securities and Exchange Commission
44 Montgomery Street, Suite 2800
San Francisco, CA 94104
DATE: Thursday, August 21, 2014
The above-entitled matter came on for hearing,
pursuant to notice, via video teleconference, at
9:51 a.m. (PST); 12:51 p.m. (EST).

Diversified Reporting Services, Inc.

(202) 467-9200

		Page 2		<del></del>	Page 4
1	APPEARANCES:	-	1	CONTENTS (CONT.)	
2	71172711011102201		2		
3	On behalf of the Securities and	Exchange Commission	3	EXHIBITS: DESCRIPTION II	DENTIFIED
4	(Via Video Teleconference):	Ū	4	49 Form S-1 81	
5	GARY MILLER, ESQ.	:	5	50 Letter dated May 10, 2013	24
6	Securities and Exchange Co	mmission	6	51 Letter dated November 25, 2013	125
7	801 Brickell Avenue, 18th F	loor	7	52 Letter dated January 10, 2013	126
8	Miami, FL 33131		8	53 Collection of emails 127	
9	(305) 982-6300		9	54 Collection of emails 128	
10			10	55 Invoice No. TTS082713	129
11	On behalf of the Witness:		11	56 Collection of emails 130	
12	GARY A. VARNAVIDES,	ESQ.	12	57 Invoice No. 1666 131	
13	Sichenzia, Ross, Friedman	& Ference, LLP	13	58 Meeting minutes 133	
14	61 Broadway, 32nd Floor		14	59 Meeting minutes 136	
15	New York, New York 1000	)6	15	60 Private Placement 137	
16	(212) 930-9700		16	Subscription Agreement	
17			17		139
18			18	Statement of Accounts	
19			19		143
20			20	Statement of Accounts	
21			21		44
22			22	64 State of Alaska 146	
23			23	Certificate of Involuntary	
24			24 25	Dissolution/Revocation	
25			25		
		Page 3			Page 5
1	CONTENTS		1	CONTENTS (CONT.)	
2			2		
3	WITNESS:	EXAMINATION	3	EXHIBITS: DESCRIPTION II	DENTIFIED
4	Christopher Weinhaupl	7	4	65 Wells Fargo Combined 1	148
5		•	5	Statement of Accounts	
6	EXHIBITS: DESCRIPTION	IDENTIFIED	6	66 Invoice No. SWS104 . 14	49
7	44 Subpocna	12	7		150
8	United States of Ameri		8	Statement of Accounts	
9	Securities and Exchang	e	9	68 Client Information Form 1	56
10	Commission		10	•	
11	Christopher Weinhaupl		11		
12	45 Subpoena	16	12		
13	United States of Ameri		13		1
14	Securities and Exchang	e	14		
15 16	Commission Custodian of Records		15 16		
17	c/o Christopher Weinha	auni	17		
18	46 Subpoena	з <del>ир</del> і 35	18		
19	United States of Ameri		19		
20	Securities and Exchang		20		
21	Commission	<del></del>	21		
22	Custodian of Records		22		
23	c/o Gary A. Vamavides	•	23		
24	47 Wiring instructions	72	24		
25	48 Wire transfer	73	25		

_	Page 26		Page 28
1	Kwon to help us do that and facilitate it with us or	1	O When did it retain Mr. Kwon?
2	with me.	2	A This would have started maybe the spring of
3	BY MR. MILLER:	3	2013.
4	Q Okay. So Mr. Jagpal and Mr. Rai told you	4	Q And at that point to present, does Mr. Kwon
5	about Mr. Kwon so that you could, on behalf of	5	have access or strike that.
6	Scription, retain Mr. Kwon so that Scription could go	6	From the time Scription retained Paul Kwon to
7	public. Did I get that right?	7	present, does Mr. Kwon have possession of all of
8	A Correct.	8	Scription's documents, corporate documents?
9	Q What did they tell you about Mr. Kwon that	وا	A Yes, he does.
10	caused you to want to use him?	10	Q Do you as CEO have any possession of any of
11	A Nothing specific. Just a	11	Scription's documents?
12	O And then —	12	A I have copies.
13	A - recommendation.	13	Q Of every document?
14	Q I apologize again. Did you finish your	14	A Yes.
15	answer?	15	Q And what about emails? Does Scription, or
16	A Just a recommendation.	16	you in your capacity as Scription's CEO, use emails?
17	Q And then when you say Mr. Kwon assisted with	17	A Yes, we do.
18	the — and a secretary, that you can't recall the name	18	O And who has custody of the emails?
19	of, assisted in the production and the search for	19	A I think I would have my emails, and Paul
20	documents pursuant to Genufood 45, did Mr. Kwon have	20	would have, for example, his — he would have his
21	access to Scription's documents?	21	emails.
22	A Yes.	22	Q What email address have you used, since
23	Q How about to documents kept electronically?	23	Scription came into existence to present, in order to
24	A I think all of our documents are in	24	communicate on behalf of Scription?
25	electronic format. Is that what you're referring to?	25	A I may have used a few email accounts, and I
<u> </u>	decident format. Is that what you're reterring to.		7. Thay have used a few chian accounts, and I
	Page 27		Page 29
1	Q I don't know if you have hard copies or not;	1	don't know which ones specifically I would have used.
2	but if you're telling me everything is electronic,	2	Q It's fine. You can just name them all. And
.3	that's your answer.	3	this starts in the period July 2011 to the present.
4	A Okay. Yeah, everything is in electronic	4	A
5	format.	5	And
6	. Q So Mr. Kwon had access to Scription's systems	6	Just those three.
7	where it keeps its electronic documents?	7	Q Nothing else?
8	A I think it would be correct to say that Paul	8	A Nothing else.
9	kept them for Scription.	9	Q Are you certain of that?
10	Q And since what period of time?	10	A I'm not sure, no. Not certain.
11	A Since we started the process for the filing.	11	Q Do you want to take a few minutes to think
12	Q And when was that, sir?	12	about it?
13	A 2013. Sometime in 2013.	13	A Those would be the email addresses I would
14	Q So when you first retained Mr. Kwon - well,	14	have used to communicate with Paul.
15	strike that.	15	Q I wasn't - I'm sorry. The question wasn't
16	Did Scription ever retain Mr. Kwon as its	16	just with Paul. I'm talking about, in general, emails
17	counsel for registration?	17	that you used in your capacity as the CEO of Scription.
18	A I'm sorry. What does that mean, "for	18	A Yes, as my - for Scription, yes, those would
19	registration"?	19	be the three email accounts.
20	Q Okay. You said you wanted - that Scription	20	Q And what about Mr. Kwon? Does he have any
21	wants to go public; is that right?	21	email accounts, that you're aware of, where he
22	A Correct.	22	communicates on behalf of well, strike that.
23	Q In order to go public, did Scription retain	23	Does Mr. Kwon, that you know of, communicate
24	Mr. Kwon?	24	on behalf of Scription using email?
25	A Yes.	25	A No.

	Page 20	Γ-	Page 20
	Page 30		Page 32
1	Q Have you ever gotten an email from Mr. Kwon?	1	question was when you're referring to "you," that was
2	A Yes.	2	to Scription, the company as a whole, Mr. Miller.
3	Q Do you know what his email address is?	3	So I believe Mr. Weinhaupl testified earlier
4	A May I look it up?	4	that the secretary for Scription had searched for
5	MR. VARNAVIDES: If you know, you know.	5	documents responsive to the subpoena, Exhibit 45.
6	MR. MILLER: Sure.	6	So to be clear, I think Mr. Miller's first
7	THE WITNESS: I don't know it at the moment,	7	question was directed to Scription on the whole,
8	but do you want me to -	8	because his subsequent question asked you specifically
9	MR. VARNAVIDES: Gary, are you -	9	as CEO. So I think there might be some confusion there.
10	MR. MILLER: Counsel, do you -	10	MR. MILLER: Thank you very much for that,
11	MR. VARNAVIDES: Gary, are you instructing	11	Counsel. You're 100 percent right.
12	Mr. Weinhaupl to look up Mr. Kwon's email? Is that	12	BY MR. MILLER:
13	the	13	Q Do you have - do you understand what the
14	MR. MILLER: No, I'm not instructing him to	14	question is now, Mr. Weinhaup!?
15	do anything. I'm asking him the question; but if he	15	A No. Pardon me.
16	has volunteered to and he'd like to assist, that's	16	Q No problem. I'll rephrase.
17	terrific.	17	A Thank you.
18	MR. VARNAVIDES: For the record, Mr.	18	Q As your counsel just correctly pointed out,
19	Weinhaupl is checking his phone to look up Paul Kwon's	19	the first one was what did Scription do in order to
20	email address.	20	comply with Exhibit 45. You said that a secretary of
21	MR. MILLER: Thank you, Counsel.	21	Scription and Mr. Kwon were responsible and did produce
22	THE WITNESS:	22	pursuant to Exhibit 45.
23		23	Now my question is, what did you personally
24	BY MR. MILLER:	24	do as CEO of Scription in order to respond to Exhibit
25	Q Did you grant Mr. Kwon the authority to use	25	45 on behalf of Scription?
	Page 31		Page 33
1	any of your email addresses to communicate on behalf of	1	A I asked Paul to prepare the documents to
2	Scription?	2	forward.
3	A No.	3	Q Did you review any of the documents before
4	Q Did you grant anyone else authority to use	4	they were sent to the SEC staff?
5	your email addresses to communicate on behalf of	5	A No.
6	Scription?	6	Q Why is that?,
7	A No.	7	A They were coming from Paul's office, and they
A	Q Did Scription produce emails pursuant to	8	were being expedited to Gary's office in New York. So
9	Exhibit 45?	9	I'm not in the same town as Paul, and that would have
10	A Not that I recall.	10	taken extra time.
11	Q Did you search for responsive emails in	11	Q So when you answered my first question that I
12	response to Exhibit 45?	12	asked a few moments ago, has Scription tendered all
13	A I'm sorry. What does that mean?	13	documents responsive to Exhibit 45, you said yes. How
14	Q Did you search your emails to see whether or	14	do you know that's the right answer if you didn't
15	not any of the emails that you had regarding Scription	15	review the documents?
16	were responsive to any of the questions and requests	16	A I was just told that it was.
17	that are made in Exhibit 45?	ı	•
		17	Q By who?
18	A No.	18	A By Paul.
19 20	Q Did you as CEO of Scription do anything in	19	Q Did you ever read the requests in Exhibit 45?
21	order to search for responsive documents to Exhibit 45?	20	A Yes.
22	A No.	21	Q Where was Scription's secretary physically
	MR. VARNAVIDES: Just to	22	located? What city?
23	BY MR. MILLER:	23	A Vancouver.
24	Q Why is that?	24	Q What address in Vancouver?
25	MR. VARNAVIDES: - to clarify, the earlier	25	A I don't know the exact address. She works

		-	D 72
	Page 70		Page 72
1	THE WITNESS: I'm more on just the	1	the street address, or is it pardon me. Vancouver's
2	semantics of it, I'm not sure if I hired Gary to	2	broken up into suburbs kind of like the greater
3	represent myself, or Scription hired Gary to represent	3	Vancouver regional area. So he would live in a suburb
4	Scription.	4	of Vancouver. I think he's either in Surrey or Delta.
5	BY MR. MILLER:	5	I apologize for not knowing. He's on the boundary of
6	Q Okay. But - but one of the two of you -	6	one of those two areas.
7	you're saying that Mr. Varnavides' firm represents	7	Q No worries. And why – what about his email
8	Scription; is that right?	8	account? What is his email address?
9	A Yes.	9	A Ajagpal J-a-g-p-a-l
10	MR. VARNAVIDES: I think he just got a little	10	@alliancevancouver.com.
11	crossed up on the semantics, Gary.	11	MR. MILLER: Madam Court Reporter, could you
12	MR. MILLER: No worries. No worries.	12	pull folder number 41 and mark that as Exhibit Genufood
13	THE WITNESS: Sorry.	13	47, and hand it to the witness?
14	BY MR. MILLER:	14	THE REPORTER: Yes.
15	Q And in order to secure Mr. Varnavides' firm	15	(SEC Exhibit No. 47 was marked for
16	to provide legal services, did Scription pay a retainer	16	identification.)
17	to Mr. Varnavides' firm?	17	BY MR. MILLER:
18	A Yes.	18	Q Mr. Weinhaupl, I think you have in front of
19	Q How much was the retainer?	19	you Genufood Exhibit 47. It should be Bates stamped at
20	A Maybe 5 or \$7,000 U.S. maybe or	20	the bottom, right-hand corner Scription 000158 through
21	Q And what was the source - I apologize. What	21	160. Are we looking at the same document?
22	was the source of the money for Mr. Varnavides' firm's	22	A Yes, yes.
23	retainer?	23	Q All right. Do you see the last page of
24	A I wanted to transfer the funds right away, so	24	Exhibit 47? In the signature block, do you see that
25	I had asked a friend with money sitting in an account	25	signature? Is that you?
	Page 71		Page 73
1	to forward the funds on my behalf to Gary's firm in a	1	A Yeah yes, that's me.
2	wire transfer for me.	2	Q And it is page Bates stamped and ends at 159
3	Q And who's the friend?	3	and 160, is that the retainer of Mr. Varnavides' firm
4	A Andy Jagpal.	4	for Scription?
5	Q Where did he wire the funds from?	5	A Yes.
6	A Andy would know. I knew it was another I	6	Q Thank you.
7	think it was one of his - I can't say, but -	7	MR. MILLER: Madam Court Reporter, could you
8	Q Has Scription paid him back?	8	please pull the folder that's labeled 42 and mark that
9	A Not yet.	9	as Exhibit 48, and hand that to the witness, please?
10	Q Have you personally paid him back?	10	THE REPORTER: Yes.
11	A No.	11	(SEC Exhibit No. 48 was marked for
12	Q Why is that?	12	identification.)
13	A I think it's just I haven't gotten to it yet.	13	THE REPORTER: (Indicating).
14	Q What's Mr. Jagpal's full mailing address and	14	THE WITNESS: Thank you.
15	phone number?	15	THE REPORTER: Uh-huh.
16	A I don't have his address. Like, his home	16	BY MR. MILLER:
17	address?	17	Q Okay. I think you have in front of you
18	Q His home address and his phone number. You	18	Genufood 48, which should be Bates stamped Scription
19	can look in your phone if you need to. What's his	19	000525. Are we looking at the same document,
20	phone number?	20	Gentlemen? Or Mr. Weinhaupl?
21	A His phone number would be so area code	21	A 48? Genufood 48?
22		22	Q Yes. Is it Bates stamped in the bottom,
23	Q And his address?	23	right-hand corner Scription 000525?
	A He lives in Vancouver, British Columbia. But	24	A Yes.
24 25	for the street address, I wouldn't know specifically		,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

	Page 102		Page 104
1	marked 18. It should be a blank page, totally blank	1	A No.
2	page. Do you see that?	2	Q Could you turn to page 21?
3	A Yes.	3	A Okay.
4	Q Turn to the next page, and there should be a	4	Q Before when you say none of those people own
5	lot of names there.	5	shares of Scription, have any of those people ever
6	A Yes.	6	owned shares of Scription?
7	Q Who are these people?	7	A No.
8	MR. VARNAVIDES: For the record, it's a list	8	Q Okay. On page 21, it says, Interest of named
9	of names identified under the heading Selling	9	experts and counsel. Do you see that?
10	Shareholders.	10	A Yes.
11	THE WITNESS: Where's Selling Shareholders?	11	Q It says, The legality of the shares offered
12	MR. VARNAVIDES: (Indicating).	12	under this registration statement is being passed upon
13	THE WITNESS: Oh, there? My understanding is	13	by Dean Law Corp. Have you ever heard of something
14	these are people that want to participate in the	14	called Dean Law Corp.?
15	company, Scription.	15	A I believe I've heard the name, but I don't
16	BY MR. MILLER:	16	recall the context.
17	Q And how did you have that understanding?	17	Q What does "legality of the shares" mean?
18	A Through Paul.	18	A I don't know.
19	Q What did he tell you?	19	Q Did Scription ever retain Dean Law Corp.?
20	A We contract or I contract staff in the	20	A I don't recall.
21	Philippines to do transcription work and do some	21	Q The next sentence says, The financial
22	management tasks, and - no, these aren't - no. Yeah,	22	statements included in this prospectus and the
23	and some of these people here are those people -	23	registration statement have been audited by Kenne,
24	Q Who?	24	K-e-n-n-e, next name is Ruan, R-u-a-n, CPA. Have you
25	A — that are participated — that I am	25	ever heard of Kenne Ruan, CPA?
	Page 103		Page 105
1	currently contracting work to to do my transcription	1	A No.
2	work.	2	Q Can you turn to the next page? It should
3	Q Who are they?	3	say, Information with respect to registrant.
4	A What do you mean by "who are they?"	4	A Yes.
5	Q Point out the names. Read the names into the	5	
		-	Q Who's the registrant?
. 6 .	record of who you contract with.	6	A Scription.
7	A Well, I would have to get a current list.	6 7	A Scription.  Q And then it says Business. Do you see that?
7 8	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by	6 7 8	A Scription.  Q And then it says Business. Do you see that?  A Yes.
7 8 9	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by	6 7 8 9	<ul> <li>A Scription.</li> <li>Q And then it says Business. Do you see that?</li> <li>A Yes.</li> <li>Q Scription Work Solutions, Inc., FKA Transtech</li> </ul>
7 8 9 10	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons	6 7 8 9	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking
7 8 9 10 11	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.	6 7 8 9 10	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription
7 8 9 10 11	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier	6 7 8 9 10 11	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?
7 8 9 10 11 12	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a	6 7 8 9 10 11 12	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.
7 8 9 10 11 12 13	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used	6 7 8 9 10 11 12 13	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA
7 8 9 10 11 12 13 14	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not	6 7 8 9 10 11 12 13 14	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription
7 8 9 10 11 12 13 14 15	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work,	6 7 8 9 10 11 12 13 14 15	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering
7 8 9 10 11 12 13 14 15 16	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that	6 7 8 9 10 11 12 13 14 15 16	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA  Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and
7 8 9 10 11 12 13 14 15 16 17	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was	6 7 8 9 10 11 12 13 14 15 16 17	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?
7 8 9 10 11 12 13 14 15 16 17 18	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm	6 7 8 9 10 11 12 13 14 15 16 17 18	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.
7 8 9 10 11 12 13 14 15 16 17 18 19 20	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm actually still doing that now, so	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.  Q Okay. So Scription is planning to provide
7 8 9 10 11 12 13 14 15 16 17 18	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm actually still doing that now, so  Q Okay. I guess my question is, do you know	6 7 8 9 10 11 12 13 14 15 16 17 18	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.  Q Okay. So Scription is planning to provide medical transcription services to the Nevada medical
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm actually still doing that now, so	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.  Q Okay. So Scription is planning to provide
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm actually still doing that now, so  Q Okay. I guess my question is, do you know any of these names that are on this list?	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.  Q Okay. So Scription is planning to provide medical transcription services to the Nevada medical community?
7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A Well, I would have to get a current list.  Some of these names look old to me. And what I mean by "old," not currently working or currently contracted by me. And one of the reasons  Q Okay.  A And one of the reasons for that was earlier this year, we took a management change or I took a management change because the approach that we had used for hiring or contracting some of the work was not being successful in that I saw a duplication of work, and it wasn't cost-effective to continue operating that way. And what we did or I did at that time was change away change the operations around. And I'm actually still doing that now, so  Q Okay. I guess my question is, do you know any of these names that are on this list?  A Not personally.	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A Scription.  Q And then it says Business. Do you see that?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtect Solutions, Inc., is a Las Vegas-based business looking to provide services in the U.S. medical transcription marketplace. Is that a true statement?  A Yes.  Q Scription Work Solutions, Inc., FKA Transtech, plans to provide medical transcription services to the Nevada medical community by offering our service through the use of digital equipment and careful proofing. Is that an accurate statement?  A Yes.  Q Okay. So Scription is planning to provide medical transcription services to the Nevada medical community?  A And Nevada would be part of the United

	Page 110	Γ-	Page 112
1	Phase 2 involves purchasing a medical	1	That part?
2	transcription platform, and we do not intend on	2	O Yes, sir.
3	entering Phase 2 until the company raises additional	3	A I see that.
4	funding either through public or private debt or sale	4	Q It says, Mr. Weinbaupl was a part of data and
5	of equity.	5	web-based business development, along with managing
6	Is that the business plan and Plan of	6	their marketing team. He was responsible for
7	Operations description, those two phases?	7	overseeing day-to-day operations.
8	A Those are two phases of the business, yes.	8	Does that say that you were an owner of
وا	Q Okay. So the other information that you gave	وا	Canada Pack or the owner?
10	before about the amalgamation of your three existing	10	A It doesn't say that.
11	medical transcription companies, is that located or	11	Q Is that a correct statement then?
12	listed under the Plan of Operations?	12	A I do that as well.
13	A Where's the Plan of Operations listed? Oh,	13	Q Okay. The next sentence says, From 2001 to
14	right there.	14	present, Mr. Weinhaupi has been a senior partner at,
15	Q I just read it to you.	15	quote, M-y-p-h-a-r-m-a-c-a-r-d, close quote, a payment
16	A Oh, pardon me. No.	16	processor solution for web-based pharma companies. Is
17	Q Why is that?	17	that a true statement?
18	A I don't know.	18	A That — that business didn't start or didn't
19	Q Have you ever read this have you ever seen	19	go anywhere, so that wouldn't be a true statement.
20	this portion or read this portion that I just read to	20	O Why is it in there?
21	you before today?	21	A Maybe someone clipped it from somewhere by
22	A No.	22	accident.
23	Q Did you authorize this information be put in	23	O Who's "someone"? Who's "someone"?
24	the — into Exhibit 49?	24	A Paul Kwon might have clipped it from a
25	A I contributed a lot of this information	25	document that I might have provided that's out of date.
	A 1 controlled a lot of this information		document has 7 mg. nave provided dated as of alle.
	Page 111		Page 113
1	that's here, and much of this information has come from	1	Q Then it says at the bottom, His
2	my business plan.	2	organizational skills, marketing skills on building a
3	Q Okay. Does what we just read there, what I	3	brand and his experience working in the medical
4	just read to you, the Plan of Operations, does that	4	industry with Mypharmacare will assist Scription Work
5	accurately portray Scription?	5	Solutions, Inc., and help grow the business.
6.	A Yes.	.6	Is that a true statement, that your
7	Q I thought you said earlier that Scription was	7	experience working in the medical industry with
8	the amalgamation of your three existing medical	8	Mypharmacare will assist Scription Work Solutions and
9	transcription businesses, and the acquisition of	9	help grow the business?
10	additional ones. Is that listed under the Plan of	10	A I'm sorry. I'm trying to oh, at the last
11	Operations here?	11	line, Mypharmacare. I'm not sure why Mypharmacare is
12	A It's not listed there.	12	in quotes. I think I believe the experience that's
13	Q Then why is that accurate?	13	being referred to is the experience I have with the
14	A We have two phases in our plan. We're	14	medical industry doing the medical transcription work
15	working those two phases. So that's part of our plan.	15	that I'm doing —
16	Q Okay. Can you turn to the page that says 27?	16	Q Okay.
17	A Sure.	17	A currently.
18	Q Okay.	18	Q It says here, quote, M-y-p-h-a-r-m-a-c-a-r-e,
19	A Directors? Yes.	19	close quote. Do you see that?
20	Q Okay. It says, Canada Pack it's got your	20	A I do.
21	name and age there. Do you see that?	21	Q Have you ever heard of something called that?
22	A Yes.	22	A No.
22	Q And then it says Canada Pack. It lists that.	23	Q Do you see above it says, quote,
23	Do you see that?	24	Munhaumaaandalaa aase 9 m
23 24 25	Do you see that?  A Canada Pack and North American, Cross Border.	24 25	M-y-p-h-a-r-m-a-c-a-r-d, close quote? Have you ever heard of that?

	Page 114		Page 116
١.		,	•
1	A Yes.	1	Q Certain Relationships and Related
2	Q Did you ever work for that company,	2	Transactions, do you see that?
3	Mypharmacard?	3	A Yes.
4	A That never became a company. That was an	4	Q It says, On August 26, 2011, the company
5	idea.	5	issued 10 million shares of its common stock at a price
6	Q When did you have the idea?	6	of - it says \$0.001 per share for a value of \$10,000
7	A 2000-2001. Year 2000-2001.	7	to Christopher Weinhaupl, its president. The company
B	Q Okay. And then if you go to the page before	8	relied on Section 4(2) of the Securities Act for this
9	that, it says — there's a bunch of line items there.	9	issuance.
10	Do you see that?	10	Did the company issue you 10 million shares
11	A Yes.	11	for a value of \$10,000 on August 26, 2011?
12	Q It says, Platform purchase time period, 10 to	12	A That would have been the time we
13	12 months. Estimated maximum expenses, \$65,000. Is	13	incorporated, and I put money in for the business to
14	that for the software we talked about before?	14	fund it.
15	A That's correct.	15	Q Okay. That's not my question. That's not my
16	Q Didn't you testify earlier that that was	16	question. Did the company issue those shares to you on
17	\$15,000?	17	August 26, 2011?
18	A Since the writing - since the writing of	18	A I don't recail.
19	this, the market's changed.	19	Q Do you have 10 million shares - do you have
20	Q Since January 21, 2014	20	10 million common shares?
21	A Yes.	21	A In Scription?
22	Q - it's gone from 15,000 to 65,000?	22	Q Yes.
23	MR. VARNAVIDES: I think the opposite of	23	A Yes.
24	that.	24	Q On September 4, 2012, the company issued
25	THE WITNESS: It's come down in price.	25	20,100,000 of its common stock at a price of \$0.001 per
	Page 115		Page 117
1	MR. MILLER: Oh, I see. Thank you for the	1	share for a value of \$20,100 to Christopher Weinhaupl,
2	clarification, Counsel.	2	its president. Is that a true statement?
3	BY MR. MILLER:	3	A I don't recall.
4	Q Let's go to page 29.	4	Q It says, The company relied on Section 4(2)
5	A Okay.	5	of the Securities Act for this issuance. What is
6	Q You see Employees and Consultants. As of the	6	Section 4(2) of the Securities Act?
7	date of this filing, the company has no full-time	7	A I don't know.
8	employees other than our sole officer and director, Mr.	8	Q If you go to the bottom of the page, it says,
9	Weinhaupl. We currently rely on Mr. Weinhaupl to	9	Mr. Weinhaupl has been the sole officer and director of
10	manage all aspects of our business. So that's just	10	the company since inception, and has founded the
11	you; is that right?	11	company, thus, he is a promoter as defined in Rule 405
12	A That's correct.	12	of Regulation C. Did you know you were a promoter
13	Q Is there any — has Scription ever had any	13	before today?
14	part-time employees?	14	A I did not know I was a promoter.
15	A Scription?	15	Q Mr. Weinhaupl has not received, nor scheduled
16	Q Scription/Transtech, the same company.	16	to receive, anything of value either directly or
17	A No, no part-time employees.	17	indirectly from the company. Have you read that
18	O How about consultants?	18	statement before today?
19	A Just Paul and the and then the person who	19	A No.
20	is doing the accounting as consultants.	20	Q Is it a true statement?
21	Q Who's the person doing the accounting?	21	A Yes.
22	A I don't recall their name here, but Paul had	22	Q Okay. If you would turn to page 34, it's the
23	administrated that for me.	23	report of the independent registered public accounting
24	Q Okay. And now let's go to page 32.	24	firm. Have you ever seen this page before today?
25	A Okay.	25	A I think I did. I don't recall though.
	,		

			<del></del>
1	Page 130		Page 132
1	(SEC Exhibit No. 56 was marked for	1	Q Sorry, 57 should be DLC 000235 through 237.
2	identification.)	2	Do you have number 57 in front of you, sir?
3	THE REPORTER: (Indicating).	3	A Yes.
4	THE WITNESS: Thanks.	4	Q Have you ever seen this before today?
5	THE REPORTER: Uh-huh.	5	A I don't recall.
6	THE WITNESS: Okay.	6	Q Why is Dean Law Corp. sending an invoice for
7	BY MR. MILLER:	7	professional services rendered to Transtech Solutions,
8	Q Have you ever seen this email thread that	8	attention Chris Weinhaupl, President? Do you have an
9	starts with Bates stamp Ruan 974 and runs through 978	9	answer?
10	before today?	10	A I'm just I'm trying to recall the
11	A No.	11	situation back in 2011 that would bring this together.
12	Q Okay. You see the first page of it, there's	12	I can't recall back then what brought this together.
13	an email from Chris Weinhaupt on May 17, 2013 at 10:50	13	Q Did you ever send any money to Mr. Dean's law
14	a.m. Do you see that? On the first page.	14	firm or Dean Law Corp.?
15	A Sorry, what pardon me. The question? I	15	A I don't recall.
16	was on the wrong page.	16	Q Did you ever talk with anyone from Dean Law
17	Q Do you see the first page, bottom of the	17	Corp.?
18	page, email from Chris Weinhaupl to Kenne Ruan, May 17,	18	A Could I have a moment?
19	2013 at 10:50 a.m.?	19	Q Let me rephrase. Have you ever heard of the
20	A Right, I see that.	20	name Faiyaz Dean before today?
21	Q Are you familiar with that email address,	21	A No.
22	scriptionworksolutions@gmail.com?	22	MR. MILLER: Madam Court Reporter, could you
23	A No.	23	mark the document in folder 16 as Exhibit 58, and hand
24	O You don't have that email address?	24	it to the witness? Did you still need a minute,
25	A No.	25	Mr. Weinhaupt?
ı	Page 131		Page 133
1	Q That's not yours?	1	THE WITNESS: Yeah, please.
2	A No.	2	MR. MILLER: Do you want to go off the
3	Q Did you ever authorize anyone to use that	3	record?
4	email address and put your name to it?	4	THE WITNESS: If that's okay, yes, please.
5	A No.	5	MR. VARNAVIDES: It should be very brief,
6	Q At the bottom it says, Hi, Kenne. And at the	. 6	Gary.
7	end it says, Thank you, Paul. Who's Paul?	7	MR. MILLER: It's 5:04 p.m. Off the record.
8	A I would only make an assumption, so I don't	8	(A brief recess was taken.)
9	know.	9	(SEC Exhibit No. 58 was marked for
10	Q That's the first time you've seen that email	10	identification.)
1	address, other than today?	11	MR. MILLER: We're back on the record at
11	A Yes.	12	5:07 p.m. And we went off the record at Mr.
11 12			
11	MR. MILLER: Can you Madam Court Reporter,		Weinhaupl's request so that he could confer with
11 12 13 14		14	Counsel. Did you have something to say, Counsel?
11 12 13	MR. MILLER: Can you Madam Court Reporter,	14 15	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised
11 12 13 14	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?	14 15 16	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his
11 12 13 14 15	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)	14 15	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about
11 12 13 14 15	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.	14 15 16	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his
11 12 13 14 15 16 17	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)	14 15 16 17	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about
11 12 13 14 15 16 17	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.	14 15 16 17 18	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about whether he had heard the name Faiyaz Dean before today.  BY MR. MILLER:  Q Go ahead, Mr. Weinhaupl.
11 12 13 14 15 16 17 18	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.  THE WITNESS: So there's two documents here?	14 15 16 17 18	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about whether he had heard the name Faiyaz Dean before today.  BY MR. MILLER:  Q Go ahead, Mr. Weinhaupl.  A So I've heard of the gentleman through
11 12 13 14 15 16 17 18 19 20	MR. MILLER: Can you - Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.  THE WITNESS: So there's two documents here?  MR. MILLER: Have you ever - 57?	14 15 16 17 18 19 20	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about whether he had heard the name Faiyaz Dean before today.  BY MR. MILLER:  Q Go ahead, Mr. Weinhaupl.
11 12 13 14 15 16 17 18 19 20 21	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.  THE WITNESS: So there's two documents here?  MR. MILLER: Have you ever 57?  THE WITNESS: I've just got two copies of the	14 15 16 17 18 19 20 21	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about whether he had heard the name Faiyaz Dean before today.  BY MR. MILLER:  Q Go ahead, Mr. Weinhaupl.  A So I've heard of the gentleman through
11 12 13 14 15 16 17 18 19 20 21	MR. MILLER: Can you Madam Court Reporter, can you pull folder 13 and put Exhibit 57 on it?  THE REPORTER: Yes.  (SEC Exhibit No. 57 was marked for identification.)  MR. MILLER: Hand it to the witness, please.  THE WITNESS: So there's two documents here?  MR. MILLER: Have you ever 57?  THE WITNESS: I've just got two copies of the same	14 15 16 17 18 19 20 21	Counsel. Did you have something to say, Counsel?  MR. VARNAVIDES: Yes. Mr. Weinhaupl advised me during the break that he would like to change his earlier answer to one of your preceding questions about whether he had heard the name Faiyaz Dean before today.  BY MR. MILLER:  Q Go ahead, Mr. Weinhaupl.  A So I've heard of the gentleman through Paul — working with Paul. And that's where that

	Page 124		
١.	Page 134		Page 136
1	A Didn't mention anything about him	1	participating in the business as it becomes profitable,
2	specifically.	2	and they could look at participating in a share
3	Q Okay. How did his name come up?	3	offering to participate in the business growth.
4	A I apologize. I don't recall.	4	Q Did these people pay any money that are
5	Q Okay.	5	listed on 58 for their shares?
6	MR. MILLER: Madam Court Reporter, we didn't	6	A Not yet.
7	mark 58 yet, did we?	7	Q Okay. And did you authorize your signature
8	THE REPORTER: Yes. I have it ready right	8	on here —
9	here.	9	A Yes.
10	MR. MILLER: Okay. That's folder 16?	10	Q — or your name being put on there?
11	THE REPORTER: Yes.	11	A Yeah,
12	MR. MILLER: You'll hand that to the witness,	12	Q And it says here, Upon motion. And then it
13	right?	13	says, Fully paid. So they didn't pay?
14	THE REPORTER: I just did.	14	A I have to
15	MR. MILLER: Okay.	15	Q Okay. Let's –
16	BY MR. MILLER:	16	A I don't recall. I apologize.
17	Q And 58 should be DLC 000347 and run through	17	Q Okay.
18	349. Do you have number 58 in front of you, sir?	18	MR. MILLER: Madam Court Reporter, can you
19	A Yes.	19	pull the documents that are in folder 14 and mark it as
20	Q Okay. This appears to be a document dated	20	59, and hand it to the witness?
21	October 15, 2012, minutes of a meeting of the director	21	THE REPORTER: Yes.
22	of the company held on October 15, 2012 at the Las	22	(SEC Exhibit No. 59 was marked for
23	Vegas address from Nevada - in Las Vegas, Nevada. Did	23	identification.)
24	you hold a meeting in Las Vegas, Nevada on October 15,	24	THE REPORTER: (Indicating).
25	2012, Mr. Weinbaupl?	25	THE WITNESS: Thanks.
_	Page 135		D 127
			Page 13/1
	_		Page 137
1	A Not in Las Vegas.	1	THE REPORTER: Uh-huh.
2	A Not in Las Vegas.  Q How about anywhere?	2	THE REPORTER: Uh-huh. BY MR. MILLER:
2	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have	2	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you
2 3 4	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.	2 3 4	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today?
2 3 4 5	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58	2 3 4 5	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes.
2 3 4 5 . 6.	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the	2 3 4 5 6	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000
2 3 4 5 . 6.	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?	2 3 4 5 6 7	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you?
2 3 4 5 . 6. 7 8	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.	2 3 4 5 6 7 8	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes.
2 3 4 5 . 6. 7 8	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?	2 3 4 5 6 7 8	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are
2 3 4 5 6 7 8 9	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate	2 3 4 5 6 7 8 9	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on
2 3 4 5 6 7 8 9 10	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.	2 3 4 5 6 7 8 9 10	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form
2 3 4 5 6 7 8 9 10 11	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?	2 3 4 5 6 7 8 9 10 11	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing?
2 3 4 5 6 7 8 9 10 11 12	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to	2 3 4 5 6 7 8 9 10 11 12	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders?
2 3 4 5 6 7 8 9 10 11	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —	2 3 4 5 6 7 8 9 10 11 12 13	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah.
2 3 4 5 6 7 8 9 10 11 12	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to	2 3 4 5 6 7 8 9 10 11 12 13 14	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how
2 3 4 5 6 7 8 9 10 11 12 13	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.	2 3 4 5 6 7 8 9 10 11 12 13	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way
2 3 4 5 6 7 8 9 10 11 12 13 14	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?	2 3 4 5 6 7 8 9 10 11 12 13 14	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate in what we were doing with the transcription business.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate in what we were doing with the transcription business.  Q Who located these people?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did ypu authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to. MR. MILLER: Okay. Madam Court Reporter, if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate in what we were doing with the transcription business.  Q Who located these people?  A We have — or I have some business people I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to. MR. MILLER: Okay. Madam Court Reporter, if you could take the documents in folder 18 and mark it
2 3 4 5 6. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate in what we were doing with the transcription business.  Q Who located these people?  A We have — or I have some business people I know in the Philippines.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to. MR. MILLER: Okay. Madam Court Reporter, if you could take the documents in folder 18 and mark it as Number 60. (SEC Exhibit No. 60 was marked for identification.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A Not in Las Vegas.  Q How about anywhere?  A Well, it would have been — it would have been me at home in my home office.  Q Okay. And have you ever seen Exhibit 58 before? And if so, what is it? Let's start with the first question. Have you ever seen it before today?  A Yes.  Q What is it?  A From my understanding, was to disseminate some shares to the shareholders here.  Q How did you get that understanding?  A We had a discussion on how we wanted to allocate shares in the company for people —  Q Who's "we"?  A Just Paul and I.  Q How did you come up with these names?  A These were people that wanted to participate in what we were doing with the transcription business.  Q Who located these people?  A We have — or I have some business people I know in the Philippines.  Q What did you tell them?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	THE REPORTER: Uh-huh. BY MR. MILLER: Q Exhibit 59 is Scription Number 34. Have you ever seen Exhibit 59 before today? A Yes. Q Okay. Did you authorize these 30,100,000 shares to be issued to you? A Yes. Q In Exhibit 58, did those shares that are depicted and those shareholders that are depicted on 58, did they have anything to do with Scription's Form S-1 filing? A In that they're shareholders? Q Yeah. A So how Q Are they going to be participating in any way in Scription's Form S-1? A They would be shareholders for participation, if that's what you're referring to. MR. MILLER: Okay. Madam Court Reporter, if you could take the documents in folder 18 and mark it as Number 60. (SEC Exhibit No. 60 was marked for

Page 142		Page 144
	1	1 agc 131
BY MR. MILLER:	1	Q Why did you withdraw those monies?
Q Have you taken - Mr. Weinhaup!?	2	A ATS had a shortfall in the accounting
A Yes?	3	statement or in the accounts for paying the vendors
Q Mr. Weinhaupl, have you ever withdrawn any	4	at that time. And because I do the banking in the same
money from the Wells Fargo bank account for Scription	5	place, I withdrew those funds to cover the vendor
•	6	payments for
A There was a transaction to help cover a bill	7	Q Did you tell anybody about that? Did you
for ATS, and then the -	8	tell anybody about that?
Q How much was that? How much was that?	9	A No.
A 1 can't recall. I just remember the	10	Q Okay. Why is that?
trans	11	A Probably at the time, it didn't seem
Q Anything - anything else?	12	important.
A Pay bills - are you asking me what all the	13	Q Okay.
transactions were? Sorry.	14	MR. MILLER: Can you, Madam Court Reporter,
Q No. I'm just asking you, did you ever	15	take folder 37 and mark it as Exhibit 63, and hand it
authorize the withdrawal of any monies from Scription's	16	to the witness?
Wells Fargo bank accounts for either yourself or any of	17	THE REPORTER: Yes.
your companies, like The Perfect Word, ATS or North	18	(SEC Exhibit No. 63 was marked for
Alliance - North American Alliance?	19	identification.)
A Not to myself, but to ATS, yes.	20	THE REPORTER: (Indicating).
Q How much?	21	THE WITNESS: Thanks.
A I don't recall.	22	THE REPORTER: Uh-huh.
MR. MILLER: Can you mark folder 31 as	23	BY MR. MILLER:
Exhibit 62, and hand them to the witness?	24	Q Folder 37 — the document from 37 is now
THE REPORTER: Yes.	25	Bates stamped as Exhibit - or is now marked as Exhibit
Page 143		Page 145
(SEC Exhibit No. 62 was marked for	1	63. Its Bates stamp number is 1428. Do you have that
<b>,</b>	2	in front of you, sir?
THE REPORTER: (Indicating).	3	A Yes, yes.
THE WITNESS: Thanks.	4	Q It's an invoice November 20, 2013. Have you
THE REPORTER: Uh-huh.	5	ever seen this document before today?
THE WITNESS; Okay.	6	A No.
BY MR. MILLER:	7	Q It says, Chris Weinhaupl/The Perfect Word,
Q This is Bates stamped — it's a Wells Fargo	8	Incorporated. And it's an invoice to Scription Work
statement Bates stamped 415 through 419. Are we looking	9	Solutions. And the description is Corporate Consulting
at the same document, sir?	10	Services, November 2013, Total, \$5,000.
A Yes.	11	Did you perform corporate - did you and The
Q Can you turn to the one that's Bates stamped	12	Perfect Word, Incorporated, perform corporate
417? It's three pages in.	13	consulting services in November 2013, and invoice
A Yes.	14	Scription for \$5,000 for those services?
Q Do you see a withdrawal of \$5,000 on November	15	A At the end of the day, I knew at the end
7th; \$5,000 on November 13th; and \$5,000 on November	16	of the day, the money was being paid to vendors that l
20th all to The Perfect Word, Incorporated?	17	had on the ATS side of things.
A Yes.	18	And what's missing here in the gap is The
Q Did you authorize those transfers?	19	Perfect Word account at Wells Fargo is the one that
A Yes.	20	makes the what we call ACH payments, so the funds go
Q Was that for were those monies used for	21	into The Perfect Word account. So I could see where
Scription?	22	the confusion came there.
A It was used for ATS.	23	Q Who directed this to be prepared, Exhibit 63?
Q Not Scription; is that right?	24	Did you direct it?
	Q Mr. Weinhaupl, have you ever withdrawn any money from the Wells Fargo bank account for Scription for any reasons for your personal use?  A There was a transaction to help cover a bill for ATS, and then the —  Q How much was that? How much was that?  A I can't recall. I just remember the trans—  Q Anything — anything else?  A Pay bills — are you asking me what all the transactions were? Sorry.  Q No. I'm just asking you, did you ever authorize the withdrawal of any monies from Scription's Wells Fargo bank accounts for either yourself or any of your companies, like The Perfect Word, ATS or North Alliance — North American Alliance?  A Not to myself, but to ATS, yes.  Q How much?  A I don't recall.  MR. MILLER: Can you mark folder 31 as Exhibit 62, and hand them to the witness?  THE REPORTER: Yes.  Page 143  (SEC Exhibit No. 62 was marked for identification.)  THE REPORTER: (Indicating).  THE WITNESS: Thanks.  THE REPORTER: Uh-huh.  THE WITNESS; Okay.  BY MR. MILLER:  Q This is Bates stamped 415 through 419. Are we looking at the same document, sir?  A Yes.  Q Can you turn to the one that's Bates stamped 417: It's three pages in.  A Yes.  Q Do you see a withdrawal of \$5,000 on November 7th; \$5,000 on November 13th; and \$5,000 on November 20th all to The Perfect Word, Incorporated?  A Yes.  Q Did you authorize those transfers?  A Yes.  Q Was that for — were those monies used for Scription?	Mr. Weinhaupl, have you ever withdrawn any money from the Wells Fargo bank account for Scription for any reasons for your personal use?  A There was a transaction to help cover a bill for ATS, and then the —  Q How much was that? How much was that?  A I can't recall. I just remember the trans—  Q Anything — anything else?  A Pay bills — are you asking me what all the transactions were? Sorry.  Q No. I'm just asking you, did you ever authorize the withdrawal of any monies from Scription's Wells Fargo bank accounts for either yourself or any of your companies, like The Perfect Word, ATS or North Alliance — North American Alliance?  A Not to myself, but to ATS, yes.  Q How much?  A I don't recall.  MR. MILLER: Can you mark folder 31 as  Exhibit 62, and hand them to the witness?  THE REPORTER: Yes.  Page 143  (SEC Exhibit No. 62 was marked for identification.)  THE REPORTER: Uh-huh.  THE WITNESS: Thanks.  THE WITNESS: Thanks.  4 THE REPORTER: Uh-huh.  THE WITNESS; Okay.  BY MR. MILLER:  Q This is Bates stamped — it's a Wells Fargo statement Bates stamped 415 through 419. Are we looking at the same document, sir?  A Yes.  Q Can you turn to the one that's Bates stamped  417? It's three pages in.  A Yes.  Q Do you see a withdrawal of \$5,000 on November 157th; \$5,000 on November 13th; and \$5,000 on November 157th; \$5,000 on November 13th; and \$5,000 on November 157th; \$5,000 on November 13th; and \$5,000 on November 157th; \$5,000 on November 15th; and \$5,000 on November 157th; \$5,000 on November 15th; and \$5,000 on November 15th; \$15,000 on November 15th; \$15,0

ł	Page 146		Page 148
1	Q Who would know that?	1	(SEC Exhibit No. 65 was marked for
2	A Maybe Paul.	2	identification.)
3	Q Scription never produced this document, do	3	BY MR. MILLER:
4	you know why —	4	Q Exhibit 65 is a Wells Fargo statement for
5	A No.	5	Transtech Bates stamped 420 through 424. Is that the
6	Q - to the SEC? Do you know why?	6	document you have in front of you, sir?
7	A No.	7	A Yes.
8	Q Did you or The Perfect Word perform corporate	8	Q Can you turn to the third page, please?
9	consulting services in November 2013 for Scription, and	9	A Yes.
10	charge Scription \$5,000?	10	Q Do you see a withdrawal on December 19th for
11	A No.	11	\$10,000 to The Perfect Word, Incorporated, business
12	Q Are there any other invoices like this that	12	checking account?
13	you're aware of?	13	A Yes.
14	A I don't want to make the not that I'm	14	Q Did you authorize that?
15	aware of.	15	A Yes.
16	MR. MILLER: Okay. Madam Court Reporter,	16	Q What's it for?
17	could you mark the document in Exhibit 36, and hand it	17	A Was this the next month after the month
18	to the witness as Exhibit 64?	18	before?
19	(SEC Exhibit No. 64 was marked for	19	Q You mean on Exhibit 62? It appears to be
20	identification.)	20	that way.
21	THE REPORTER: (Indicating).	21	A That might have been all in the same — as I
22	THE WITNESS: Thanks, Yes.	22	described before, there was a short in the ATS account
23	BY MR. MILLER:	23	for paying the vendors, so that might have - I don't
24	Q Okay. Is this Exhibit 64, State of Alaska,	24	recall all the totals, but that's what I was doing at
25	Certificate of Involuntary Dissolution/Revocation, is	25	that time, from what I recall.
	Page 147		Page 149
1	that the document you have in front of you dated	1	MR. MILLER: Madam Court Reporter, can you
2	June 11, 2013?	2	take the document in folder 40 and mark it as 66?
3	A Yes.	3	THE REPORTER: Yes.
4	Q And is that for The Perfect Word,	4	(SEC Exhibit No. 66 was marked for
5	Incorporated?	5	identification.)
6	A Yes.	6	THE WITNESS: Okay.
7	O Okay. So is The Perfect Word, Incorporated	7	BY MR. MILLER:
В	current in the state of Alaska —	8	Q Okay. Number 66 is another invoice. It's
9	A It appears not to be.	9	Ruan 542. And it's dated December 19, 2013. Have you
10	Q — with its — were you aware of that before	10	ever seen - is that the document you're looking at,
11	today?	11	Number 66, sir?
12	A No.	12	A Yes.
13	Q Besides Exhibit 62 where monies were taken	13	Q Okay. Have you ever seen this before today?
14	out of Trans — of Scription's bank accounts and moved	14	A No.
15	over to The Perfect Word, were there any other	15	Q Are these true statements here, that Chris
16	instances?	16	Weinhaupl, The Perfect Word, is providing corporate
17	A That I moved the funds over to The Perfect	17	consulting services to Scription in December 2013 in
18	Word?	18	the amount of \$5,000, and corporate consulting services
19	Q Yes, sir.	19	in January 2014 for \$5,000? Is that accurate?
20	A I believe it was just that one time or the	20	A No.
	one month.	21	Q Who prepared Exhibit 66?
21		22	• • •
21 22	MR. MILLER: Madam Court Reporter, can you	22	A I don't know.
	MR. MILLER: Madam Court Reporter, can you take the folder marked as 32 and mark that as Exhibit	23	
22	• • •		MR. MILLER: Okay. And the last exhibit is folder 32B, please. Madam Court Reporter, if you

Page 162 1 PROOFREADER'S CERTIFICATE 2 3 In the Matter of: GENUFOOD ENERGY ENZYMES CORP. Witness: Christopher Weinhaupl File Number: FL-03857-A 6 Date: Thursday, August 21, 2014 7 Location: San Francisco, CA 94104 8 9 This is to certify that I, Donna S. Raya, (the undersigned), do hereby swear and affirm that the 10 11 attached proceedings before the U.S. Securities and Exchange Commission were held according to the record 12 13 and that this is the original, complete, true and accurate transcript that has been compared to the 14 15 reporting or recording accomplished at the hearing. 16 17 (Date) 18 19 20 21 22 23

24

25


1	STATE OF CALIFORNIA )	
2	County of Sonoma )	
3		
4	I, Diane Dearmore, holding CSR License No. 12736,	
5	a Certified Shorthand Reporter, licensed by the State of	
6	California, hereby certify that, pursuant to Notice to	
7	take the foregoing deposition, said witness was by me	
8	duly sworn to tell the truth, the whole truth and	:
9	nothing but the truth in the within-entitled cause; that	
10	the testimony of the said witness was recorded by me by	
11	stenotypy, and that said deposition was under my	
12	direction thereafter reduced to computer transcript and,	
13	when completed, was available to said witness for	:
14	signature before any Notary Public.	
15	I further certify that I am not of counsel or	
16	attorney for either of the parties to said deposition,	
17	nor in any way interested in the outcome of the cause	
18	named in the caption.	•
19	IN WITNESS WHEREOF, I have hereunto set my hand	
20	this, 2014.	
21		
22		
23	yea Oloco	
24	Diane Dearmore Certified Shorthand Reporter	
25	California License No. 12736 Texas License No. 4947	


.


1

,					
,					
•					
				•	
		•			
			•		
				t	
·					
		COMPOSITE EX	KHIBIT G		
				•	
		•			
and and					
•					
		,			
	•				
H					
				•	
	•			•	
					•
				•	
		•			

COMPOSITE EXHIBIT G











**EXHIBIT H** 
















**COMPOSITE EXHIBIT I** 

# COMPOSITE EXHIBIT I

# Wells Fargo Combined Statement of Accounts

Primary account number:

November 1, 2013 - November 30, 2013 Page 1 of 5



TRANSTECH SOLUTIONS INC. 848 N RAINBOW BLVD UNIT 1175 LAS VEGAS NV 89107-1103

## Questions?

Available by phone 24 hours a day, 7 days a week: 1-800-CALL-WELLS (1-800-225-5935)

TTY: 1-800-877-4833 En español: 1-877-337-7454

Online: wellsfargo.com/biz

Write: Wells Fargo Bank, N.A. (120)

P.O. Box 6995

-Portland, OR-97228-6995-

# Your Business and Wells Fargo

Applying for financing can seem like a numbers game of credit scores and financial statements. Find out what lenders are really looking for at well-stargobusinessinsights.com/enders.

#### Account options

A check mark in the box indicates you have these convenient services with your account. Go to well-stergo.com/biz or call the number above if you have questions or if you would like to add new services.

Business Online Banking
Online Statements
Business Bill Pay
Business Spending Report
Overdraft Protection

# Summary of accounts

# Checking/Prepaid and Savings

Account	Pago	Account number	Ending balance last statement	Ending balance this statement
Gold Business Services Package	2		912.49	912.49
Business Market Rate Savings	3		30,071.28	15,071.91
	Total denosi	taccounts	\$30 983 77	\$15 984 40

■ November 1, 2013 - November 30, 2013 ■ Page 2 of 5



# Gold Business Services Package

Activity summary		Account number:	
Beginning balance on 11/1	5912.49	TRANSTECH SOLUTIONS INC.	
Deposits/Credits	0.00	Washington account terms and conditions apply	
Withdrawals/Debits	- 0.00	For Direct Deposit and Automatic Payments use	
Ending balance on 11/30	\$912.49	Routing Number (RTN): 125008547	
Average ledger balance this period	\$912.49	For Wire Transfers use Routing Number (RTN): 121000248	
Overdraft Protection			
Your account is linked to the following for Ove	rdraft Protection:		
■ Savings -			

#### Monthly service fee summary

For a complete list of fees and detailed account information, please see the Wells Fargo Fee and Information Schedule and Account Agreement applicable to your account or talk to a banker. Go to wellstargo.com/feefaq to find answers to common questions about the monthly service fee on your account.

Fee period 11/01/2013 - 11/30/2013	Standard monthly service fee \$14.00	00.02 blaq uoY
How to avoid the monthly service fee (complete 1 AND 2)	Minimum required	This fee period
1) Have any ONE of the following account requirements		
Average lødger balance	\$7,500.00	\$912.00
<ul> <li>Qualifying transaction from a linked Wels Fargo Business Payroll Serv</li> </ul>	ices account 1	0 🗆
<ul> <li>Qualifying transaction from a linked Wells Fargo Merchant Services acc</li> </ul>	count 1	0 🗆
· Automatic transfer to an eligible Wells Fargo business savings account	\$150.00	\$0.00
<ul> <li>Linked Direct Pay Service through Wells Fargo Business Online</li> </ul>	1	0 🗆
<ul> <li>Combined balances in linked accounts, which may include</li> </ul>	\$10,000.00	
- Avaraga ledger balances in business checking, savings, and time ac	counts	
<ul> <li>Most recent atatement balances of: business credit card, Wells Farge Equity* and BusinessLine* lines of credit, Wells Farge BusinessLoan</li> <li>Average daily balances from previous month in business PrimeLine* credit and Business PrimeLoan* account, Wals Farge Express Equit</li> </ul>	term loan line of	
Equipment Express* loans 2) Complete the package requirements		
Have qualifying linked accounts or services in separate categories*	3	

Did you know that you can review your safe deposit box Information through Wells Fargo Business Online Banking? Sign on to
soline banking at wellsfargo, com/sz and go to your account summary page of preview details.



# **Business Market Rate Savings**

Activity summary	
Beginning balance on 11/1	\$30,071.28
Deposits/Credits	0.87
Withdrawals/Debits	- 15,000.24
Ending balance on 11/30	\$15,071.91
Average ledger balance this period	\$21,237.94

Account number:

Weshington account torms and conditions apply For Direct Deposit and Automatic Payments use Routing Number (RTN): 125008547

For Wire Transfers use

Routing Number (RTN): 121000248

Interest summary		Interest withheld	
Interest paid this statement	\$0.87	Interest withheld this period	\$0.24
Average collected balance	\$21,237.94	Interest withheld this year	\$4.31
Annual percentage yield earned	0.05%		
Interest earned this statement period	\$0.87		
Interest paid this year	\$15.62		

## Transaction history

		Deposits/	W#hdrawals/	Ending daily
Date	Description	Crodits	Dobite	balanca
11/7	Online Transfer to The Perfectiverd Inc. Business Checking xxxxxx7073 Ref #Ibetr7PI23 on 11/07/13		5,000.00	25,071.28
11/13	<ul> <li>Online Transfer to The Perfectword Inc., Business Checking xxxxxx7073 Ret #lbek34Przb on 11/13/13</li> </ul>		5,000.00	20,071.28
11/20	<ul> <li>Online Transfer to The Perfectiverd Inc. Business Checking xxxxx7073 Ref #Ibec93Pqhk on 11/20/13</li> </ul>		5,000.00	15,071.28
11/29	irderest Payment	0.87		
11/29	Federal Tax Withheld		0.24	15,071.91
Ending	balance on 11/30			15,071.91
Totale		50.87	\$15,000.24	

The Ending Daily Balance does not reflect any pending withdrawals or holds on deposited funds that may have been outstanding on your account when your transactions posted. If you had insufficient available funds when a transaction posted, lees may have been assessed.

## Monthly service fee summary

For a complete list of fees and detailed account information, please see the Wells Fargo Fee and Information Schedule and Account Agreement applicable to your account or talk to a banker. Go to wellsfargo.com/leefaq to find answers to common questions about the monthly service fee on your account.

Fee period 11/01/2013 - 11/30/2013	Standard monthly service fee \$6.00	You paid \$0.00
How to avoid the monthly service fee	Minimum required	This fee period
Have any ONE of the following account requirements		
Average collected balance	\$500.00	\$21,238.00 🗹
<ul> <li>Automatic transfer from an eligible Wells Fargo business checking account</li> </ul>	\$100.00	\$0.00
Years		

Indicates transactions that count toward Federal Reserve Board Regulation D limits. Please refer to your Account Agreement for complete details of the foderally-mandated transaction limits for savings accounts.

■ November 1, 2013 - November 30, 2013 ■ Page 4 of 5





# MIMPORTANT ACCOUNT INFORMATION

Online and Telephone Transfers from a Savings Account May Be Declined

Beginning December 11, 2013, transfers from this savings account through online banking (including mobile and text) or by telephone may be declined for the remainder of the monthly statement period if the federal limit of six (6) transfers is reached. We are taking this step to help customers stay within the federal limit.

As stated in your Account Agreement, most transfers from savings accounts are limited by Regulation D to six (6) per month including transfers for overdraft protection coverage, online banking, or by telephone (automated and banker assisted). If the limit is exceeded, an excess activity fee applies and the account may be converted to a checking account.

There are no limits on transfers or withdrawals made in person at ATMs or Wells Fargo banking locations or on any types of deposits.

If you have questions, please contact your local banker or call the phone number on the top of your statement.



■ November 1, 2013 - November 30, 2013 ■ Page 5 of 5



## General statement policies for Wells Fargo Bank

B Notice: Wells Fargo Bank, N.A. may furnish information about accounts belonging to individuals, including sole proprietorships, to consumer reporting agencies. If this applies to you, you have the right to dispute the accuracy of information that we have reported by writing to us at: Overdraft Cottections and Recovery, P.O. Box 5058, Portland, OR 97208-5058. You must describe the specific information that is inaccurate or in dispute and the basis for any dispute with supporting documentation. In the case of information that relates to an identity theft, you will need to provide us with an identity theft report.

Account Balance Calculation Worksheet	Number	Itoms Outstanding	Amount	
Use the following worksheet to calculate your overall account balance.				
<ol> <li>Go through your register and mark each check, withdrawal, ATM transaction, payment, deposit or other credit listed on your statement.</li> <li>Be sure that your register shows any interest paid into your account and any service charges, automatic payments or ATM transactions withdrawn from your account during this statement period.</li> </ol>				
<ol> <li>Use the chart to the right to list any deposits, transfers to your account, outstanding checks, ATM withdrawals, ATM payments or any other withdrawals (including any from previous months) which are fisted in your register but not shown on your statement.</li> </ol>				
ENTER				
A. The ending balance				
shown on your statement				
•				
ADD		* ( 112-312-107-108-108-107-117-117-117-117-117-117-117-117-117		
B. Any deposits listed in your S				
register or transfers into S				
B. Any deposits listed in your S S S S S S S S S S S S S S S S S S S				
shown on your statement. + \$				
CALCULATE THE SUBTOTAL				
(Add Parts A and B)				
• Control of the cont				
TOTAL S				
SUBTRACT				
C. The total cutstanding checks and				
withdraweb from the chart above				
CALCULATE THE ENDING BALANCE				
(Part A + Part B - Part C)				
This amount should be the same				
as the current balance shown in				
your check register				
		Total amor	t	

\$2016 Wells Fargo Bank, N.A. Allrights reserved. Member FDIC. NMLSR ID 399601

# Wells Fargo Combined Statement of Accounts

Primary account number:

■ December 1, 2013 - December 31, 2013 ■ Page 1 of 5



TRANSTECH SOLUTIONS INC. 848 N RAINBOW BLVD UNIT 1175 LAS VEGAS NV 89107-1103

#### Questions?

Available by phone 24 hours a day, 7 days a week: 1-800-CALL-WELLS (1-800-225-5935)

TTY: 1-800-877-4833 En español: 1-877-337-7454 Online: wellstargo.com/biz

Write: Wells Fargo Bank, N.A. (120)

P.O. Box 6935 Portland, OR 97228-6995

### Your Business and Wells Fargo

Cetting ready for tax season can be a challengel Greating is checklist, and preparing in advance will set you up for a successful meeting with your tax preparer. Remember to bring your deposit routing and account number when preparing your taxes and you may be able to take advantage of using direct deposit for your tax refund into one of your Wells Fargo checking or savings accounts.

#### Account options

A check mark in the box indicates you have those convenient survices with your account. Go to waitsfarge combit or call the number above if you have questions or if you would like to add new services.

Susiness Online Banking

Online Statements

Business Bill Pay

Business Spending Report

Overdraft Protection

Your statement includes a "Monthly service fee summary" section that gives you the ability to proactively manage the monthly service fee on your account. This section provides you with the view of your checking or savings account monthly service fee, the requirements to waive the monthly service fee, if applicable, and the current status for each requirement. You may view this information on your statement or in your secure online banking session by clicking "View Monthly Service Fee" on the left-hand eavigation bar. If you'd like to schedule an account review or to learn about other accounts or services we offer, please contact Wells Fargo at 1-850-225-5335 or visit your local Wells Fargo store.

# Summary of accounts

# Checking/Prepaid and Savings

Account	Page	Account number	Ending balance last statement	Ending balance this statement
Gold Businesa Services Package	2		912.49	912.49
Business Market Rate Savings	3		15,071.91	5,072.25

Total deposit accounts

\$15,084.40

\$5,984.74

(120) Short Seq = 0050146 Sheet 20001 of 00003



Primary account number: 6040087065 = December 1, 2013 - December 31, 2013 = Page 2 of 5



# Gold Business Services Package

Activity summary	
Beginning balance on 12/1	\$912.49
Deposits/Credits	0.00
Withdrawals/Debits	- 0.00
Ending balanco on 12/31	\$912.49
Average ledger batince this period	\$912.49

Account number:

TRANSTECH SOLUTIONS INC.

Washington account tarms and conditions apply

For Direct Deposit and Automatic Payments use

Routing Number (RTN): 125008547

For Wire Transfers use

Routing Number (RTN): 121000248

Overdraft Protection

Your account is linked to the following for Overdraft Protection:

Savings -



#### Monthly service fee summary

For a complete fat of fees and detailed account information, please see the Wells Fargo Fee and Information Schedule and Account Agreement applicable to your account or talk to a banker. Go to wellstargo.com/feefag to find answers to common questions about the monthly service fee on your account.

Foo period 12/01/2013 - 12/31/2013	Sandard monthly service fee \$14.00	You paid \$0.00
How to avoid the monthly service fee (complete 1 AND 2)	Minimum required	This fee period
1) Have any ONE of the following account requirements		
Average ledger halanco	57,500.00	\$912.00
· Qualifying transaction from a tinked Wels Fargo Business Payroll Services acc	ount 1	0 🗆
· Qualifying transaction from a linked Wels Fargo Merchant Services account	<b>:</b>	0 🗆
· Automatic transfer to an efigible Welle Ferge business savings occount	\$150.00	\$0.00
Linked Direct Pay Service through Wells Fargo Business Online	1	0 🗆
Combined balances in linked accounts, which may include	\$10,000.00	2
- Average ledger balances in husiness checking, savings, and time accounts		
<ul> <li>Most recent statement bataneous et business credit card. Wells Fargo Expres Equity* and Businesst.ine* lines of credit, Wells Fargo Businesst.cam* tam le Avarage daily balances from provious menth in business Primetine* line of credit and Business Primet.can** peccount. Wells Fargo Express Equity*, SDA Equipment Express* loans</li> </ul>	sın	
) Complete the package requirements		
<ul> <li>Have qualifying linked accounts or services in separate categories.</li> </ul>	3	<b>⊡</b>

Tinclades Wells Fargo business accounts and pervices such as debit card, savings accounts, active Online Banking, credit card, loans and lines of credit. CIC2

Did you know that you can review your safe deposit box information through Wells Fargo Business Online Banking? Sign on to business online banking at wellstargo.com/biz and go to your account summary page to review details.



# **Business Market Rate Savings**

Activity summary	
Beginning balance on 12/1	\$15,071.91
Deposits/Credits	0.46
Withdrawsis/Debits	- 10,000.12
Ending balance on 12/31	\$5,072,25
Average ledger balance this period	\$10,878.36

Account number: TRANSTECH SOLUTIONS INC.

Washington account mms and conditions apply....

For Direct Deposit and Automatic Payments use Routing Number (RTN): 125008547

For Wire Transfors use

Routing Number (RTN): 121000248

Interest summary	. 1.19
Interest maid this state	emant .

Interest paid this statement	\$0.46
Average collected balance	\$10,878.38
Annual porcentage yield earned	0.05%
Interest earned this statement period	\$0.48
Interest paid this year	\$16.08

#### Interest withheld

Interest withheld this period	50,12
Interest withheld this year	\$4.43

## Transaction history

Cato	Docaription	Deposits! Crudis	Wähdamats/ Dobits	Ending dady balance
12/19	6 China Transfer to The Porfectword Inc. Business Checking xxxxxx7073 Ref #laexnn57Pp on 12/19/13		10,000 00	5,071 91
12/31	Interest Payment	0.46		
12/31	Federal Tox Waltheld		0.12	5,072.25
Ending	balance on 12/31		_	5,072.25
Totals		\$0.46	\$10,000.12	

The Ending Daily Balance does not reflect any pending withdrawals or holds on deposited funds that may have been outstanding on your account when your bansactions posted. If you had insufficient available funds when a transaction posted, leas may have been assessed,

 Indicates transactions that count toward Federal Roserve Board Regulation D limits. Prease refer to your Account Agreement for complate details of the federally-mandated transaction limits for savings accounts.

#### Monthly service fee summary

For a complete list of fees and detailed account information, please see the Wells Fargo Fee and Information Schedulu and Account Agreement applicable to your account or talk to a banker. Go to wellolarge com/leefag to find answers to common questions about the morthly service tee on your account.

Fee period 12/01/2013 - 12/31/2013	Standard monthly service fee \$6.00	You paid \$0.00
How to avoid the monthly service fee	barlupon musinitā	This too perked
Have any ONE of the following account requirements  Average collected balance	. \$500.00	\$10,878.00
<ul> <li>Automatic transfer from an eligible Wells Fargo business checking account</li> </ul>	\$100.60	S0.00 🗀
YOMC .		



Sheet Soy = 0050147 Sheet 00002 ct 00003

m December 1, 2013 - December 31, 2013 m Page 4 of 5



Online and Telephone Transfers from a Savings Account May Be Declined

Beginning December 11, 2013, transfers from this savings account through online banking (including mobile and text) or by telephone may be declined for the remainder of the monthly statement period if the federal limit of six (6) transfers is reached. We are taking this step to help customers stay within the federal limit.

As stated in your Account Agreement, most transfere from savings accounts are limited by Regulation D to exit (6) per month including transfers for overdraft protection coverage, online banking, or by telephone (automated and transfer assisted). If the limit is exceeded, an excess activity fee applies and the account may be converted to a checking account.

There are no limits on transfers or withdrawals made in person at ATMs or Wells Fargo banking locations or on any types of deposits.

If you have questions, please contact your local banker or call the phone number on the top of your statement.

We want to let you know of the following fee change effective April 1, 2014:

- Collections - Domestic: Auto Draft - \$25 per item

If you have questions about these changes, or would like a complimentary financial review to ensure that you have the right accounts to meet your financial goals, please contact your local banker or call the phone number listed at the top of your statement.

■ December 1, 2013 - December 31, 2013 ■ Page 5 of 5

Number



Amount

## General statement policies for Wells Fargo Bank

Account Balance Calculation Worksheet

» Notice: Weës Fargo Bank, N.A. may furnish information about accounts belonging to individuals, including sole proprietorships, to consumer reporting agencies. If this applies to you, you have the right to dispute the accuracy of information that we have reported by writing to us at: Overdroft Collections and Recovery, P.O. Box 5058, Portland, OR 97208-5058.

1. Use the following worksheet to calculate your overall account balance.

You must describe the specific information that is inaccurate or in dispute and the basis for any dispute with supporting documentation. In the case of information that relates to an identity that, you will need to provide us with an identity that report.

Items Outstanding

2.	Go through your register and mark each check, withdravial, ATM	
	transaction, payment, deposit or other credit listed on your statement.  Be sure that your register shows any interest paid into your account and	
_	any service charges, automatic payments or ATM transactions withdrawn	
	from your account during this statement period.	
3.	Use the chart to the right to list any deposits, transfers to your account, outstanding checks, ATM withdrawals, ATM payments or any other withdrawals (including any from provious months) which are listed in	
	your register but not shown on your statement.	 
7	ITER	
۸.	The ording balance	
	shown on your staloment	 
31	do	
	Any deposits listed in your S	
٥.	register or transfera into	
	your account which are not	
	shown on your statement.   • S	
	STATE OF THE STATE	
	TOTAL S	
C	ALCULATE THE SUBTOTAL	
7	(Add Parts A and 8)	
^	BTRACT	
	The total outstanding checks and withdraweb from the chart above	
	whorewas from the contributions	
Ct	ALCULATE THE ENDING BALANCE	
	(Part A + Part B - Part C)	
	This amount should be the same	
	as the current balance shown in	
	your check register	
	Marie Harris Company of the Company	

\$2010 Wells Fisher Bank, N.A. Allifolds reserved, Member FDIC, NMLST(10 399001

Sheet C0003 of C0003

Total amount \$





# Miami Regional Office

DATE:

January 6, 2016

TO:

OFFICE OF THE SECRETARY

Elizabeth Murphy, Secretary

FROM:

Christine Nestor, Esq.

By: Ilonka Almonte, Paralegal

RE:

In the Matter of the Registration Statement of Scription Work Solutions, Inc.,

AP File No. 3-17010

Enclosed please find the original and three copies of the Division of Enforcement's Motion and Memorandum of Law Supporting Entry of A Stop Order by Default Against Scription Work Solutions, Inc. for filing in the above referenced Administrative Proceeding.

Thank you.